REGISTRATION NO. 333-13215
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 23, 1996
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 1 TO
FORM S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------
MAXXIM MEDICAL, INC.
(Exact Name of Registrant as specified in its charter)
TEXAS 3841, 3842, 3845 76-0291634
(State or other jurisdicion (Primary Standard Industrial (I.R.S. Employer
incorporation or organization Classification Code Numbers) Identification No.)
104 INDUSTRIAL BLVD.
SUGAR LAND, TEXAS 77478
(713) 240-5588
(Address, including zip code, and telephone number, including area
code, of Registrant's principal executive offices)
------------------------
KENNETH W. DAVIDSON
MAXXIM MEDICAL, INC.
104 INDUSTRIAL BLVD.
SUGAR LAND, TEXAS 77478
(713) 240-5588
(Name, address, including zip code, and telephone number, including area code,
of agent for service)
------------------------
WITH A COPY TO:
JOHN R. BOYER, JR.
DAVID A. JONES, JR.
BOYER, EWING & HARRIS, INCORPORATED
9 GREENWAY PLAZA, SUITE 3100
HOUSTON, TEXAS 77046
(713) 871-2025
------------------------
APPROXIMATE DATE OF COMMENCEMENT OF SALE TO THE PUBLIC: As soon as
practicable after this Registration Statement becomes effective.
If the securities being registered on this Form are to be offered in connection
with the formation of a holding company and there is compliance with General
Instruction G, check the following box. [ ]
CALCULATION OF REGISTRATION FEE
================================================================================
PROPOSED PROPOSED
TITLE OF EACH MAXIMUM MAXIMUM AMOUNT OF
CLASS OF SECURITIES AMOUNT TO BE OFFERING AGGREGATE REGISTRATION
TO BE REGISTERED REGISTERED PRICE OFFERING FEE
PER UNIT (1) PRICE (1)
- --------------------------------------------------------------------------------
10-1/2% Senior $100,000,000 100% $ 100,000,000 $34,482.76
Subordinated Notes
due 2006
================================================================================
(1) Estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457.
The Registrant hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933, as amended, or until the Registration Statement
shall become effective on such date as the Commission, acting pursuant to such
Section 8(a), may determine.
<PAGE>
MAXXIM MEDICAL, INC.
CROSS REFERENCE SHEET
Pursuant to Item 501(b) of Regulation S-K showing location in the
Prospectus of Information Required by Items in Form S-4
<TABLE>
<CAPTION>
ITEM IN FORM S-4 CAPTION IN PROSPECTUS
- ------------------------------------------------------------------------------
<S> <C>
1. Forepart of the Registration Statement and Facing Page; Cross-Reference Sheet; Outside Front
Outside Front Cover Page of Prospectus....... Cover Page of Prospectus
2. Inside Front and Outside Back Cover Pages Available Information; Table of Contents; Inside Front
of Prospectus................................ Cover Pages of Prospectus
3. Risk Factors, Ratio of Earnings to Fixed Summary; Risk Factors; Ratio of Earnings to Fixed
Charges and Other Information................ Charges; The Exchange Offer; Selected Consolidated
Financial Data
4. Terms of the Transaction..................... Summary; Risk Factors; The Prior Offer; Exchange
Offer; Description of Notes; Incorporation of Certain
Documents by Reference
5. Pro Forma Financial Information.............. Summary; Unaudited Pro Forma Financial Data
6. Material Contracts with the Company Being
Acquired..................................... Not Applicable
7. Additional Information Required for
Reoffering by Persons and Parties Deemed to
be Underwriters.............................. Not Applicable
8. Interests of Named Experts and Counsel....... Legal Matters; Experts
9. Disclosure of Commission Position on
Indemnification for Securities Act
Liabilities.................................. Not Applicable
10. Information with Respect to S-3 Registrants.. Prospectus Cover Page; Available Information;
Incorporation of Certain Documents by Reference;
Summary; Unaudited Pro Forma Financial Data; Selected
Consolidated Financial Data; Management's Discussion
and Analysis of Financial Condition and Results of
Operations; Index to Financial Statements
11. Incorporation of Certain Information by
Reference....................................Incorporation of Certain Documents by Reference
12. Information with Respect to S-2 or S-3
Registrants Not Applicable
13. Incorporation of Certain Information by
Reference.................................... Not Applicable
14. Information with Respect to Registrants
Other than S-3 or S-2 Registrants............ Not Applicable
15. Information with Respect to S-3 Companies.... Not Applicable
16. Information with Respect to S-2 or S-3
Companies.................................... Not Applicable
17. Information with Respect to Companies other
than S-3 or S-2 Companies.................... Not Applicable
18. Information if Proxies, Consents or
Authorizations are to be Solicited........... Not Applicable
19. Information if Proxies, Consents or Incorporation of Certain Documents by Reference
Authorizations are not to be Solicited or in
an Exchange Offer
</TABLE>
2
<PAGE>
******************************************************************************
* *
* INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A *
* REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED *
* WITH THE SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT *
* BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE *
* REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT *
* CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR *
* SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH *
* OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR *
* QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE. *
* *
******************************************************************************
SUBJECT TO COMPLETION, DATED OCTOBER 23, 1996
MAXXIM MEDICAL, INC.
Offer to Exchange
All Outstanding
10-1/2% Senior Subordinated Notes due 2006
($100,000,000 principal amount outstanding)
For 10-1/2% Senior Subordinated Notes due 2006
The Exchange Offer and withdrawal rights will expire at 5:00 p.m., New York
City time, on November 25, 1996 (as such date may be extended, the "Expiration
Date").
Maxxim Medical, Inc., a Texas corporation ("Maxxim" or the "Company") hereby
offers (the "Exchange Offer"), upon the terms and subject to the conditions set
forth in this Prospectus and the accompanying letter of transmittal (the "Letter
of Transmittal"), to exchange $1,000 in principal amount of its 10-1/2% Senior
Subordinated Notes due 2006 (the "New Notes") for each $1,000 in principal
amount of its outstanding 10-1/2% Senior Subordinated Notes due 2006 (the "Old
Notes") (the Old Notes and the New Notes are collectively referred to herein as
the "Notes"). An aggregate principal amount of $100,000,000 of Old Notes is
outstanding. See "The Exchange Offer."
Each broker-dealer that receives New Notes for its own account pursuant to
the Exchange Offer must acknowledge that it will deliver a prospectus in
connection with any resale of such New Notes. The Letter of Transmittal states
that by so acknowledging and by delivering a prospectus, a broker-dealer will
not be deemed to admit that it is an "underwriter" within the meaning of the
Securities Act. This Prospectus, as it may be amended or supplemented from time
to time, may be used by a broker-dealer in connection with resales of New Notes
received in exchange for Notes where such Notes were acquired by such
broker-dealer as a result of market-making activities or other trading
activities. The Company has agreed that, starting on the Expiration Date (as
defined herein) and ending on the close of business one year after the
Expiration Date, it will make this Prospectus available to any broker-dealer for
use in connection with any such resale. See "Plan of Distribution."
The Company will accept for exchange any and all Old Notes that are validly
tendered prior to 5:00 p.m., New York City time, on the Expiration Date. Tenders
of Old Notes may be withdrawn at any time prior to 5:00 p.m., New York City
time, on the Expiration Date. The Exchange Offer is not conditioned upon any
minimum principal amount of the Old Notes being tendered for exchange. However,
the Exchange Offer is subject to the terms and provisions of the Registration
Rights Agreement, dated as of July 30, 1996 (the "Registration Rights
Agreement"), among the Company, NationsBanc Capital Markets, Inc. and Bear,
Stearns & Co. Inc. (the "Initial Purchasers"). The Old Notes may be tendered
only in multiples of $1,000. See "The Exchange Offer."
SEE "RISK FACTORS" BEGINNING ON PAGE 16 HEREIN FOR A DISCUSSION OF CERTAIN
RISKS THAT SHOULD BE CONSIDERED BY HOLDERS IN EVALUATING THE EXCHANGE OFFER
THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE
The date of this Prospectus is _____________ , 1996
1
<PAGE>
The Old Notes were issued in a transaction (the "Prior Offering") pursuant
to which the Company issued an aggregate of $100,000,000 principal amount of the
Old Notes to the Initial Purchasers on July 30, 1996 (the "Closing Date")
pursuant to a Purchase Agreement, dated July 18, 1996 (the "Purchase
Agreement"), among the Company and the Initial Purchasers. The Initial
Purchasers subsequently resold the Old Notes in reliance on Rule 144A under the
Securities Act of 1933, as amended (the "Securities Act"). The Company and the
Initial Purchasers also entered into the Registration Rights Agreement, pursuant
to which the Company granted certain registration rights for the benefit of the
holders of the Old Notes. The Exchange Offer is intended to satisfy certain of
the Company's obligations under the Registration Rights Agreement with respect
to the Old Notes. See "The Exchange Offer - Purpose and Effect."
The Old Notes were issued, and the New Notes will be issued, under the
Indenture, dated as of July 30, 1996 among the Company, Maxxim Medical, Inc., a
Delaware corporation and a wholly owned subsidiary of the Company ("Maxxim
Delaware"), Fabritek la Romana, Inc., a Mississippi corporation and a wholly
owned subsidiary of Maxxim Delaware ("Fabritek"), Maxxim Medical Canada Limited,
a Canadian corporation and a wholly owned subsidiary of Maxxim Delaware ("Maxxim
Canada"), Medica B.V., a Netherlands corporation and a wholly owned subsidiary
of Maxxim Delaware ("Maxxim Netherlands"), Medica Hospital Supplies, N.V., a
Belgian corporation and a wholly owned subsidiary of Maxxim Delaware ("Maxxim
Belgium"), and Maxxim Acquisition Co., a Virginia corporation and a wholly owned
subsidiary of Maxxim Delaware ("Maxxim Acquisition"), and First Union National
Bank of North Carolina, as trustee (in such capacity, the "Trustee"). Such
Indenture is to be amended by Supplemental Indenture No. 1, to be executed by
and among the Company, Maxxim Delaware, Fabritek, Maxxim Canada, Maxxim
Netherlands, Maxxim Belgium, Sterile Concepts Holdings, Inc., a Virginia
corporation, successor by merger to Maxxim Acquisition and a wholly owned
subsidiary of Maxxim Delaware ("Sterile Concepts"), Sterile Concepts, Inc., a
Virginia corporation and a wholly owned subsidiary of Sterile Concepts ("SCI"),
Associated Medical Products Company ("AMP"), a Minnesota corporation and a
wholly owned subsidiary of Sterile Concepts, and Sterile Concepts Limited, a
corporation existing under the laws of the United Kingdom and a wholly owned
subsidiary of Sterile Concepts ("Sterile Limited"), pursuant to which Sterile
Concepts, SCI, AMP and Sterile Limited became guarantors of the Notes (the
Indenture, as supplemented, being hereinafter referred to as the "Indenture").
The form and terms of the New Notes will be identical in all material
respects to the form and terms of the Old Notes, except that (i) the New Notes
have been registered under the Securities Act and, therefore, will not bear
legends restricting the transfer thereof, (ii) holders of New Notes will not be
entitled to liquidated damages equal to $.05 per week per $1,000 principal
amount of Old Notes held by such holders (up to a maximum amount of $0.30 per
week per $1,000 principal amount) otherwise payable under the terms of the
Registration Rights Agreement in respect of the Old Notes held by such holders
during any period in which a Registration Default (as defined) is continuing
(the "Liquidated Damages") and (iii) holders of New Notes will not be, and upon
the consummation of the Exchange Offer, holders of Old Notes will no longer be,
entitled to certain rights under the Registration Rights Agreement intended for
the holders of unregistered securities. The Exchange Offer shall be deemed
consummated upon the occurrence of the delivery by the Company to First Union
National Bank of North Carolina, as registrar of the Old Notes (in such
capacity, the "Registrar") under the Indenture of New Notes in the same
aggregate principal amount as the aggregate principal amount of Old Notes that
are validly tendered by holders thereof pursuant to the Exchange Offer. See "The
Exchange Offer - Termination of Certain Rights" and "Procedures for Tendering
Old Notes" and "Description of Notes."
The New Notes will bear interest at a rate equal to 10-1/2% per annum.
Interest on the New Notes is payable semiannually, commencing February 1, 1997,
on February 1 and August 1 of each year (each, an "Interest Payment Date") and
shall accrue from July 30, 1996 or from the most recent Interest Payment Date
with respect to the Old Notes to which interest was paid or for which interest
was duly provided. The New Notes will mature on August 1, 2006. See "Description
of Notes."
The New Notes will not be redeemable at the Company's option prior to August
1, 2001. Thereafter, the New Notes will be redeemable by the Company at the
redemption prices, plus accrued and unpaid interest and Liquidated Damages, if
any, thereon to the applicable redemption date, and subject to the conditions
set forth in "Description of Notes - Optional Redemption." Upon the occurrence
of a Change of Control (as defined herein), each Holder of a
2
<PAGE>
New Note will have the right to require the Company to repurchase all or any
part (equal to $1,000 or an integral multiple thereof) of such Holder's New
Notes at 101% of the aggregate principal amount thereof, plus accrued and unpaid
interest thereon, if any, to the date of purchase. There is no assurance that
the Company will have adequate funds to repurchase the New Notes upon a Change
in Control. See "Description of Notes - Repurchase of New Notes at the Option of
the Holders - Change of Control."
The New Notes will be general unsecured obligations of the Company
subordinated in right of payment to all existing and future Senior Indebtedness
(as defined herein) of the Company, including borrowings under the Credit
Agreement (as defined herein). The New Notes will also be effectively
subordinated to all of the indebtedness of the Company's Subsidiaries. As of
August 4, 1996, the Notes will be subordinate to approximately $122,300,000 of
outstanding Senior Indebtedness and senior to approximately $28,750,000 of
indebtedness. See "Description of Notes." See also "Management's Discussion and
Analysis of Financial Condition and Results of Operations Liquidity and Capital
Resources." The Indenture permits the Company and its subsidiaries to incur
additional indebtedness, including additional Senior Indebtedness subject to
certain financial covenants.
Based on existing interpretations of the Securities Act by the staff of the
Securities and Exchange Commission (the "Commission") set forth in "no-action"
letters issued to third parties, the Company believes that New Notes issued
pursuant to the Exchange Offer to any holder of Old Notes in exchange for Old
Notes may be offered for resale, resold and otherwise transferred by such holder
(other than a broker-dealer who purchased Old Notes directly from the Company
for resale pursuant to Rule 144A under the Securities Act or any other available
exemption under the Securities Act) without compliance with the registration and
prospectus delivery provisions of the Securities Act, provided that such holder
is not an affiliate of the Company, is acquiring the New Notes in the ordinary
course of business and is not participating, and has no arrangement or
understanding with any person to participate, in the distribution of the New
Notes. Holders wishing to accept the Exchange Offer must represent to the
Company, as required by the Registration Rights Agreement, that such conditions
have been met. In addition, if such holder is not a broker-dealer, it must
represent that it is not engaged in, and does not intend to engage in, a
distribution of the New Notes. Each broker-dealer that receives New Notes for
its own account in exchange for Old Notes, where such Notes were acquired by
such broker-dealer as a result of market-making activities or other trading
activities, must acknowledge that it will deliver a prospectus in connection
with any resale of such New Notes. See "The Exchange Offer - Resales of the New
Notes" and "Plan of Distribution." This Prospectus, as it may be amended or
supplemented from time to time, may be used by a broker-dealer in connection
with resales of New Notes received in exchange for Old Notes where such Old
Notes were acquired by such broker-dealer as a result of market-making or other
trading activities.
As of October 15, 1996, Cede & Co. ("Cede"), as nominee for The Depository
Trust Company, New York, New York ("DTC"), was the sole registered holder of the
Old Notes and held the Old Notes for twenty-two (22) of its participants. The
Company believes that no such participant is an affiliate (as such term is
defined in Rule 405 of the Securities Act) of the Company. There has previously
been only a limited secondary market, and no public market, for the Old Notes.
The Old Notes are eligible for trading in the Private Offering, Resales and
Trading through Automatic Linkages ("PORTAL") market. In addition, the Initial
Purchasers have advised the Company that they currently intend to make a market
in the New Notes; however, the Initial Purchasers are not obligated to do so and
any market making activities may be discontinued by the Initial Purchasers at
any time. Therefore, there can be no assurance that an active market for the New
Notes will develop. If such a trading market develops for the New Notes, future
trading prices will depend on many factors, including, among other things,
prevailing interest rates, the Company's results of operations and the market
for similar securities. Depending on such factors, the New Notes may trade at a
discount from their face value. See "Risk Factors - Lack of Public Market."
The Company will not receive any proceeds from this Exchange Offer. Pursuant
to the Registration Rights Agreement, the Company will bear certain registration
expenses.
THE EXCHANGE OFFER IS NOT BEING MADE TO, NOR WILL THE COMPANY ACCEPT
SURRENDERS FOR EXCHANGE FROM, HOLDERS OF OLD NOTES IN ANY JURISDICTION IN WHICH
3
<PAGE>
THE EXCHANGE OFFER OR THE ACCEPTANCE THEREOF WOULD NOT BE IN COMPLIANCE WITH THE
SECURITIES OR BLUE SKY LAWS OF SUCH JURISDICTION.
The Old Notes were issued originally in global form (the "Global Old Note").
The Global Old Note was deposited with, or on behalf of, DTC, as the initial
depository with respect to the Old Notes (in such capacity, the "Depositary").
The Global Old Note is registered in the name of Cede, as nominee of DTC, and
beneficial interests in the Global Old Note are shown on, and transfers thereof
are effected only through, records maintained by the Depositary and its
participants. The use of the Global Old Note to represent certain of the Old
Notes permits the Depositary's participants, and anyone holding a beneficial
interest in an Old Note registered in the name of such a participant, to
transfer interests in the Old Notes electronically in accordance with the
Depositary's established procedures without the need to transfer a physical
certificate. New Notes issued in exchange for the Global Old Note will also be
issued initially as a note in global form (the "Global New Note," and, together
with the Global Old Note, the "Global Notes") and deposited with, or on behalf
of, the Depositary. After the initial issuance of the Global New Note, New Notes
in certificated form will be issued in exchange for a holder's proportionate
interest in the Global New Note only as set forth in the Indenture.
4
<PAGE>
TABLE OF CONTENTS
Page
----
Available Information............................................. 6
Incorporation of Certain Documents
by Reference..................................................... 6
Prospectus Summary................................................ 8
Risk Factors...................................................... 16
The Exchange Offer................................................ 22
Use of Proceeds................................................... 29
Ratio of Earnings to Fixed Charges................................ 29
Unaudited Pro Forma Financial Data................................ 29
Selected Consolidated Financial Data.............................. 34
Management's Discussion and
Analysis of Financial Condition
and Results of Operations........................................ 35
Description of Notes.............................................. 42
Description of Certain Indebtedness............................... 67
Plan of Distribution.............................................. 69
Legal Matters..................................................... 70
Experts........................................................... 70
5
<PAGE>
AVAILABLE INFORMATION
The Company has filed a registration statement on Form S-4 (together with
any amendments thereto, the "Registration Statement") with the Commission under
the Securities Act with respect to the New Notes. This Prospectus, which
constitutes a part of the Registration Statement, omits certain information
contained in the Registration Statement and reference is made to the
Registration Statement and the exhibits and schedules thereto for further
information with respect to the Company and the New Notes offered hereby. This
Prospectus contains summaries of the material terms and provisions of certain
documents and in each instance reference is made to the Registration Statement
and the exhibits and schedules thereto for further information with respect to
the Company and the New Notes offered hereby. This Prospectus contains summaries
of the material terms and provisions of certain documents and in each instance
reference is made to the copy of such document filed as an exhibit to the
Registration Statement. Each such summary is qualified in its entirety by such
reference.
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934 (the "Exchange Act") and, in accordance therewith, is
required to file periodic reports, proxy statements and other information with
the Commission relating to its business, financial condition and other matters.
Information as of particular dates concerning the directors and officers of the
Company, their remuneration, options granted to them and other matters, the
principal holders of the securities issued by the Company, and any material
interest of such persons in transactions with the Company, is required to be
disclosed in such filings. The Company has further agreed that, whether or not
it is required to do so by the rules and regulations of the Commission, for so
long as any of the Notes remain outstanding, it will furnish to the holders of
the Notes and file with the Trustee, within 15 days after it is or would have
been required to file such with the Commission (i) all quarterly and annual
financial information that would be required to be contained in a filing with
the Commission on Forms 10-Q and 10-K if the Company is or were required to file
such forms, including a "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and, with respect to the annual information
only, a report thereon by the Company's independent accountants, and (ii) all
reports that are or would be required to be filed with the Commission on Form
8-K if the Company is or were required to file such reports. In addition,
whether or not required by the rules and regulations of the Commission, at any
time after the Company files a registration statement with respect to the
Exchange Offer or a Shelf Registration Statement, the Company will file a copy
of all such information and reports with the Commission for public availability
(unless the Commission will not accept such a filing) and make such information
available to securities analysts and prospective investors upon request. In
addition, for so long as any of the Notes remain outstanding, the Company has
agreed to furnish to the Holders and to securities analysts and prospective
investors, upon their request, the information required by Rule 144A(d)(4) under
the Securities Act.
The Registration Statement (including the exhibits and schedules thereto)
and the periodic reports and other information filed by the Company with the
Commission may be inspected without charge at the public reference facilities of
the Commission at Room 1024, 450 Fifth Street, NW, Washington, DC 20549, and at
the regional offices of the Commission located at 7 World Trade Center, Suite
1300, New York, NY 10048 and Citicorp Center, 500 West Madison Street, Suite
1400, Chicago, IL 60661. Copies of such information may be obtained by mail,
upon payment of the Commission's customary charges, by writing to the
Commission's principal office at 450 Fifth Street, NW, Washington, DC 20549.
Such material should also be available for inspection at the library of the New
York Stock Exchange, 20 Broad Street, New York, New York 10005. The Company's
shares are listed and traded on the NYSE under the symbol "MAM."
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by the Company or by Sterile Concepts
Holdings, Inc. with the Commission pursuant to the Exchange Act, are hereby
incorporated by reference, except as superseded or modified herein: (i) the
Company's Annual Report on Form 10-K for the fiscal year ended October 29, 1995,
(ii) the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended
February 4, 1996, (iii) the Company's Quarterly Report on Form 10-Q for the
fiscal quarter ended May 5, 1996, (iv) the Company's Quarterly Report on Form
10-Q for the fiscal quarter ended August 4, 1996, (v) the Company's Report on
Form 8-K describing the acquisition by the Company of Sterile Concepts
6
<PAGE>
Holdings, Inc., filed with the Commission on August 14, 1996, as amended by
Amendment No. 1 to Form 8-K filed with the Commission on October 11, 1996, (vi)
the Annual Report on Form 10-K of Sterile Concepts Holdings, Inc. for the fiscal
year ended September 30, 1995, and (vii) the Quarterly Report on Form 10-Q of
Sterile Concepts Holdings, Inc. for the fiscal quarter ended March 31, 1996.
All documents filed by the Company with the Commission pursuant to Section
13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof and prior to
termination of the Exchange Offer shall be deemed to be incorporated by
reference into this Prospectus and to be a part hereof from the respective dates
of filing of such documents. Any statement contained herein or in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to
be modified or superseded for purposes of this Prospectus to the extent that a
statement contained herein or in any other subsequently filed document which
also is or is deemed to be incorporated by reference herein modifies or
supersedes such statement. Any statement or document so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part
of this Prospectus.
As used herein, the terms "Prospectus" and "herein" mean this Prospectus,
including the documents incorporated or deemed to be incorporated herein by
reference, as the same may be amended, supplemented or otherwise modified from
time to time. Statements contained in this Prospectus as to the contents of any
contract or other document referred to are not necessarily complete and in each
instance reference is made to the copy of such contract or other document,
copies of which are available from the Company as described below, each such
statement being qualified in all respects by such reference.
The Company undertakes to provide, without charge, to each person,
including any beneficial owner, to whom a copy of this Prospectus is delivered,
upon written or oral request of such person, a copy of any and all of the
documents or information referred to above that has been or may be incorporated
by reference in this Prospectus (excluding exhibits to such documents unless
such exhibits are specifically incorporated by reference). Requests should be
directed to Maxxim Medical, Inc., 104 Industrial Boulevard, Sugar Land, Texas,
77478, Attn: Chief Operating Officer, telephone (713) 240-5588. In order to
ensure timely delivery of the documents, any request should be made by November
20, 1996.
7
<PAGE>
PROSPECTUS SUMMARY
THE FOLLOWING SUMMARY INFORMATION IS QUALIFIED IN ITS ENTIRETY BY, AND
SHOULD BE READ IN CONJUNCTION WITH, THE MORE DETAILED INFORMATION AND FINANCIAL
DATA INCLUDED ELSEWHERE IN THIS PROSPECTUS, INCLUDING THE FINANCIAL STATEMENTS
AND NOTES THERETO INCORPORATED HEREIN BY REFERENCE. MARKET DATA USED THROUGHOUT
THIS PROSPECTUS WERE OBTAINED OR EXTRAPOLATED FROM INDUSTRY PUBLICATIONS WHICH
THE COMPANY BELIEVES TO BE RELIABLE, BUT THE ACCURACY THEREOF IS NOT GUARANTEED.
AS USED IN THIS PROSPECTUS, UNLESS THE CONTEXT OTHERWISE REQUIRES, THE TERM
"COMPANY" REFERS TO MAXXIM MEDICAL, INC., A TEXAS CORPORATION, TOGETHER WITH
MAXXIM DELAWARE AND ITS DIRECT AND INDIRECT SUBSIDIARIES, TOGETHER WITH ANY
PREDECESSORS. THE ISSUANCE OF THE OLD NOTES AND THE CONSUMMATION OF THE
TRANSACTION CONTEMPLATED IN THE CREDIT AGREEMENT ARE HEREINAFTER SOMETIMES
REFERRED TO AS THE "FINANCING TRANSACTIONS." FOR A DISCUSSION OF CERTAIN MATTERS
THAT SHOULD BE CONSIDERED BY PROSPECTIVE PARTICIPANTS IN THE EXCHANGE OFFER, SEE
"RISK FACTORS."
THE COMPANY
On July 30, 1996, the Company consummated the acquisition (the
"Acquisition") of 98.4% of the issued and outstanding common stock of Sterile
Concepts Holdings, Inc., a Virginia corporation ("Sterile Concepts"), the second
largest supplier of custom procedure trays in the United States, for cash of
approximately $144.7 million, which includes the repayment of $34.2 million of
Sterile Concepts' debt. On September 18, 1996, the Company merged Maxxim
Acquisition with and into Sterile Concepts. The Company's acquisition of Sterile
Concepts has significantly enhanced the Company's position as a major
diversified manufacturer of single-use specialty medical products, and
substantially increased the Company's market share in the custom procedure tray
industry. On a pro forma basis, after giving effect to the Acquisition, the
Company would have had combined sales of $502.3 million, and EBITDA (as defined
herein) of $56.6 million, for the Company's fiscal year ended October 29, 1995.
COMPANY OVERVIEW
The Company is a major manufacturer and developer of a diversified range
of specialty medical products and a leading supplier of single-use, custom
procedure trays and non-latex medical examination gloves to hospitals, clinics
and outpatient surgery centers. The primary business of the Company is the
manufacture and sale of approximately 20,000 single-use specialty medical
products, most of which are used on a daily basis in medical treatment
facilities throughout the world. In addition, upon consummation of the
Acquisition the Company became the second largest supplier of custom procedure
trays in the United States. Custom procedure trays are sterilized kits
containing the single-use products used in surgical or other medical procedures,
and serve as a distribution vehicle for Company-manufactured products. The
custom procedure trays increasingly include Company-manufactured products, which
results in higher margins than inclusion of components purchased from others.
Hospitals and other surgical centers are using more custom procedure trays, in
part because these trays promote efficiency and productivity by consolidating
into a single package the disposable products used in specific medical
procedures, thereby reducing set-up time and lowering inventory levels
maintained by hospitals and clinics. Use of custom procedure trays also reduces
the risks of product contamination and transmission of infectious disease and
allows easier identification of costs associated with specific medical
procedures.
The Company conducts its operations through three divisions. The Case
Management division manufactures, assembles and sells custom procedure trays for
a wide variety of operating room procedures, complete lines of surgical gloves
and medical exam gloves, infection control apparel for operating room personnel,
patient draping systems, and electrosurgical products. The Argon Medical
division manufactures and markets guidewires, needles, introducers, catheters,
manifolds, transducers, high pressure syringes and certain other sterilized
single-use medical and surgical specialty products, which are used in the
Company's procedure trays or are sold separately. This division also assembles
and markets procedure trays for use primarily in cardiology and interventional
radiology procedures. MAXXIM Medical Europe, the Company's third division,
serves as the European manufacturer and distributor of the Company's products.
The Company is currently in the process of integrating Sterile Concepts into its
Case Management Division.
8
<PAGE>
Since its inception, the Company has grown through a series of
acquisitions and development of new products. As a result, the Company has a
diversified product mix, with no single product constituting more than 5% of net
sales. The Company has experienced significant growth since 1991, principally by
successfully integrating six major acquisitions (prior to the Acquisition) into
its existing specialty medical products business.
STERILE CONCEPTS OVERVIEW
Prior to the Acquisition, Sterile Concepts was the second largest producer
of custom procedure trays in the United States, with net sales of $146.8 million
in fiscal 1995. Sterile Concepts assembles, packages and sterilizes custom
procedure trays for hospitals, outpatient surgery centers and medical clinics.
All of the items included in the Sterile Concepts' custom procedure trays are
disposable and include such items as gowns and drapes, sutures, endoscopic
instruments, needles, gloves, tubing, sponges, towels and gauze. Sterile
Concepts' trays are designed to meet individual customer specifications and
range from simple basin sets to complex trays for open heart surgery. As of
September 30, 1995, Sterile Concepts was selling custom procedure trays to
approximately 2,300 individual accounts composed primarily of hospitals and
affiliated outpatient surgery centers.
ACQUISITION STRATEGY
The Company's prior acquisitions have allowed the Company either to expand
its customer base, increase product offerings or achieve further vertical
integration. Management believes that the highly fragmented medical products
industry, in conjunction with recent trends by buyers of medical products to
consolidate supply purchases among fewer suppliers, will continue to provide
strategic acquisition opportunities for the Company. The goal of the Company's
acquisition strategy is to broaden its offering of single-use products into the
surgical suite, and enhance profit margins by including more
Company-manufactured products in its custom procedure trays. Management will
continue to consider acquisitions that complement or expand its product lines.
Management believes that the Acquisition has provided or will provide the
following benefits: (i) increased market share in the custom tray market, (ii)
greater access to national buying groups, (iii) critical mass to compete more
efficiently in the changing healthcare industry, (iv) enhanced ability to
service efficiently a geographically diverse customer base through expanded
nationwide operations, (v) greater efficiencies of scale through improved
facility utilization, enhanced purchasing power and improved logistics, (vi)
improved profit margin through vertical integration, and (vii) a broadened
management team.
INDUSTRY TRENDS
The Company's products compete in the multi-billion dollar market for
specialty medical products. Management believes that demand for products
manufactured and distributed by the Company has been favorably impacted by the
emphasis on less invasive surgical procedures, outpatient care and the
continuing pressure to utilize low-cost, single-use medical products to improve
productivity, contain costs and reduce the transmission of infectious diseases.
Demographic trends, such as the aging of the population, have also had a
favorable effect on the demand for the Company's products since older people
generally require more medical care and undergo more surgical procedures. Many
hospitals and other healthcare providers are forming alliances and purchasing
their medical products on a national accounts basis, which favors suppliers who
can bundle multiple products and supply a large volume and variety of these
products. Management believes that these trends will continue to benefit the
Company as it grows and diversifies its product lines.
Efforts to contain rising healthcare costs have increased the demand for
medical products that improve the productivity of healthcare professionals and
reduce overall provider costs. The ease of set-up and decreased turnaround times
resulting from the use of custom procedure trays are particularly beneficial to
outpatient surgery centers, which typically have limited storage space and fewer
staff members than hospitals. The risks of transmission of infectious diseases
such as AIDS, hepatitis and tuberculosis, and related concerns about the
occupational safety of healthcare professionals, have also contributed to an
increased demand for sterile, single-use products and, consequently, custom
procedure trays. The Company believes that industry sales growth has been
limited by the inability to increase average
9
<PAGE>
unit price as a result of increased price competition and pressure from
hospitals to lower costs. Group buying contracts have also increased pricing
pressure as they have become a more important factor in the hospital's
purchasing decision.
Although the number of surgical procedures performed in Europe is
approximately equivalent to the number of surgical procedures performed in the
U.S., the use of single-use products and custom procedure trays in Europe is not
as prevalent as in the U.S. The Company believes that European healthcare
providers will increase their use of disposable products and custom procedure
trays for substantially the same reasons that caused U.S. healthcare providers
to do so. Certain European countries have implemented healthcare price controls
and experienced consolidation of hospitals and shifting of surgical procedures
away from hospitals towards outpatient surgery centers. The Company believes
that these developments will increase the demand among European healthcare
providers for the greater efficiency and productivity associated with the
single-use products of the type it manufactures.
STRATEGIC OBJECTIVES
The Company's long-term strategic objectives are to (i) improve its
profitability, (ii) reduce its long-term indebtedness, (iii) pursue strategic
acquisitions that promote its vertical integration strategy, or complement its
existing product offering and increase market share, (iv) accelerate the
development of new products that complement existing product lines, (v) expand
international operations, (vi) emphasize the sale of the entire range of the
Company's products to large buying groups and healthcare provider networks, and
(vii) increase productivity by maximizing the utilization of existing
facilities.
RECENT TRANSACTIONS BY THE COMPANY
In July and September, 1996, respectively, the Company completed the
tender offer (the "Tender Offer"), and the merger of Maxxim Acquisition with and
into Sterile Concepts (the "Merger"), pursuant to which the Company acquired all
of the stock of Sterile Concepts for $20.00 per share in cash, in accordance
with the terms of a Plan and Agreement of Merger dated as of June 10, 1996 (the
"Merger Agreement"). The total amount of funds required to complete the
Acquisition and pay related fees and expenses, was approximately $127.3 million.
In connection with the closing of the Tender Offer, the Company also refinanced
existing Maxxim Delaware debt of approximately $72.6 million and Sterile
Concepts debt of approximately $34.2 million. Funds for the Acquisition and such
debt repayment consisted of (i) cash on hand, (ii) net proceeds from the Prior
Offering, and (iii) approximately $127.3 million of borrowings under a $165
million Credit Agreement (the "Credit Agreement") between Maxxim and NationsBank
of Texas, N.A. ("NationsBank"), an affiliate of NationsBanc Capital Markets,
Inc. ("NCMI"), one of the Initial Purchasers. See "Available Information;"
"Incorporation of Certain Documents by Reference;" "Description of Certain
Indebtedness -- Credit Agreement."
THE PRIOR OFFERING
The outstanding $100.0 million principal amount of Old Notes were sold by
the Company to the Initial Purchasers on the Closing Date pursuant to the
Purchase Agreement among the Company and the Initial Purchasers. The Initial
Purchasers subsequently resold the Old Notes in reliance on Rule 144A under the
Securities Act. The Company and the Initial Purchasers also entered into the
Registration Rights Agreement pursuant to which the Company granted certain
registration rights for the benefit of the holders of the Old Notes. The
Exchange Offer is intended to satisfy certain of the Company's obligations under
the Registration Rights Agreement with respect to the Old Notes. See "The
Exchange Offer" and "The Exchange Offer - Purpose and Effect."
10
<PAGE>
THE EXCHANGE OFFER
The Exchange Offer....... The Company is offering upon the terms and subject
to the conditions set forth herein and in the
accompanying letter of transmittal (the "Letter of
Transmittal"), to exchange $1,000 in principal
amount of its 10-1/2% Senior Subordinated Notes
due 2006 (the "New Notes," with the Old Notes and
the New Notes collectively referred to herein as
the "Notes") for each $1,000 in principal amount
of the outstanding Old Notes (the "Exchange
Offer"). As of the date of this Prospectus, $100.0
million in aggregate principal amount of the Old
Notes is outstanding, the maximum amount
authorized by the Indenture for all Notes. As of
October 15, 1996, there was one registered holder
of the Old Notes, Cede & Co. ("Cede"), which held
the Old Notes for twenty-two (22) of its
participants. See the "Exchange Offer - Terms of
the Exchange Offer."
Expiration Date.......... 5:00 p.m., New York City time, on November 25,
1996 as the same may be extended. See "The
Exchange Offer - Expiration Date; Extensions;
Amendments."
Conditions of the
Exchange Offer........... The Exchange Offer is not conditioned upon any
minimum principal amount of Old Notes being
tendered for exchange. The only condition to the
Exchange Offer is the declaration by the
Commission of the effectiveness of the
Registration Statement of which this Prospectus
constitutes a part. See "The Exchange Offer -
Conditions of the Exchange Offer."
Termination of Certain
Rights................... Pursuant to the Registration Rights Agreement,
holders of Old Notes (i) have rights to receive
Liquidated Damages and (ii) have certain rights
intended for the holders of unregistered
securities. "Liquidated Damages" means damages of
$0.05 per week per $1,000 principal amount of Old
Notes (up to a maximum of $0.30 per week per
$1,000 principal amount) during the period in
which a Registration Default is continuing
pursuant to the terms of the Registration Rights
Agreement. Holders of New Notes will not be and,
upon consummation of the Exchange Offer, holders
of Old Notes will no longer be, entitled to (i)
the right to receive the Liquidated Damages or
(ii) certain other rights under the Registration
Rights Agreement intended for holders of
unregistered securities. See "The Exchange Offer -
Termination of Certain Rights" and "Procedures for
Tendering Old Notes."
11
<PAGE>
Accrued Interest......... The New Notes will bear interest at a rate equal
to 10- 1/2% per annum. Interest accrues from July
30, 1996 or from the most recent Interest Payment
Date with respect to the Old Notes to which
interest was paid or duly provided for. See
"Description of Notes - Principal, Maturity and
Interest."
Procedures for Tendering
Old Notes................ Unless a tender of Old Notes is effected pursuant
to the procedures for book-entry transfer as
provided herein, each holder desiring to accept
the Exchange Offer must complete and sign the
Letter of Transmittal, have the signature thereon
guaranteed if required by the Letter of
Transmittal, and mail or deliver the Letter of
Transmittal, together with the Old Notes or a
Notice of Guaranteed Delivery and any other
required documents (such as evidence of authority
to act, if the Letter of Transmittal is signed by
someone acting in a fiduciary or representative
capacity), to the Exchange Agent (as defined) at
the address set forth on the back cover page of
this Prospectus prior to 5:00 p.m., New York City
time, on the Expiration Date. Any Beneficial Owner
(as defined) of the Old Notes whose Old Notes are
registered in the name of the nominee, such as a
broker, dealer, commercial bank or trust company
and who wishes to tender Old Notes in the Exchange
Offer, should instruct such entity or person to
promptly tender on such Beneficial Owner's behalf.
See "The Exchange Offer - Procedures for Tendering
Old Notes."
Guaranteed Delivery
Procedures............... Holders of Old Notes who wish to tender their Old
Notes and (i) whose Old Notes are not immediately
available or (ii) who cannot deliver their Old
Notes or any other documents required by the
Letter of Transmittal to the Exchange Agent prior
to the Expiration Date (or complete the procedure
for book- entry transfer on a timely basis), may
tender their Old Notes according to the guaranteed
delivery procedures set forth in the Letter of
Transmittal. See "The Exchange Offer - Guaranteed
Delivery Procedures."
Acceptance of Old Notes
and Delivery of New
Notes.................... Upon effectiveness of the Registration Statement
of which this Prospectus constitutes a part and
consummation of the Exchange Offer, the Company
will accept any and all Old Notes that are
properly tendered in the Exchange Offer prior to
5:00 p.m., New York City time, on the Expiration
Date. The New Notes issued pursuant to the
Exchange Offer will be delivered promptly after
acceptance of the Old Notes. See "The Exchange
Offer - Acceptance of Old Notes for Exchange;
Delivery of New Notes.
12
<PAGE>
Withdrawal Rights........ Tenders of Old Notes may be withdrawn at any time
prior to 5:00 p.m., New York City time, on the
Expiration Date. See "The Exchange Offer -
Withdrawal Rights."
The Exchange Agent....... First Union National Bank of North Carolina is the
exchange agent (in such capacity, the "Exchange
Agent"). The address and telephone number of the
Exchange Agent are set forth in "The Exchange
Offer - The Exchange Agent; Assistance."
Fees and Expenses........ All expenses incident to the Company's
consummation of the Exchange Offer and compliance
with the Registration Rights Agreement will be
borne by the Company. The Company will also pay
certain transfer taxes applicable to the Exchange
Offer. See "The Exchange Offer - Fees and
Expenses."
Resales of the New Notes. Based on existing interpretations by the staff of
the Commission set forth in no-action letters
issued to third parties, the Company believes that
New Notes issued pursuant to the Exchange Offer to
a holder in exchange for Old Notes may be offered
for resale, resold and otherwise transferred by a
holder (other than (i) a broker-dealer who
purchased the Old Notes directly from the Company
for resale pursuant to Rule 144A under the
Securities Act or any other available exemption
under the Securities Act or (ii) a person that is
an affiliate of the Company within the meaning of
Rule 405 under the Securities Act), without
compliance with the registration and prospectus
delivery provisions of the Securities Act,
provided that such holder is acquiring the New
Notes in the ordinary course of business and is
not participating, and has no arrangement or
understanding with any person to participate, in a
distribution of the New Notes. Each broker-dealer
that receives New Notes for its own account in
exchange for Old Notes, where such Old Notes were
acquired by such broker as a result of
market-making or other trading activities, must
acknowledge that it will deliver a prospectus in
connection with any resale of such New Notes. See
"The Exchange Offer - Resales of the New Notes"
and "Plan of Distribution."
Effect of Not Tendering
Old Notes for Exchange... Old Notes that are not tendered or that are not
properly tendered will, following the expiration
of the Exchange Offer, continue to be subject to
the existing restrictions upon transfer thereof.
The Company will have no further obligations to
provide for the registration under the Securities
Act of such Old Notes and such Old Notes will,
following the expiration of the Exchange Offer,
bear interest at the same rate as the New Notes.
13
<PAGE>
DESCRIPTION OF NEW NOTES
The form and terms of the New Notes will be identical in all material
respects to the form and terms of the Old Notes, except that (i) the New Notes
have been registered under the Securities Act and, therefore, will not bear
legends restricting the transfer thereof, (ii) holders of New Notes will not be
entitled to Liquidated Damages, and (iii) holders of New Notes will not be, and
upon the consummation of the Exchange Offer, holders of Old Notes will no longer
be, entitled to certain rights under the Registration Rights Agreement intended
for the holders of unregistered securities. The Exchange Offer shall be deemed
consummated upon the occurrence of the delivery by the Company to the Registrar
under the Indenture of New Notes in the same aggregate principal amount as the
aggregate principal amount of Old Notes that are validly tendered by holders
thereof pursuant to the Exchange Offer. See "The Exchange Offer - Termination of
Certain Rights" and "-Procedures for Tendering Old Notes" and "Description of
Notes."
<TABLE>
<S> <C>
Securities Offered............ $100 million aggregate principal amount of 10-1/2%
Senior Subordinated Notes Due 2006.
Maturity Date................. August 1, 2006.
Interest Payment Dates........ February 1 and August 1, commencing February 1,
1997.
Note Guarantees............... The Notes will be unconditionally guaranteed on a
senior subordinated basis by each of the existing
subsidiaries of Maxxim and, subject to certain
exceptions, each of the future subsidiaries of Maxxim.
Each of the Note Guarantees (as defined herein) will be
a guarantee of payment and not of collection. Non-U.S.
subsidiaries of Maxxim properly designated by the
Company as Unrestricted Subsidiaries (as defined
herein) will not guarantee the Notes. See "Description
of Notes -- Note Guarantees."
Subordination................. The Notes will be general unsecured obligations of the
Company, subordinated in right of payment to all
existing and future Senior Indebtedness of the
Company, which will include borrowings under the
Credit Agreement. At September 24, 1996, the
Company had $127.3 million of outstanding Senior
Indebtedness, which ranked senior in right of payment
to the Notes. The Note Guarantees will be subordinated
in right of payment to all existing and future Senior
Indebtedness of the relevant Guarantor. The Indenture
permits Maxxim and its subsidiaries to incur additional
indebtedness, including additional Senior Indebtedness,
subject to certain limitations. See "Description of the
Notes -- Subordination;" and " -- Subordination of Note
Guarantees; Release of Note Guarantees."
Optional Redemption........... On or after August 1, 2001, the Company may redeem
the Notes, in whole or in part, at the redemption prices
set forth herein, plus accrued and unpaid interest, if
any, to the date of redemption. See "Description of
Notes -- Optional Redemption."
</TABLE>
14
<PAGE>
<TABLE>
<S> <C>
Mandatory Redemption.......... None, except at maturity on August 1, 2006.
Change of Control............. Upon a Change of Control (as defined herein), the
Company will be required to make an offer to
repurchase all outstanding Notes at 101% of the
principal amount thereof plus accrued and unpaid
interest thereon to the date of repurchase. See
"Description of Notes -- Repurchase at Option of
Holders."
Covenants..................... The Indenture restricts, among other things, the
Company's ability to incur additional indebtedness, pay
dividends or make certain other restricted payments,
incur liens to secure PARI PASSU or subordinated
indebtedness, sell stock of subsidiaries, apply net
proceeds from certain asset sales, merge or consolidate
with any other person, sell, assign, transfer, lease,
convey or otherwise dispose of substantially all of the
assets of the Company, enter into certain transactions
with affiliates, or incur indebtedness that is subordinate
in right of payment to any Senior Indebtedness and
senior in right of payment to the Notes. Under certain
circumstances, the Company may designate non-U.S.
subsidiaries as Unrestricted Subsidiaries and thus not
subject to the restrictions of the Indenture. See
"Description of Notes -- Certain Covenants."
Absence of a Public Market
for the New Notes............ The New Notes are a new issue of securities with no
established market. Accordingly, there can be no
assurance as to the development or liquidity of any
market for the New Notes. The Initial Purchasers have
advised the Company that they currently intend to
make a market in the New Notes. However, the Initial
Purchasers are not obligated to do so, and any market
making with respect to the New Notes may be
discontinued at any time without notice. The Company
does not intend to apply for listing of the New Notes on
a securities exchange.
</TABLE>
RISK FACTORS
For a discussion of certain matters that should be considered by
prospective investors in connection with the Exchange Offer, see "Risk Factors."
15
<PAGE>
RISK FACTORS
In addition to the other information contained in this Prospectus, holders
of Notes should carefully consider the following risk factors affecting the
business of the Company.
SIGNIFICANT LEVERAGE AND DEBT SERVICE
Upon consummation of the Acquisition, the Merger and the Financing
Transactions, the Company became highly leveraged. At September 24, 1996, the
Company had total consolidated outstanding debt (including current maturities)
of approximately $256.1 million. In addition, subject to the restrictions in the
Credit Agreement and the Indenture, the Company and its subsidiaries may incur
additional indebtedness (including additional Senior Indebtedness) from time to
time to finance acquisitions or capital expenditures or for general corporate
purposes. At September 24, 1996, the Company had unused borrowing capacity of up
to approximately $37.7 million under the revolving portion of the Credit
Agreement.
The level of the Company's indebtedness could have important consequences
to holders of the Notes, including: (i) a substantial portion of the Company's
cash flow from operations must be dedicated to debt service and will not be
available for other purposes; (ii) the Company's ability to obtain additional
debt financing in the future for other acquisitions, working capital, capital
expenditures or research and development may be limited; and (iii) the Company's
level of indebtedness could limit its flexibility in reacting to changes in its
industry or economic conditions generally.
The Company's ability to pay interest on the Notes and to satisfy its
other debt obligations will depend upon its future operating performance, which
will be affected by prevailing economic conditions and financial, business and
other factors, certain of which are beyond its control, as well as the
availability of borrowings under the Credit Agreement or successor credit
facilities. The Company will require substantial amounts of cash to fund
scheduled payments of principal and interest on its outstanding indebtedness as
well as future capital expenditures and any increased working capital
requirements. If the Company is unable to meet its cash requirements out of cash
flow from operations and its available borrowings, there can be no assurance
that it will be able to obtain alternative financing or that it will be
permitted to do so under the terms of the Credit Agreement or other debt
instruments. In the absence of such financing, the Company's ability to respond
to changing business and economic conditions, to make future acquisitions, to
absorb adverse operating results or to fund capital expenditures or research and
development may be adversely affected. In addition, actions taken by the lending
banks under the Credit Agreement are not subject to approval by the holders of
the Notes. Finally, it is anticipated that in order to pay the principal balance
of the Notes due at maturity, the Company will have to obtain alternative
financing.
SUBORDINATION OF NOTES AND NOTE GUARANTEES; HOLDING COMPANY STRUCTURE
The Notes will be subordinated in right of payment to all existing and
future Senior Indebtedness of the Company, including borrowings under the Credit
Agreement. In the event of bankruptcy, liquidation or reorganization of the
Company, the assets of the Company will be available to pay obligations on the
Notes only after all Senior Indebtedness has been paid in full, and there may
not be sufficient assets remaining to pay amounts due on any or all of the Notes
then outstanding. Each Note Guarantee is similarly subordinated in right of
payment to all existing and future Senior Indebtedness of the relevant
Guarantor, including such Guarantor's guaranty of the Company's indebtedness
under the Credit Agreement. In addition, under certain circumstances the Company
will not be permitted to pay its obligations under the Notes in the event of a
default under certain Senior Indebtedness. The aggregate principal amount of
outstanding Senior Indebtedness of the Company, as of September 24, 1996, was
approximately $127.3 million. Additional Senior Indebtedness may be incurred by
the Company from time to time, subject to certain restrictions. If the Company
is unable to satisfy all or any portion of its obligations with respect to the
Notes, it is unlikely that the Guarantors will be able, or will be permitted by
the terms of the Credit Agreement, to pay all or any portion of such unsatisfied
obligations. See "Description of Notes -- Subordination"; "-- Subordination of
Note Guarantees; Release of Note Guarantees."
16
<PAGE>
The Company is a holding company whose material assets consist primarily
of the capital stock of the Guarantors. Consequently, the Company is dependent
upon dividends paid by the Guarantors to pay its operating expenses, service its
debt obligations, including the Notes, and satisfy any mandatory repurchase
obligations relating to the Notes, as a result of a Change of Control or a sale
or other disposition of certain assets. See "Description of Certain
Indebtedness" and "Description of Notes."
ABILITY TO SUCCESSFULLY INTEGRATE STERILE CONCEPTS
The integration and consolidation of Sterile Concepts into the Company
will require substantial management, financial and other resources and may pose
risks with respect to production, customer service and market share. While the
Company believes that it has sufficient financial and management resources to
accomplish the integration of Sterile Concepts, there can be no assurance in
this regard that the Company will not experience difficulties with customers,
personnel or others. In addition, although the Company's management believes
that the Acquisition has enhanced and will enhance the competitive position and
business prospects of the Company, there can be no assurance that such benefits
will be realized or that the combination of the Company and Sterile Concepts
will be successful.
As the Company adapts to the current healthcare environment and integrates
Sterile Concepts, it will make certain operational changes, including the
consolidation of operations, designed to improve the future profitability of the
Company. There can be no assurance, however, as to the timing or amount of any
cost savings that are actually realized as a result of such operational changes.
These operational changes may also result in significant disruption to the
Company's operations, which could have a material adverse effect on the
Company's business. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations."
RESTRICTIONS IMPOSED BY TERMS OF THE COMPANY'S INDEBTEDNESS
The Indenture restricts, among other things, the ability of the Company
and its subsidiaries to incur additional indebtedness, pay dividends or make
certain other restricted payments, incur liens to secure PARI PASSU or
subordinated indebtedness, sell stock of subsidiaries, apply net proceeds from
certain asset sales, merge or consolidate with any other person, sell, assign,
transfer, lease, convey or otherwise dispose of substantially all of the assets
of the Company, enter into certain transactions with affiliates, or incur
indebtedness that is subordinate in right of payment to any Senior Indebtedness
and senior in right of payment to the Notes. In addition, the Credit Agreement
contains other and more restrictive covenants and prohibits the Company from
prepaying other indebtedness (including the Notes) before Senior Indebtedness.
As a result of these covenants, the ability of the Company to respond to
changing business and economic conditions and to secure additional financing, if
needed, may be significantly restricted, and the Company may be prevented from
engaging in transactions that might otherwise be considered beneficial to the
Company. See "Description of Notes -- Certain Covenants" and "Description of
Certain Indebtedness -- Credit Agreement."
The Credit Agreement contains more extensive and restrictive covenants and
restrictions than the Indenture, and requires the Company to maintain specified
financial ratios and satisfy certain financial condition tests. The Company's
ability to meet those financial ratios and tests can be affected by events
beyond its control, and there can be no assurance that the Company will meet
those tests. A breach of any of these covenants could result in a default under
the Credit Agreement. Upon the occurrence of an event of default under the
Credit Agreement, the lenders thereunder could elect to declare all amounts
outstanding under the Credit Agreement, including accrued interest or other
obligations, to be immediately due and payable. If the Company were unable to
repay those amounts, such lenders could proceed against the collateral granted
to them to secure that indebtedness. If any Senior Indebtedness were to be
accelerated, there can be no assurance that the assets of the Company would be
sufficient to repay in full that indebtedness and the other indebtedness of the
Company, including the Notes. One hundred percent of the capital stock of the
Company's domestic subsidiaries and 65% of the capital stock of certain foreign
subsidiaries of the Company have been pledged as security under the Credit
Agreement. See "Description of Certain Indebtedness -- Credit Agreement."
17
<PAGE>
FRAUDULENT CONVEYANCE STATUTES
Under applicable provisions of federal bankruptcy law or comparable
provisions of state fraudulent transfer law, if, among other things, the Company
or any Guarantor, at the time it incurred the indebtedness evidenced by the
Notes or its Note Guarantee, (i)(a) was or is insolvent or rendered insolvent by
reason of such occurrence or (b) was or is engaged in a business or transaction
for which the assets remaining with the Company or such Guarantor constituted
unreasonably small capital or (c) intended or intends to incur, or believed or
believes that it would incur, debts beyond its ability to pay such debts as they
mature, and (ii) the Company or such Guarantor received or receives less than
reasonably equivalent value or fair consideration for the incurrence of such
indebtedness, the Notes and the Note Guarantee, and any pledge or other security
interest securing such indebtedness, could be voided, or claims in respect of
the Notes or the Note Guarantees could be subordinated to all other debts of the
Company or such Guarantor, as the case may be. The voiding or subordination of
any of such pledges or other security interests or of any of such indebtedness
could result in an Event of Default (as defined in the Indenture) with respect
to such indebtedness, which could result in acceleration thereof. In addition,
the payment of interest and principal by the Company pursuant to the Notes or
the payment of amounts by a Guarantor pursuant to a Note Guarantee could be
voided and required to be returned to the person making such payment, or to a
fund for the benefit of the creditors of the Company or such Guarantor, as the
case may be.
The measures of insolvency for purposes of the foregoing considerations
will vary depending upon the law applied in any proceeding with respect to the
foregoing. Generally, however, the Company or a Guarantor would be considered
insolvent if (i) the sum of its debts, including contingent liabilities, were
greater than the fair saleable value of all of its assets at a fair valuation or
if the present fair saleable value of its assets were less than the amount that
would be required to pay its probable liability on its existing debts, including
contingent liabilities, as they become absolute and mature or (ii) it could not
pay its debts as they become due.
On the basis of their historical financial information, recent operating
history as discussed in "Selected Consolidated Financial Information" and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" and other factors, the Company and each Guarantor believes that,
after giving effect to the indebtedness evidenced by the Notes, it (i) will not
be insolvent, will not have unreasonably small capital for the businesses in
which it is engaged and will not incur debts beyond its ability to pay such
debts as they mature and (ii) will have sufficient assets to satisfy any
probable money judgment against it in any pending action. There can be no
assurance, however, as to what standard a court would apply in making such
determinations. In addition, a Note Guarantee given by a Subsidiary of the
Company incorporated outside the United States might not be enforceable under
the laws of the jurisdiction of incorporation.
FUTURE ACQUISITIONS
The Company's growth has been primarily the result of acquisitions. The
Company is continually reviewing possible acquisitions of businesses or product
lines that are complementary to the Company's existing business or product
lines, such as the Acquisition. There can be no assurance that suitable
acquisition candidates will be found, or that financing for any such future
acquisitions will be obtainable or permitted by the Credit Agreement. In
addition, the terms of the Credit Agreement and the Indenture restrict the
Company's ability to pursue and consummate additional acquisitions. The
inability of the Company to find or consummate suitable acquisitions in the
future would impede future growth. Furthermore, even if the Company is able to
complete such acquisitions, there can be no assurance that the acquired
companies or assets will be successfully integrated into the Company. Any such
failure to integrate successfully future acquisitions may adversely impact
operations or profitability. See "Risk Factors -- Restrictions Imposed by Terms
of the Company's Indebtedness."
18
<PAGE>
DEPENDENCE ON KEY PERSONNEL
The Company believes that its continued success will depend to a
significant extent upon the efforts and abilities of its senior management team,
including Kenneth W. Davidson, its Chairman of the Board, President and Chief
Executive Officer, and its other executive officers. Mr. Davidson has entered
into an employment agreement with the Company that requires him to serve as
President of the Company on a full-time basis through October 31, 1997. The
Company has not entered into employment agreements with any of its other
executive officers. Failure of the Company to retain Mr. Davidson or other
executive officers, or to attract and retain additional qualified personnel,
could adversely affect the Company's operations.
PRODUCT LIABILITY EXPOSURE
The manufacturing and marketing of the Company's products entail risks of
product liability. Although the Company maintains liability insurance in amounts
which it believes to be reasonable and standard in the industry, the amount and
scope of any coverage may be inadequate to fully protect the Company in the
event of a substantial adverse product liability judgment.
Since March 1996 the Company has been served with various lawsuits
alleging various adverse reactions to the latex used in certain of the medical
gloves alleged to have been manufactured by the Company or the prior owner of
the assets relating to the Company's Glove Operations acquired in June 1995. The
Company believes that most, if not all, of such claims relate to gloves produced
and sold prior to June 1995, and that such prior owner will be obligated to
indemnify the Company with respect to most, if not all, of these liabilities.
The Company is aware that there have been an increasing number of lawsuits
brought against latex glove manufacturers with respect to such allergic
reactions. The Company, like its competitors, has continued to manufacture and
sell latex gloves subsequent to acquisition of the Glove Operations. Therefore,
it is anticipated that there may in the future be claims brought against the
Company with respect to latex gloves manufactured by the Company. The Company
may have future material liability in lawsuits relating to allergic reactions to
latex.
COMPETITION AND TECHNOLOGICAL CHANGE
The Company's products compete with those of numerous other companies
engaged in the businesses of developing, manufacturing and distributing
specialty medical products. Several of these competitors have more extensive
financial resources, research and development facilities and marketing
organizations than those of the Company. In addition, the Company believes that
the barriers to entry into the custom procedure tray business are fairly low and
it would be reasonably easy for medical products companies currently not in the
custom procedure tray business or others to enter the business. This is because
the business is not very capital or technology intensive, to the extent a
supplier of trays does not manufacture specialty medical products. Custom
procedure trays originated when medical product manufacturers bundled together
several products in sterile packaging as an alternative to the in-hospital
preparation of those same components. There are currently many manufacturers
that bundle sterile and non-sterile medical specialty products that may not
technically be "custom procedure trays" but effectively compete with trays or
could be bundled with other products so as to directly compete with the
Company's custom procedure trays. There are also numerous companies that supply
medical procedure trays to various niche markets (e.g. dental and eye) that
could, in the Company's view, easily broaden their product lines. In addition,
certain of the Company's specialty medical products compete in markets
characterized in many respects by rapid and significant technological change.
Although the Company continuously pursues product research and development
efforts, there can be no assurance that technological change will not render one
or more of the Company's present or proposed products obsolete.
GOVERNMENT REGULATION
The manufacturing and marketing of the Company's products are subject to
regulation by the U.S. Food and Drug Administration (the "FDA") pursuant to the
U.S. Food, Drug and Cosmetic Act and regulations promulgated
19
<PAGE>
thereunder (collectively the "FDA Act") and numerous other federal, state and
foreign governmental authorities. Although the Company has obtained all
necessary clearances for the manufacture and sale of all of the products that
the Company currently produces and sells, any products developed in the future
are likely to require FDA approval before they can be sold in the U.S. To date,
all FDA approvals of the Company's products have been obtained under Section
510(k) of the FDA Act, which provides for FDA marketing approval on an expedited
basis for products that can be shown to be substantially equivalent to devices
in interstate commerce prior to May 1976 (the month and year of enactment of the
FDA Act). The Company anticipates that virtually all of the products currently
being developed will qualify for marketing approval under Section 510(k);
however, if marketing approval for any product cannot be obtained under Section
510(k), alternative approval procedures are likely to be costly and time
consuming and there can be no assurance that the required approvals for
marketing any newly developed products will be obtained. Even if granted, all
products and manufacturing facilities are subject to continual review and
periodic inspections by various governmental authorities, and the discovery of
previously unknown problems with a product, the Company or its facilities may
result in product labeling restrictions, recall or withdrawal of the products
from the market.
HEALTHCARE REFORM
In recent years, there have been a number of government initiatives to
reduce healthcare costs. Congress and various state legislatures have proposed
changes in law and regulation that could effect a major restructuring of the
healthcare industry. Changes in governmental support of healthcare services, the
methods by which such services are delivered, the prices for such services, or
other legislation or regulations governing such services or mandated benefits
may have a material adverse effect on the Company's results of operations.
POTENTIAL INABILITY TO FUND A CHANGE OF CONTROL OFFER
Upon a Change of Control as defined in the Indenture, the Company is
required to offer to repurchase all outstanding Notes at 101% of the principal
amount thereof plus accrued and unpaid interest to the date of repurchase.
However, there can be no assurance that sufficient funds will be available at
the time of any Change of Control to make any required repurchases of Notes
tendered, or that restrictions in the Credit Agreement will allow the Company to
make such required repurchases. Notwithstanding these provisions, the Company
could enter into certain transactions, including certain recapitalizations, that
would not constitute a Change of Control but would increase the amount of debt
outstanding at such time. See "Description of Notes -- Repurchase at Option of
Holders."
ABSENCE OF PUBLIC MARKET
The New Notes are a new issue of securities, have no established trading
market and may not be widely distributed. The Company does not intend to list
the New Notes on any national securities exchange or to seek admission thereof
to trading in the National Association of Securities Dealers Automation
Quotation system. The Initial Purchasers have advised the Company that they
currently intend to make a market in the New Notes; however, the Initial
Purchasers are not obligated to do so and any market making activities may be
discontinued at any time without notice. In addition, such market making
activity will be subject to the limitations imposed by the Securities Act and
the Exchange Act, and may be limited during the Exchange Offer and, if required,
the pendency of the Shelf Registration Statement (as defined below). No
assurance can be given that an active public or other market will develop for
the New Notes or as to the liquidity of or trading market for the New Notes. If
a trading market does not develop or is not maintained, holders of the New Notes
may experience difficulty in reselling the New Notes or may be unable to sell
them at all. If a market for the New Notes develops, any such market may be
discontinued at any time. If a public trading market develops for the New Notes,
future trading prices of the New Notes will depend on many factors, including,
among other things, prevailing interest rates, the Company's results of
operations and the market for similar securities. Depending on prevailing
interest rates, the market for similar securities and other facts, including the
financial condition of the Company, the New Notes may trade at a discount from
their principal amount.
20
<PAGE>
CONSEQUENCES OF FAILURE TO EXCHANGE
Holders of Old Notes who do not exchange their Old Notes for New Notes
pursuant to the Exchange Offer will continue to be subject to the restrictions
on transfer of such Old Notes as set forth in the legend thereon as a
consequence of the issuance of the Old Notes pursuant to exemptions from, or in
transactions not subject to, the registration requirements of the Securities Act
and applicable state securities laws. In general, the Old Notes may not be
offered or sold, unless registered under the Securities Act, except pursuant to
an exemption from, or in a transaction not subject to, the Securities Act and
applicable state securities laws. The Company does not currently anticipate that
it will register the Old Notes under the Securities Act. To the extent that Old
Notes are tendered and accepted in the Exchange Offer, the trading market for
untendered and tendered but unaccepted Old Notes could be adversely affected.
21
<PAGE>
THE EXCHANGE OFFER
The summary herein of certain provisions of the Registration Rights
Agreement does not purport to be complete and reference is made to the
provisions of the Registration Rights Agreement, which has been filed as an
exhibit to the Registration Statement and a copy of which is available upon
request to the Trustee.
PURPOSE AND EFFECT
The Old Notes were sold by the Company to the Initial Purchasers on July
30, 1996, pursuant to the Purchase Agreement. The Initial Purchasers
subsequently resold the Old Notes in reliance on Rule 144A under the Securities
Act. The Company and the Initial Purchasers also entered into the Registration
Rights Agreement, pursuant to which the Company agreed, with respect to the Old
Notes and subject to the Company's determination that the Exchange Offer is
permitted under applicable law, to (i) cause to be filed, on or prior to October
1, 1996, a registration statement with the Commission under the Securities Act
concerning the Exchange Offer, (ii) use its best efforts (a) to cause such
registration statement to be declared effective by the Commission on or prior to
November 15, 1996, and (b) to consummate the Exchange Offer on or prior to
December 15, 1996. The Company will keep the Exchange Offer open for a period of
not less than 30 days and not more than 45 days (or longer if required by
applicable law) after the date the notice of the Exchange Offer is mailed to the
holders of the Old Notes. This Exchange Offer is intended to satisfy the
Company's exchange offer obligations under the Registration Rights Agreement.
CONSEQUENCES OF FAILURE TO EXCHANGE OLD NOTES
Following the expiration of the Exchange Offer, holders of Old Notes not
tendered, or not properly tendered will not have any further registration rights
and such Old Notes will continue to be subject to the existing restrictions on
transfer thereof. Accordingly, the liquidity of the market for a holder's Old
Notes could be adversely affected upon expiration of the Exchange Offer if such
holder elects to not participate in the Exchange Offer.
TERMS OF THE EXCHANGE OFFER
The Company hereby offers, upon the terms and subject to the conditions
set forth herein and in the accompanying Letter of Transmittal, to exchange
$1,000 in principal amount of the New Notes for each $1,000 in principal amount
of the outstanding Old Notes. The Company will accept for exchange any and all
Old Notes that are validly tendered on or prior to 5:00 p.m., New York City
time, on the Expiration Date. Tenders of the Old Notes may be withdrawn at any
time prior to 5:00 p.m., New York City time, on the Expiration Date. The
Exchange Offer is not conditioned upon any minimum principal amount of Old Notes
being tendered for exchange. However, the Exchange Offer is subject to the terms
and provisions of the Registration Rights Agreement. See "The Exchange
Offer--Conditions of the Exchange Offer."
Old Notes may be tendered only in multiples of $1,000. Subject to the
foregoing, holders of Old Notes may tender less than the aggregate principal
amount represented by the Old Notes held by them, provided that they
appropriately indicate this fact on the Letter of Transmittal accompanying the
tendered Old Notes (or so indicate pursuant to the procedures for book-entry
transfer).
As of the date of this Prospectus, $100 million in aggregate principal
amount of the Old Notes is outstanding, the maximum amount authorized by the
Indenture for all Notes. As of October 15, 1996, there was one registered
holder of the Old Notes, Cede, which held the Old Notes for twenty-two (22) of
its participants. Solely for reasons of administration (and for no other
purpose), the Company has fixed the close of business on Tuesday, October 15,
1996, as the record date (the "Record Date") for purposes of determining the
persons to whom this Prospectus and the Letter of Transmittal will be mailed
initially. Only a holder of the Old Notes (or such holder's legal representative
or attorney-in-fact) may participate in the Exchange Offer. There will be no
fixed record date for determining holders
22
<PAGE>
the Old Notes entitled to participate in the Exchange Offer. The Company
believes that, as of the date of this Prospectus, no such holder is an affiliate
(as defined in Rule 405 under the Securities Act) of the Company.
The Company shall be deemed to have accepted validly tendered Old Notes
when, as and if the Company has given oral or written notice thereof to the
Exchange Agent. The Exchange Agent will act as agent for the tendering holders
of Old Notes and for the purposes of receiving the New Notes from the Company.
If any tendered Old Notes are not accepted for exchange because of an
invalid tender, the occurrence of certain other events set forth herein or
otherwise, certificates for any such unaccepted Old Notes will be returned,
without expense, to the tendering holder thereof as promptly as practicable
after the Expiration Date.
EXPIRATION DATE; EXTENSIONS; AMENDMENTS
The Expiration Date shall be November 25, 1996 at 5:00 p.m., New York City
time, unless the Company, in its sole discretion, extends the Exchange Offer, in
which case the Expiration Date shall be the latest date and time to which the
Exchange Offer is extended.
In order to extend the Exchange Offer, the Company will notify the
Exchange Agent of any extension by oral or written notice and will make a public
announcement thereof, each prior to 9:00 a.m., New York City time, on the next
business day after the previously scheduled Expiration Date.
The Company reserves the right, in its sole discretion, (i) to delay
accepting any Old Notes, (ii) to extend the Exchange Offer, in which event the
term "Expiration Date" shall mean the latest time and date to which the Exchange
Offer is extended, and (iii) to amend the terms of the Exchange Offer in any
manner. If the Exchange Offer is amended in a manner determined by the Company
to constitute a material change, the Company will promptly disclose such
amendments by means of a prospectus supplement that will be distributed to the
registered holders of the Old Notes. Modifications of the Exchange Offer,
including but not limited to extension of the period during which the Exchange
Offer is open, may require that at least five business days remain in the
Exchange Offer. In order to extend the Exchange Offer, the Company will notify
the Exchange Agent of any extension by oral or written notice and will make a
public announcement thereof, each prior to 9:00 a.m., New York City time, on the
next business day after the previously scheduled Expiration Date.
CONDITIONS OF THE EXCHANGE OFFER
The Exchange Offer is not conditioned upon any minimum principal amount of
the Old Notes being tendered for exchange. However, the Exchange Offer is
conditioned upon the declaration by the Commission of the effectiveness of the
Registration Statement of which this Prospectus constitutes a part.
TERMINATION OF CERTAIN RIGHTS
The Registration Rights Agreement provides that, subject to certain
exceptions, in the event of a Registration Default (as defined below), holders
of Old Notes are entitled to receive Liquidated Damages of $0.05 per week per
$1,000 principal amount of Old Notes held by such holders (up to a maximum n of
$0.30 per week per $1,000 principal amount of Old Notes). A "Registration
Default" with respect to the Exchange Offer shall occur if: (i) the Company
fails to consummate the Exchange Offer on or prior to December 15, 1996, or (ii)
the Shelf Registration Statement or the Exchange Offer Registration Statement is
declared effective but thereafter ceases to be effective during the period
specified in the Registration Rights Agreement. Holders of New Notes will not be
and, upon consummation of the Exchange Offer, holders of Old Notes will no
longer be, entitled to (i) the right to receive the Liquidated Damages or (ii)
certain other rights under the Registration Rights Agreement intended for
holders of Old Notes. The Exchange Offer shall be deemed consummated upon the
occurrence of the delivery by the Company to the Registrar under the Indenture
23
<PAGE>
of New Notes in the same aggregate principal amount as the aggregate principal
amount of Old Notes that are tendered by holders thereof pursuant to the
Exchange Offer.
ACCRUED INTEREST
The New Notes will bear interest at a rate equal to 10-1/2% per annum,
which interest shall accrue from July 30, 1996 or from the most recent Interest
Payment Date with respect to the Old Notes to which interest was paid or duly
provided for. See "Description of Notes - Principal, Maturity and Interest."
PROCEDURES FOR TENDERING OLD NOTES
The tender of a holder's Old Notes as set forth below and the acceptance
thereof by the Company will constitute a binding agreement between the tendering
holder and the Company upon the terms and subject to the conditions set forth in
this Prospectus and in the accompanying Letter of Transmittal. Except as set
forth below, a holder who wishes to tender Old Notes for exchange pursuant to
the Exchange Offer must transmit such Old Notes, together with a properly
completed and duly executed Letter of Transmittal, including all other documents
required by such Letter of Transmittal, to the Exchange Agent at the address set
forth on the back cover page of this Prospectus prior to 5:00 p.m., New York
City time, on the Expiration Date. THE METHOD OF DELIVERY OF OLD NOTES, LETTERS
OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS IS AT THE ELECTION AND RISK OF
THE HOLDER. IF SUCH DELIVERY IS BY MAIL, IT IS RECOMMENDED THAT REGISTERED MAIL,
PROPERLY INSURED, WITH RETURN RECEIPT REQUESTED, BE USED. INSTEAD OF DELIVERY BY
MAIL, IT IS RECOMMENDED THAT THE HOLDER USE AN OVERNIGHT OR HAND DELIVERY
SERVICE. IN ALL CASES, SUFFICIENT TIME SHOULD BE ALLOWED TO ASSURE TIMELY
DELIVERY.
Any financial institution that is a participant in DTC's Book-Entry
Transfer Facility system may make book-entry delivery of the Old Notes by
causing DTC to transfer such Old Notes into the Exchange Agent's account in
accordance with DTC's procedures for such transfer. In connection with a
book-entry transfer, a Letter of Transmittal need not be transmitted to the
Exchange Agent, provided that the book-entry transfer procedure must be complied
with prior to 5:00 p.m., New York City time, on the Expiration Date.
Each signature on a Letter of Transmittal or a notice of withdrawal, as
the case may be, must be guaranteed unless the Old Notes surrendered for
exchange pursuant hereto are tendered (i) by a registered holder of the Old
Notes who has not completed either the box entitled "Special Exchange
Instructions" or the box entitled "Special Delivery Instructions" in the Letter
of Transmittal, or (ii) by an Eligible Institution (as defined). In the event
that a signature on a Letter of Transmittal or a notice of withdrawal, as the
case may be, is required to be guaranteed, such guarantee must be by a firm
which is a member of a registered national securities exchange or the National
Association of Securities Dealers, Inc., a commercial bank or trust company
having an office or correspondent in the United States or otherwise be an
"eligible guarantor institution" within the meaning of Rule 17Ad-15 under the
Exchange Act (collectively, "Eligible Institutions"). If the Letter of
Transmittal is signed by a person other than the registered holder of the Old
Notes, the Old Notes surrendered for exchange must either (i) be endorsed by the
registered holder, with the signature thereon guaranteed by an Eligible
Institution, or (ii) be accompanied by a bond power, in satisfactory form as
determined by the Company in its sole discretion, duly executed by the
registered holder, with the signature thereon guaranteed by an Eligible
Institution. The term "registered holder" as used herein with respect to the Old
Notes means any person in whose name the Old Notes are registered on the books
of the Registrar.
All questions as to the validity, form, eligibility (including time of
receipt), acceptance and withdrawal of Old Notes tendered for exchange will be
determined by the Company in its sole discretion, which determination shall be
final and binding. The Company reserves the absolute right to reject any and all
Old Notes not properly tendered and to reject any Old Notes the Company's
acceptance of which might, in the judgment of the Company or its counsel, be
unlawful. The Company also reserves the absolute right to waive any defects or
irregularities or conditions of the
24
<PAGE>
Exchange Offer as to particular Old Notes either before or after the Expiration
Date (including the right to waive the ineligibility of any holder who seeks to
tender Old Notes in the Exchange Offer). The interpretation of the terms and
conditions of the Exchange Offer (including the Letter of Transmittal and the
instructions thereto) by the Company shall be final and binding on all parties.
Unless waived, any defects or irregularities in connection with tenders of Old
Notes for exchange must be cured within such period of time as the Company shall
determine. The Company will use reasonable efforts to give notification of
defects or irregularities with respect to tenders of Old Notes for exchange but
shall not incur any liability for failure to give such notification. Tenders of
the Old Notes will not be deemed to have been made until such irregularities
have been cured or waived.
If any Letter of Transmittal, endorsement, bond power, power of attorney
or any other document required by the Letter of Transmittal is signed by a
trustee, executor, corporation or other person acting in a fiduciary or
representative capacity, such person should so indicate when signing, and,
unless waived by the Company, proper evidence satisfactory to the Company, in
its sole discretion, of such person's authority to so act must be submitted.
Any beneficial owner of the Old Notes (a "Beneficial Owner") whose Old
Notes are registered in the name of a broker, dealer, commercial bank, trust
company or other nominee and who wishes to tender Old Notes in the Exchange
Offer should contact such registered holder promptly and instruct such
registered holder to tender on such Beneficial Owner's behalf. If such
Beneficial Owner wishes to tender directly, such Beneficial Owner must, prior to
completing and executing the Letter of Transmittal and tendering Old Notes, make
appropriate arrangements to register ownership of the Old Notes in such
Beneficial Owner's name. Beneficial Owners should be aware that the transfer of
registered ownership may take considerable time.
By tendering, each registered holder will represent to the Company that,
among other things (i) the New Notes to be acquired in connection with the
Exchange Offer by the holder and each Beneficial Owner of the Old Notes are
being acquired by the holder and each Beneficial Owner in the ordinary course of
business of the holder and each Beneficial Owner, (ii) the holder and each
Beneficial Owner are not participating, do not intend to participate, and have
no arrangement or understanding with any person to participate, in the
distribution of the New Notes, (iii) the holder and each Beneficial Owner
acknowledge and agree that any person participating in the Exchange Offer for
the purpose of distributing the New Notes must comply with the registration and
prospectus delivery requirements of the Securities Act in connection with a
secondary resale transaction of the New Notes acquired by such person and cannot
rely on the position of the staff of the Commission set forth in no-action
letters that are discussed herein under "Resales of New Notes," (iv) that if the
holder is a broker-dealer that acquired Old Notes as a result of market making
or other trading activities, it will deliver a prospectus in connection with any
resale of New Notes acquired in the Exchange Offer, (v) the holder and each
Beneficial Owner understand that a secondary resale transaction described in
clause (iii) above should be covered by an effective registration statement
containing the selling security holder information required by Item 507 of
Regulation S-K of the Commission, and (vi) neither the holder nor any Beneficial
Owner is an "affiliate," as defined under Rule 405 of the Securities Act, of the
Company except as otherwise disclosed to the Company in writing. In connection
with a book-entry transfer, each participant will confirm that it makes the
representations and warranties contained in the Letter of Transmittal.
GUARANTEED DELIVERY PROCEDURES
Holders who wish to tender their Old Notes and (i) whose Old Notes are not
immediately available or (ii) who cannot deliver their Old Notes or any other
documents required by the Letter of Transmittal to the Exchange Agent prior to
the Expiration Date (or complete the procedure for book-entry transfer on a
timely basis), may tender their Old Notes according to the guaranteed delivery
procedures set forth in the Letter of Transmittal. Pursuant to such procedures:
(i) such tender must be made by or through an Eligible Institution and a Notice
of Guaranteed Delivery (as defined in the Letter of Transmittal) must be signed
by such Holder, (ii) on or prior to the Expiration Date, the Exchange Agent must
have received from the Holder and the Eligible Institution a properly completed
and duly executed Notice of Guaranteed Delivery (by facsimile transmission, mail
or hand delivery) setting forth the name and address of the Holder, the
certificate number or numbers of the tendered Old Notes, and the principal
amount of tendered Old Notes, stating that
25
<PAGE>
the tender is being made thereby and guaranteeing that, within four (4) business
days after the date of delivery of the Notice of Guaranteed Delivery, the
tendered Old Notes, a duly executed Letter of Transmittal and any other required
documents will be deposited by the Eligible Institution with the Exchange Agent,
and (iii) such properly completed and executed documents required by the Letter
of Transmittal and the tendered Old Notes in proper form for transfer (or
confirmation of a book-entry transfer of such Old Notes into the Exchange
Agent's account at DTC) must be received by the Exchange Agent within four (4)
business days after the Expiration Date. Any Holder who wishes to tender Old
Notes pursuant to the guaranteed delivery procedures described above must ensure
that the Exchange Agent receives the Notice of Guaranteed Delivery and Letter of
Transmittal relating to such Old Notes prior to 5:00 p.m., New York City time,
on the Expiration Date.
ACCEPTANCE OF OLD NOTES FOR EXCHANGE; DELIVERY OF NEW NOTES
Upon satisfaction or waiver of all the conditions to the Exchange Offer,
the Company will accept any and all Old Notes that are properly tendered in the
Exchange Offer prior to 5:00 p.m., New York City time, on the Expiration Date.
The New Notes issued pursuant to the Exchange Offer will be delivered promptly
after acceptance of the Old Notes. For purposes of the Exchange Offer, the
Company shall be deemed to have accepted validly tendered Old Notes, when, as,
and if the Company has given oral or written notice thereof to the Exchange
Agent.
In all cases, issuances of New Notes for Old Notes that are accepted for
exchange pursuant to the Exchange Offer will be made only after timely receipt
by the Exchange Agent of such Old Notes, a properly completed and duly executed
Letter of Transmittal and all other required documents (or of confirmation of a
book-entry transfer of such Old Notes into the Exchange Agent's account at DTC);
provided, however, that the Company reserves the absolute right to waive any
defects or irregularities in the tender or conditions of the Exchange Offer. If
any tendered Old Notes are not accepted for any reason, such unaccepted Old
Notes will be returned without expense to the tendering Holder thereof as
promptly as practicable after the expiration or termination of the Exchange
Offer.
WITHDRAWAL RIGHTS
Tenders of the Old Notes may be withdrawn by delivery of a written notice
to the Exchange Agent, at its address set forth on the back cover page of this
Prospectus, at any time prior to 5:00 p.m., New York City time, on the
Expiration Date. Any such notice of withdrawal must (i) specify the name of the
person having deposited the Old Notes to be withdrawn (the "Depositor"), (ii)
identify the Old Notes to be withdrawn (including the certificate number or
numbers and principal amount of such Old Notes, as applicable), (iii) be signed
by the Holder in the same manner as the original signature on the Letter of
Transmittal by which such Old Notes were tendered (including any required
signature guarantees) or be accompanied by a bond power in the name of the
person withdrawing the tender, in satisfactory form as determined by the Company
in its sole discretion, duly executed by the registered holder, with the
signature thereon guaranteed by an Eligible Institution together with the other
documents required upon transfer by the Indenture, and (iv) specify the name in
which such Old Notes are to be re-registered, if different from the Depositor,
pursuant to such documents of transfer. Any questions as to the validity, form
and eligibility (including time of receipt) of such notices will be determined
by the Company, in its sole discretion. The Old Notes so withdrawn will be
deemed not to have been validly tendered for exchange for purposes of the
Exchange Offer. Any Old Notes which have been tendered for exchange but which
are withdrawn will be returned to the Holder thereof without cost to such Holder
as soon as practicable after withdrawal. Properly withdrawn Old Notes may be
retendered by following one of the procedures described under "The Exchange
Offer--Procedures for Tendering Old Notes" at any time on or prior to the
Expiration Date.
THE EXCHANGE AGENT; ASSISTANCE
First Union National Bank of North Carolina is the Exchange Agent. All
tendered Old Notes, executed Letters of Transmittal and other related documents
should be directed to the Exchange Agent. Questions and requests for
26
<PAGE>
assistance and requests for additional copies of the Prospectus, the Letter of
Transmittal and other related documents should be addressed to the Exchange
Agent as follows:
BY HAND, REGISTERED OR CERTIFIED MAIL OR OVERNIGHT COURIER:
FIRST UNION NATIONAL BANK OF NORTH CAROLINA
230 SOUTH TRYON STREET, 11TH FLOOR
CHARLOTTE, NORTH CAROLINA 28288-1153
ATTENTION: MARILYN JOHNSON
BY FACSIMILE:
(704) 383-9716
ATTENTION: MARILYN JOHNSON
CONFIRM BY TELEPHONE (704) 383-0048
FEES AND EXPENSES
All expenses incident to the Company's consummation of the Exchange Offer
and compliance with the Registration Rights Agreement will be borne by the
Company, including, without limitation: (i) all registration and filing fees
(including, without limitation, fees and expenses of compliance with state
securities or Blue Sky laws), (ii) printing expenses (including, without
limitation, expenses of printing certificates for the New Notes in a form
eligible for deposit with DTC and of printing Prospectuses), (iii) messenger,
telephone and delivery expenses, (iv) fees and disbursements of counsel for the
Company, (v) fees and disbursements of independent certified public accountants,
(vi) rating agency fees, (vii) internal expenses of the Company (including,
without limitation, all salaries and expenses of officers and employees of the
Company performing legal or accounting duties), and (ix) fees and expenses
incurred in connection with the listing of the New Notes on a securities
exchange.
The Company has not retained any dealer-manager in connection with the
Exchange Offer and will not make any payments to brokers, dealers or others
soliciting acceptance of the Exchange Offer. The Company, however, will pay the
Exchange Agent reasonable and customary fees for its services and will reimburse
it for its reasonable out-of-pocket expenses in connection therewith.
The Company will pay all transfer taxes, if any, applicable to the
exchange of Old Notes pursuant to the Exchange Offer. If, however, a transfer
tax is imposed for any reason other than the exchange of Old Notes pursuant to
the Exchange Offer, then the amount of any such transfer taxes (whether imposed
on the registered holder or any other persons) will be payable by the tendering
holder. If satisfactory evidence of payment of such taxes or exemption is not
submitted with the Letter of Transmittal, the amount of such transfer taxes will
be billed directly to such tendering holder.
ACCOUNTING TREATMENT
The New Notes will be recorded at the same carrying value as the Old
Notes, as reflected in the Company's accounting records on the date of the
exchange. Accordingly, no gain or loss will be recognized by the Company for
accounting purposes. The expenses of the Exchange Offer will be amortized over
the term of the New Notes.
RESALES OF THE NEW NOTES
Based on an interpretation by the staff of the Commission set forth in
no-action letters issued to third parties, the Company believes that the New
Notes issued pursuant to the Exchange Offer to a holder in exchange for Old
Notes
27
<PAGE>
may be offered for resale, resold and otherwise transferred by such holder
(other than (i) a broker-dealer who purchased Old Notes directly from the
Company for resale pursuant to Rule 144A under the Securities Act or any other
available exemption under the Securities Act, or (ii) a person that is an
affiliate of the Company within the meaning of Rule 405 under the Securities
Act) without compliance with the registration and prospectus delivery provisions
of the Securities Act, provided that such holder is acquiring the New Notes in
the ordinary course of business and is not participating, and has no arrangement
or understanding with any person to participate, in the distribution of the New
Notes. The Company has not requested or obtained an interpretive letter from the
Commission staff with respect to this Exchange Offer, and the Company and the
holders are not entitled to rely on interpretive advice provided by the staff to
other persons, which advice was based on the facts and conditions represented in
such letters. However, the Exchange Offer is being conducted in a manner
intended to be consistent with the facts and conditions represented in such
letters. If any holder acquires New Notes in the Exchange Offer for the purpose
of distributing or participating in a distribution of the New Notes, such holder
cannot rely on the position of the staff of the Commission enunciated in MORGAN
STANLEY & CO., INCORPORATED (available June 5, 1991) and EXXON CAPITAL HOLDINGS
CORPORATION (available April 13, 1989), or interpreted in the Commission's
letter to SHEARMAN AND STERLING (available July 2, 1993), or similar no-action
or interpretive letters and must comply with the registration and prospectus
delivery requirements of the Securities Act in connection with a secondary
resale transaction, unless an exemption from registration is otherwise
available. Each broker-dealer that receives New Notes for its own account in
exchange for Old Notes, where such Old Notes were acquired by such broker-dealer
as a result of market making or other trading activities, must acknowledge that
it will deliver a prospectus in connection with any resale of such New Notes.
See "Plan of Distribution."
It is expected that the New Notes will be freely transferable by the
holders thereof, subject to the limitations described in the immediately
preceding paragraph. Sales of New Notes acquired in the Exchange Offer by
holders who are "affiliates" of the Company within the meaning of the Securities
Act will be subject to certain limitations on resale under Rule 144 of the
Securities Act. Such persons will only be entitled to sell New Notes in
compliance with the volume limitations set forth in Rule 144, and sales of New
Notes by affiliates will be subject to certain Rule 144 requirements as to the
manner of sale, notice and the availability of current public information
regarding the Company. The foregoing is a summary only of Rule 144 as it may
apply to affiliates of the Company. Any such persons must consult their own
legal counsel for advice as to any restrictions that might apply to the resale
of their Notes.
28
<PAGE>
USE OF PROCEEDS
There will be no cash proceeds payable to the Company from the issuance of
the New Notes pursuant to the Exchange Offer. The Company is conducting the
Exchange Offer in order to satisfy certain of the Company's obligations under
the Registration Rights Agreement executed in connection with the issuance of
the Old Notes. The proceeds from the issuance of the Old Notes were used to fund
a portion of the purchase price for the Acquisition and to pay related fees and
expenses.
RATIO OF EARNINGS TO FIXED CHARGES
For each of the five fiscal years ended October 29, 1995, the Company's
ratios of earnings to fixed charges were 3.12x, 6.33x, 6.50x, 6.74x and 2.18x,
respectively. For the nine months ended June 30, 1995, and August 4, 1996, the
Company's ratios of earnings to fixed charges were 1.04x and 3.47x,
respectively, on a historical basis, and 1.16x and 1.56x, respectively, on a pro
forma basis. For purposes of computing the ratio of earnings to fixed charges,
earnings consist of income before income taxes and extraordinary items plus
fixed charges (excluding capitalized interest). Fixed charges consist of
interest (including capitalized interest) on all indebtedness, amortization of
deferred financing costs and that portion of rental expense that management
believes to be representative of interest.
UNAUDITED PRO FORMA FINANCIAL DATA
The following presents summary unaudited combined pro forma financial data
of the Company and Sterile Concepts. The pro forma statements of operations were
prepared as if the Acquisition occurred on October 31, 1994. The pro forma
statements of operations data also give effect to the acquisition by the Company
of the Glove Operations (as defined herein), the divestiture by the Company of
the Henley Healthcare division in April, 1996, and the acquisitions by Sterile
Concepts of AMP and Medical Design Concepts, as if the acquisitions and the
divestiture occurred on October 31, 1994. Management believes that the following
presentation will assist holders of the Notes in evaluating the ability of the
Company to meet debt service requirements and other obligations.
The pro forma information for the year ended October 29, 1995 is based on
the historical financial statements of the Company for the year ended October
29, 1995 and Sterile Concepts for the year ended September 30, 1995. The pro
forma financial information for the nine months ended August 4, 1996 is based on
the historical financial statements of the Company for the nine months ended
August 4, 1996 and those of Sterile Concepts for the nine months ended June 30,
1996.
The summary unaudited combined pro forma financial data do not necessarily
reflect the results of operations of the Company and Sterile Concepts that
actually would have resulted had the Sterile Concepts Acquisition, the
acquisition of the Glove Operations, the divestiture of Henley Healthcare and
the acquisitions by Sterile Concepts of AMP and Medical Design Concepts, Inc.
been consummated as of the dates referred to above. Accordingly, such data
should not be viewed as fully representative of the past performance of the
Company or Sterile Concepts or indicative of future results. The summary
unaudited combined pro forma financial data should be read together with the
Selected Historical Financial Data and the Financial Statements and Notes of the
Company and Sterile Concepts included elsewhere in this Prospectus or
incorporated herein by reference. See "Selected Consolidated Financial Data" and
"Unaudited Pro Forma Financial Data."
29
<PAGE>
PRO FORMA STATEMENT OF OPERATIONS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
<TABLE>
<CAPTION>
Maxxim Sterile Concepts
Historical Historical Pro Forma
Year Ended Year Ended Combined
October 29, September 30, Year Ended
1995 1995 Pro forma October 29,
As Reported As Reported Adjustments 1995
----------- ----------- ------------------------ --------
<S> <C> <C> <C> <C> <C>
Net sales ................ $265,726 $146,833 $ 18,680 $ 68,363(g,f) $502,349
-- -- 4,611 --(h) --
-- -- -- 44,718(i) --
Cost of sales ............ 186,495 113,977 54,764 8,463(f,g) 380,737
-- -- -- 4,611(h) --
-- -- 38,575 --(i) --
-------- -------- -------- -------- --------
Gross profit ............. 79,231 32,856 116,630 126,155 121,612
Operating expenses ....... 59,493 19,350 1,806 4,000(c,d) 84,377
-- -- 11,960 --(f) --
-- -- 5,217 9,449(i,g) --
Nonrecurring charges ..... 10,845 -- -- -- 10,845
-------- -------- -------- -------- --------
Income from operations ... 8,893 13,506 135,613 139,604 26,390
Interest expense ......... 4,088 512 467 --(c) 22,865
-- -- 17,484 --(e) --
-- -- 314 --(i) --
Other income, net ........ 28 177 31 --(f) 159
-- -- 15 --(i) --
-------- -------- -------- -------- --------
Income before income taxes 4,833 13,171 153,924 139,604 3,684
Income taxes ............. 1,904 4,979 -- 4,679(f) 2,204
-------- -------- -------- -------- --------
Net income ............... $ 2,929 $ 8,192 $153,924 $144,283 $ 1,480
======== ======== ======== ======== ========
Net income per share ..... $ 0.36 $ 1.48 -- -- $ 0.18
======== ======== ========
Weighted average shares
outstanding ............ 8,159 5,526 -- -- 8,159
===== ===== =====
</TABLE>
30
<PAGE>
PRO FORMA STATEMENT OF OPERATIONS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
<TABLE>
<CAPTION>
Maxxim Sterile Concepts
Historical Historical Pro Forma
Nine Months Nine Months Combined
Ended Ended Nine Months
August 4, 1996 June 30, 1996 Pro forma Ended
As Reported As Reported Adjustments August 4, 1996
-------------- ------------- ------------------ --------------
<S> <C> <C> <C> <C> <C>
Net sales .................. 261,587 146,515 8,339 - (g) 396,386
-- -- 3,377 - (h) --
Cost of sales .............. 188,531 118,599 -- 3,712(g) 300,041
-- -- -- 3,377(h) --
------ ----- ------ ------ ------
Gross profit ............... 73,056 27,916 11,716 7,089 96,345
Operating expenses ......... 53,438 20,397 1,355 3,000(c,d) 67,882
-- -- -- 4,308(g) --
------ ----- ------ ------ ------
Income from operations ..... 19,618 7,519 13,071 14,397 28,463
Interest expense ........... 5,582 1,513 350 -(c) 18,125
-- -- 10,680 -(e) --
Other Income (Expense), net (265) 110 -- -- (155)
------ ----- ------ ------ ------
Income before income taxes . 13,771 6,116 24,101 14,397 10,183
Income taxes ............... 5,142 2,631 -- 3,375(f) 4,398
------ ----- ------ ------ ------
Net income................. $ 8,629 $ 3,485 $24,101 $17,772 $ 5,784
======== ======== ======= ======= =========
Net income per share....... $ 1.04 $ 0.63 -- -- $ 0.70
======== ======== =========
Weighted average shares
outstanding .............. 8,304 5,526 -- -- 8,304
===== ===== =====
</TABLE>
31
<PAGE>
NOTES TO PRO FORMA FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)
PRO FORMA ACQUISITION ADJUSTMENTS
(a) Maxxim purchased all of the outstanding Sterile Concepts Common Shares
at a price of $20.00 per share net to the sellers.
Maxxim has also agreed to acquire certain options held by employees of
Sterile Concepts for $1,800 in cash. Transaction costs are estimated at $15,000,
of which $4,000 relate to financing costs.
Giving effect to the above, the Acquisition will result in the following:
Assets Acquired
Current assets................. $ 66,509
Property and equipment......... 3,551
Goodwill....................... 120,000
---------
$ 190,060
=========
Liabilities assumed and consideration paid
Current liabilities............ $ 27,956
Long-term debt................. 34,208
Other liabilities.............. 568
Cash Paid...................... 127,328
---------
$ 190,060
=========
(b) In conjunction with the Acquisition, the Company entered into a new
$165 million credit facility agreement and issued $100 million of 10 1/2% Senior
Subordinated Notes. The new credit facility and 10 1/2% SenioR Subordinated
Notes were used to repay approximately $34.2 million of Sterile Concepts debt,
refinance approximately $72.6 million of existing Maxxim debt, and pay the cash
portion of the purchase price identified at (a) above. To finance the cash
portion of the transaction, the Company utilized the $97 million net proceeds
from the offering of the 10 1/2% Senior Subordinated Notes and approximately
$127.3 million of the new credit facility.
(c) Reflects increased amortization related to costs in excess of net
assets acquired, amortized over 40 years, and amortization of deferred financing
cost of the Senior Subordinated Notes over 10 years and the bank debt over 6
years.
Year Ended Nine Months Ended
October 29, 1995 August 4, 1996
---------------- -----------------
Amortization of goodwill of $120,000 . $ 3,000 $ 2,250
Less Sterile Concepts historical
goodwill amortization ............. (1,194) (896)
------- -------
$ 1,806 $ 1,355
======= =======
Amortization of deferred financing
costs of $4,000 ................... $ 467 $ 350
======= =======
(d) Reflects the elimination of salaries, benefits and related costs
incurred during 1995 and the first nine months of 1996 of personnel who will be
redundant to the combined entity and thus not retained on an ongoing basis.
(e) Reflects an adjustment to interest expense due to additional debt that
would have been outstanding. As Maxxim incurred bank debt of $127,300 and
$100,000 related to the Notes, each increase of 1/4 percentage point in the
borrowing rate will result in additional interest of approximately $318 annually
or $80 quarterly.
32
<PAGE>
(f) Reflects an adjustment for the Glove Operations acquired on June 30,
1995.
(g) Reflects an adjustment for the sale of Henley Healthcare in May 1996.
(h) Reflects an adjustment for sales to Sterile Concepts by Maxxim.
(i) Reflects an adjustment for the operations of Associated Medical
Products Co. and Medical Design Concepts acquired by Sterile Concepts on May 1,
1995 and October 4, 1995, respectively.
(j) Reflects an adjustment to income tax expense related to the above
adjustments, except the amortization of goodwill, at a rate of 37%.
33
<PAGE>
SELECTED CONSOLIDATED FINANCIAL DATA
The following table presents selected historical financial data of the
Company as of and for each of the five fiscal years ended October 29, 1995, and
each of the nine months ended July 30, 1995 and August 4, 1996. The information
presented for each of the five fiscal years ended October 29, 1995, has been
derived from the financial statements of the Company as audited by KPMG Peat
Marwick LLP, independent certified public accountants for the three years ended
October 29, 1995 and by Arthur Andersen LLP, independent certified public
accountants for the two years ended October 31, 1992. The information presented
for the nine months ended July 30, 1995 and August 4, 1996, has been derived
from unaudited interim financial statements of the Company, and, in the opinion
of management, reflects a fair presentation of the Company's financial
information. The following information should be read in conjunction with the
Unaudited Pro Forma Financial Data, "Management's Discussion and Analysis of
Financial Condition and Results of Operations," and the Financial Statements of
the Company and notes thereto included elsewhere in this Prospectus or
incorporated herein by reference.
<TABLE>
<CAPTION>
Nine Months Ended Fiscal Years Ended
----------------------------------- ----------------------------------------------------
August 4, July 30, October 29, October 30, October 31, October 31, October 31,
1996 1995 1995 1994 1993 1992 1991
----------- -------- ------ ----------- ----------- ----------- ------
(UNAUDITED) (DOLLARS IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net sales.............................. $261,587 $182,547 $265,726 $191,382 $129,740 $ 74,525 $ 45,293
Cost of Sales.......................... 188,531 126,602 186,495 129,569 85,247 44,372 25,731
--------- -------- -------- --------- --------- -------- ---------
Gross profit........................... 73,056 55,945 79,231 61,813 44,493 30,153 19,562
Operating expenses..................... 53,438 42,602 59,493 48,349 35,606 24,300 16,068
Nonrecurring charges................... - 10,845 10,845 - - - -
--------- -------- -------- --------- --------- -------- ---------
Income from operations................. 19,618 2,498 8,893 13,464 8,887 5,853 3,494
Interest expense and other, net........ 5,847 2,411 4,060 1,641 768 531 1,034
--------- -------- -------- --------- --------- -------- ---------
Income before income taxes............. 13,771 87 4,833 11,823 8,119 5,322 2,460
Income taxes........................... 5,142 80 1,904 4,138 2,582 1,860 861
Change in accounting for income
taxes................................ - - - 380 - - -
--------- -------- -------- --------- --------- -------- ---------
Net income............................. $ 8,629 $ 7 $ 2,929 $ 8,065 $ 5,537 $ 3,462 $ 1,599
========= ========== ========= ========= ========= ========= =========
BALANCE SHEET DATA(1):
Working capital........................ $117,353 $ 68,698 $ 73,286 $ 82,886 $ 52,722 $ 43,755 $ 20,699
Total assets........................... 442,137 257,564 264,490 165,416 114,040 70,560 48,304
Long-term obligations(2):
Bank debt and other.................... 117,915 65,709 67,412 1,181 2,086 2,339 22,549
6 3/4% Convertible
subordinated debentures.............. 28,750 28,750 28,750 28,750 28,750 - -
10 1/2% Senior Subordinated Notes 100,000 - - - - - -
Shareholders' equity................... 122,110 112,681 116,351 111,470 68,458 58,954 14,330
- -------------
</TABLE>
(1) At period end.
(2) Excludes current maturities of long-term debt.
34
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The Company has grown significantly during the past five years. Net sales
grew from $45,293,000 in 1991 to $265,726,000 in 1995, a compound annual growth
rate of 55.5%. Over the same period, net income increased from $1,599,000 in
1991 to $10,005,000 in 1995, excluding the nonrecurring charge of $10,845,000
which was incurred in fiscal 1995. This represents a compound annual growth rate
of 58.2%. This growth resulted primarily from acquisitions of established
companies or product lines. Maxxim Delaware operates the Company's three
divisions: Case Management, Argon Medical, and Maxxim Medical Europe. The
Company's fourth division, Henley Healthcare, was sold to Lasermedics, Inc. in
the second quarter of fiscal 1996. Set forth below is a brief description of the
most significant acquisitions made by the Company since 1991, exclusive of the
Acquisition.
ACQUISITIONS BY THE COMPANY SINCE 1991
STERILE CONCEPTS. Maxxim completed the Tender Offer and the Merger in July
and September, 1996, respectively, for cash of approximately $144,700,000, which
includes the repayment of $34,200,000 of Sterile Concepts debt, and thereby
became the second largest producer of custom procedure trays in the United
States. The Acquisition has increased the Company's share of the custom
procedure tray market, enhanced its ability to service a geographically diverse
customer base through expanded nationwide operations, and increased its access
to national buying groups. The Company is currently in the process of
integrating Sterile Concepts into its Case Management Division.
GLOVE OPERATIONS. In June 1995, the Company acquired the world wide glove
business ("Glove Operations") from Becton Dickinson & Company and various
affiliates ("Becton Dickinson") for approximately $70,600,000 in cash, in order
to expand the Company's customer base and increase the Company's product
offering into the surgical suite. The gloves, which are sold under such brand
names as Tru-TouchT, SensiCareT, TraditionT, EudermicT, DextrenT and NeolonT,
include latex and non-latex surgical and examination versions. The Glove
Operations are part of the Case Management division.
BOVIE ELECTROSURGERY. In June 1995, the Company acquired the Bovie line of
electrosurgical products for approximately $2,600,000 in cash, primarily to
increase the Company's vertical integration. The Bovie product lines include
electrosurgical generators, as well as related disposable products and supplies
which may be included in the Company's trays.
MEDICA. On January 1, 1995, the Company purchased Medica B.V., a
Netherlands corporation ("Medica") for approximately $11,000,000 in cash, as a
means of obtaining Medica's expertise in manufacturing, fabricating,
distributing and selling various types of disposable medical supplies in Europe,
principally in The Netherlands and Belgium. Since July 1995 the Medica products
have been sold in Europe through the Maxxim Medical Europe division.
STERILE DESIGN. Maxxim became one of the country's largest providers of
sterile custom procedure trays and significantly expanded its customer base in
July 1993 when it combined the "Sterile Design" tradename and certain inventory
and related assets acquired from a subsidiary of Johnson & Johnson with the
Company's existing procedure tray business that was not specific to the
cardiology and radiology markets. The Johnson & Johnson assets were acquired for
approximately $25,000,000 in cash. Since June 1995 the Sterile Design products
have been assembled, packaged and sold under the management of the Case
Management division. Prior to that time, Sterile Design was a separate operating
division of Maxxim.
BOUNDARY. In December 1992, the Company acquired Boundary Healthcare
Products Corp. ("Boundary") and assets of affiliated companies for $9,000,000 in
cash and approximately 484,000 shares of Common Stock issued by Maxxim-Texas.
Boundary manufactures and sells infection control apparel for operating room and
other medical personnel and disposable, non-woven patient draping systems, which
has allowed the Company to increase its vertical integration and increase the
profit margin on procedure trays including these types of products. Boundary
sells its
35
<PAGE>
products to non-affiliated customers and transfers its products to Argon Medical
and Sterile Design for inclusion in procedure trays. Since June 1995 Boundary
products have been manufactured and sold under the management of the Case
Management division. Prior to that time, Boundary Healthcare was a separate
operating division of Maxxim.
ARGON MEDICAL. In July 1991, the Company purchased the Argon Medical
operations ("Argon") of Edward Weck Incorporated, a subsidiary of Bristol-Myers
Squibb Company, for $13,400,000 in cash and a $1,800,000 promissory note. Argon
manufactures and markets disposable medical specialty products and assembles
procedural trays principally for the cardiology and radiology markets. This
acquisition allowed the Company to expand its customer base, increase its tray
volume, and achieve further vertical integration. Since its acquisition, Argon
has been a separate operating division of Maxxim.
Due to the number, magnitude and timing of the Company's acquisitions, the
Company's operating results, as reflected in the consolidated financial
statements, are not directly comparable on a year-to-year or quarter-to-quarter
basis. Thus, the results of operations for fiscal 1994 reflect the partial
results of operations from acquisitions, while the results of operations for
fiscal 1995 reflect such operations for the full twelve months and the inclusion
of the Medica acquisition, the Bovie product line and the Glove Operations for
ten, five and four months, respectively. For the purposes of historical
comparison, the financial information and related discussions concerning the
operations of the Case Management division for 1995, 1994 and 1993 have been
prepared as if Sterile Design and Boundary had been combined as part of the Case
Management division during those entire periods, even though the Case Management
division was not formed until June 1995. In addition, fiscal 1995 includes the
results of the Maxxim Medical Europe division, which was formed in the fiscal
third quarter of 1995 as a result of the combination of the Medica and foreign
Glove Operations which were acquired during 1995.
The following discussion should be read in conjunction with the
consolidated financial statements and the related notes thereto and other
detailed information appearing elsewhere herein.
RESULTS OF OPERATIONS
QUARTER AND NINE MONTHS ENDED AUGUST 4, 1996 COMPARED TO SAME PERIODS
ENDED JULY 30, 1995
The following table sets forth, for the periods indicated, the percentage
which selected items in the Condensed Consolidated Statements of Operations bear
to net sales:
Percentage of Net Sales
---------------------------------------
Three Months Ended Nine Months Ended
------------------- ------------------
August 4, July 30, August 4, July 30,
1996 1995 1996 1995
---------- -------- ---------- --------
Net sales................... 100.0% 100.0% 100.0% 100.0%
Cost of sales............... 73.5% 70.2% 72.1% 69.4%
---------- -------- ---------- --------
Gross profit................ 26.5% 29.8% 27.9% 30.6%
Operating expenses.......... 18.9% 22.4% 20.4% 23.3%
Nonrecurring charges........ 0.0% 16.5% 0.0% 5.9%
---------- -------- ---------- --------
Income (loss) from operations 7.6% (9.1%) 7.5% 1.4%
Interest expense............ (2.1%) (1.4%) (2.1%) (1.1%)
Other income (expense), net. 0.2% (0.6%) (0.1%) (0.2%)
---------- -------- ---------- --------
Income (loss) before taxes.. 5.7% (11.1%) 5.3% 0.0%
Income taxes (benefit)...... 2.2% (3.9%) 2.0% 0.0%
---------- -------- ---------- --------
Net income (loss)........... 3.5% (7.3%) 3.3% 0.0%
========== ======== ========== ========
36
<PAGE>
Net Sales for the third quarter of fiscal 1996 were $84,100,000, an
increase of 28.1% over the $65,700,000 reported for the third quarter of fiscal
1995. Net sales for the first nine months of fiscal 1996 were $261,600,000, a
43.3% increase over the $182,500,000 reported for the previous year. The
Company's gross profit increased to $22,300,000 in the third quarter of fiscal
1996 compared to $19,600,000 for the same quarter last year. For the nine months
ended August 4, 1996, gross profit was $73,100,000 versus the $55,900,000
reported for the same period last year. The increase in sales and gross profit
for both the quarter and the nine month periods was primarily due to world-wide
glove operation acquisition completed in July of fiscal 1995. The Company's
gross profit rate declined from 29.8% to 26.5% for the third quarter and from
30.6% to 27.9% for the nine month period of fiscal 1996 versus fiscal 1995. The
decline in gross margin rate was caused by the acquisition of the lower margin
glove products and the divestiture of the higher margin product lines of the
Henley Healthcare division.
Operating expenses for the third quarter were $15,900,000 or 18.9% of net
sales for fiscal 1996, compared to $14,700,000 or 22.4% of net sales for fiscal
1995. For the first nine months of fiscal 1996 and 1995 operating expenses were
$53,400,000 and $42,600,000, or 20.4% and 23.3% of net sales, respectively. The
increase in operating expenditures was directly attributable to the glove
operations acquisition and the decrease in the operating expense rate to sales
was attributable to cost savings that resulted from combining the sales and
distribution functions of the glove operations with the existing operations of
the Company. During the third quarter of fiscal 1995, the Company recorded a
non-recurring charge of $10,800,000 related to the formation of its Case
Management Division.
Interest expense was $1,795,000 or 2.1% of net sales for the third quarter
of fiscal 1996 and $943,000 or 1.4% of net sales for the third quarter of 1995.
For the nine months ended August 4, 1996 and the nine months ended July 30, 1995
interest expense was $5,582,000 and $2,001,000, or 2.1% and 1.1% of net sales
respectively. The increase in interest expense for both the quarter and the nine
month periods is directly related to the credit facility established to finance
the glove operation acquisition. The Company's effective tax rate for the
quarter and nine months ended August 4, 1996 was 38.0% and 37.3% of income
before income taxes, respectively.
The Company is currently integrating the operations of Sterile Concepts
with its already existing operations; however, the Company is experiencing
issues relating to the Merger. These issues could affect earnings in the fourth
quarter and into fiscal 1997. In addition, the Company anticipates taking a
one-time charge in the fourth quarter of fiscal 1996 in connection with the
Merger. Since the Tender Offer was consummated just prior to the end of the
third quarter, no operating results of Sterile Concepts are included in the
consolidated operating results reported herein.
Certain of the matters discussed in this report contain forward-looking
statements that involve risks and uncertainties. Although the Company believes
that its expectations are based upon reasonable assumptions, it can give no
assurance that anticipated results will occur.
As a result of the foregoing, net income for the third fiscal quarter of
1996 was $2,952,000 or $0.36 a share, primary, versus a loss of $4,778,000 or
($0.59) a share, primary, for fiscal 1995. For the first nine months of fiscal
1996 and 1995, net income was $8,629,000 or $1.04 a share, primary, versus
$7,000 or $0.00 a share, primary, respectively.
37
<PAGE>
COMPANY FISCAL YEARS 1995, 1994 & 1993
The following table presents selected financial information for the
periods indicated as a percentage of net sales and sets forth the percentage
dollar increase (decrease) of such items from period to period.
FISCAL YEAR ENDED
1995 1994 1993
---------- ---------- ---------
Net sales.................. 100.0 % 100.0% 100.0 %
Cost of sales.............. 70.2 67.7 65.7
---------- ---------- ---------
Gross profit............... 29.8 32.3 34.3
Operating expenses......... 22.4 25.3 27.4
Nonrecurring charges....... 4.1 -- --
---------- ---------- ---------
Income from operations..... 3.3 7.0 6.9
Interest expense........... 1.5 1.0 1.1
Other income, net.......... -- 0.2 0.5
---------- ---------- ---------
Income before taxes........ 1.8 6.2 6.3
Income taxes............... 0.7 2.2 2.0
---------- ---------- ---------
Income, before accounting change 1.1 4.0 4.3
Accounting change.......... -- 0.2 --
---------- ---------- ---------
Net income................. 1.1 4.2 4.3
=========== ========== =========
COMPANY FISCAL 1995 COMPARED TO 1994
NET SALES -- Net sales for fiscal 1995 were $265,726,000, a 38.9% increase
over the $191,382,000 reported for fiscal 1994. Formed in June 1995, the Case
Management division had sales of $168,295,000 for fiscal 1995 compared to sales
of $130,357,000 for fiscal 1994. The increase is primarily due to new product
introductions and the Bovie and Glove Operation acquisitions (see Note 2 of the
Notes to Consolidated Financial Statements). The Argon Medical division's fiscal
1995 sales of $54,991,000 are 32.2% higher than the $41,610,000 recorded for
fiscal 1994. This increase is primarily attributable to the introduction of the
manifold and introducer products and an expanded line of pressure monitoring
kits. In its first year, Maxxim Medical Europe recorded $23,649,000 of sales
during fiscal 1995. In the Henley Healthcare division, sales decreased 3.2% to
$18,791,000 in fiscal 1995 from $19,415,000 in fiscal 1994. The Company believes
the country's general economic climate, together with concern over levels of
reimbursement for physical therapy under prospective healthcare reform
proposals, softened demand for the higher cost clinical equipment products of
the Henley Healthcare division. The Company has since divested itself of the
Henley Healthcare division.
GROSS PROFIT -- The Company's gross profit was $79,231,000 for fiscal
1995, a 28.2% increase over the $61,813,000 for fiscal 1994. As anticipated, the
gross profit margin declined to 29.8% in fiscal 1995 from 32.3% in fiscal 1994,
primarily due to increased price pressure on procedure trays and the Company's
continued increased product mix of lower-margin hospital products. In 1995,
hospital product sales accounted for 92.9% of total sales compared to 1994
hospital product sales of 89.9%.
MARKETING AND SELLING EXPENSES -- Marketing and selling expenses increased
to $41,430,000 in fiscal 1995, versus $33,547,000 in fiscal 1994, although as a
percentage of sales marketing and selling expenses decreased to 15.6% from
17.5%, respectively. The increase in marketing and selling expenses is directly
attributable to the increased sales level of the Company. The decreased
marketing and selling expenses, as a percentage of sales, are primarily
attributable to leveraging the expenses against incremental sales increases and
the reduced expenses achieved as a result of the restructuring.
38
<PAGE>
GENERAL AND ADMINISTRATIVE EXPENSES -- General and administrative expenses
increased to $18,063,000 in fiscal 1995 from $14,802,000 in fiscal 1994, while
as a percent of sales it decreased to 6.8% from 7.7%, respectively. Similar to
marketing and selling expenses the decrease, as a percentage of sales, is
primarily attributable to achieving economies of scale associated with the
Company's higher sales level.
NONRECURRING CHARGES -- During the third quarter of fiscal 1995 the
Company recorded a nonrecurring charge of $10,845,000. This charge, which
consists of restructuring expenses, facility consolidation expenses and
intangible asset write-downs, had an $0.80 per share impact on fiscal 1995 fully
diluted earnings.
INCOME FROM OPERATIONS -- Income from operations decreased to $8,893,000
in fiscal 1995, from $13,464,000 in fiscal 1994. The decrease is attributable to
the nonrecurring charge. Excluding the nonrecurring charge income from
operations increased to $19,738,000, a 46.6% increase over fiscal 1994.
INTEREST EXPENSE -- The Company's interest expense increased to $4,088,000
in fiscal 1995 from $2,059,000 in fiscal 1994. This increase is the result of
the Company borrowing $75,000,000 to purchase the Glove Operation during the
Company's third quarter.
INCOME TAXES -- The effective income tax rate for fiscal 1995 increased to
39.4% from 35.0% in fiscal 1994. This increase is primarily due to the Company
experiencing increased nondeductible amortization expenses.
CUMULATIVE EFFECT OF THE CHANGE IN ACCOUNTING FOR INCOME TAXES -- During
1994, the Company adopted the provisions of Statement of Financial Accounting
Standards No. 109 ("FAS 109"), "Accounting for Income Taxes." The cumulative
effect of $380,000 is reported as a one-time benefit during fiscal 1994.
NET INCOME -- As a result of the foregoing, fiscal 1995 net income was
$2,929,000 compared to fiscal 1994 income, before the FAS 109 accounting change
of $7,685,000. Excluding the fiscal 1995 nonrecurring charge and the fiscal 1994
FAS 109 accounting change, net income increased to $10,005,000 in fiscal 1995,
or 30.2% over fiscal 1994. Fully diluted earnings per share decreased 64% to
$0.36 in fiscal 1995, versus $1.00 in fiscal 1994. Fully diluted earnings per
share, excluding the 1995 nonrecurring charge and excluding the 1994 FAS 109
accounting change, increased 16.0% to $1.16 in fiscal 1995 versus $1.00 in
fiscal 1994. This increase is despite the weighted average number of shares
increasing to 8,159,000 in fiscal 1995 from 7,326,000 in 1994.
COMPANY FISCAL 1994 COMPARED TO 1993
NET SALES -- Net sales for fiscal 1994 were $191,382,000, a 47.5% increase
over the $129,740,000 reported for fiscal 1993. The Case Management division's
fiscal 1994 sales increased by 88% to $130,357,000 from $69,234,000 in fiscal
1993. The increase is primarily due to the expansion of the custom procedure
tray operations as the result of the July 1993 purchase of certain assets from
Johnson & Johnson Medical, Inc., a wholly owned subsidiary of Johnson & Johnson.
The Argon Medical division's fiscal 1994 sales of $41,610,000 were 8.2% higher
than the $38,449,000 recorded for fiscal 1993. In the Henley Healthcare
division, sales decreased 12.0% to $19,415,000 in fiscal 1994 from $22,057,000
in fiscal 1993. The Company believes the country's general economic climate,
together with concern over levels of reimbursement for physical therapy under
prospective healthcare reform proposals, softened demand for the higher cost
products of the Henley Healthcare division. The Company has since divested
itself of the Henley Healthcare division.
GROSS PROFIT -- The Company's gross profit was $61,813,000 for fiscal
1994, a 38.9% increase over the $44,493,000 for fiscal 1993. As anticipated, the
gross profit margin declined to 32.3% in fiscal 1994 from 34.3% in fiscal 1993,
primarily due to the continued increase in sales of lower-margin hospital
products. In fiscal 1994 hospital product sales accounted for 89.9% of total
sales compared to fiscal 1993 hospital product sales of 83.0%.
39
<PAGE>
MARKETING AND SELLING EXPENSES -- Marketing and selling expenses increased
to $33,547,000, or 17.5% of sales in fiscal 1994, versus $23,285,000, or 17.9%
of sales, in fiscal 1993. The increase in marketing and selling expenses is due
to the expansion of the Case Management tray operations. The decrease in
marketing and selling expenses as a percentage of sales to 17.5% in fiscal 1994
from 17.9% in fiscal 1993 is primarily because of the lower expense rate
experienced in the Company's expanded hospital supply operations. In particular,
custom procedure tray sales, which typically are made through independent
representatives and generally involve lower marketing and selling costs, now
represent a larger proportion of total sales.
GENERAL AND ADMINISTRATIVE EXPENSES -- General and administrative expenses
increased to $14,802,000 or 7.7% of sales in fiscal 1994, from $12,321,000, or
9.5% of sales, in fiscal 1993. The decrease in general and administrative
expenses as a percentage of sales is due to the Company's consolidation of
certain administrative functions of operations acquired in prior years.
INCOME FROM OPERATIONS -- Income from operations increased 51.5% to
$13,464,000 in fiscal 1994, from $8,887,000 in fiscal 1993, as a result of the
sales increases discussed above. As a percentage of sales, income from
operations increased to 7.0% in 1994 from 6.9% in 1993.
INTEREST EXPENSE -- The Company's interest expense increased by 39.5% to
$2,059,000 in fiscal 1994 from $1,476,000 in fiscal 1993. The increase is due to
$28,750,000 in Convertible Subordinated Debentures being outstanding the entire
year of 1994 compared to approximately seven months in 1993.
INCOME TAXES -- The effective income tax rate for fiscal 1994 and 1993 did
not materially differ from the statutory rates for each of the respective years.
CUMULATIVE EFFECT OF THE CHANGE IN ACCOUNTING FOR INCOME TAXES -- As
required, the Company adopted the provisions of Statement of Financial
Accounting Standards No. 109, "Accounting for Income Taxes." The cumulative
effect of $380,000 is reported as a one-time benefit.
NET INCOME -- As a result of the foregoing, net income increased by
$2,528,000, or 45.7%, to $8,065,000 in fiscal 1994 compared to fiscal 1993 net
income of $5,537,000. Primary earnings per share increased 17.0% to $1.10 in
fiscal 1994 versus $0.94 in fiscal 1993, despite a 24.3% increase in the
weighted average number of shares to approximately 7,326,000 in 1994 from
approximately 5,890,000 in 1993. On a fully diluted basis earnings per share
increased 14.3% to $1.04 in fiscal 1994 from $0.91 in fiscal 1993.
LIQUIDITY AND CAPITAL RESOURCES
At August 4, 1996 the Company had cash and cash equivalents of
approximately $2,700,000, working capital of approximately $117,400,000,
long-term liabilities of $246,700,000, and shareholders' equity of $122,100,000.
For the nine months ended August 4, 1996, net cash provided by operations was
$6,700,000 versus $700,000 net cash used in operations for the nine months ended
July 30, 1995.
During the second quarter of fiscal 1996 the Company received
approximately $6,000,000 in cash from the sale of certain assets of the Henley
Healthcare division. In accordance with the terms of the Company's credit
facility, $5,600,000 was used to retire a portion of the term loan.
On July 30, 1996, the Company completed a private placement offering of
$100,000,000 10 1/2% Senior Subordinated Notes, from which net proceeds of
approximately $97,000,000 were received by the Company (see Note 8). In
addition, pursuant to the terms of an amended Credit Agreement with its primary
lender dated July 30, 1996, the Company established a $90,000,000 term loan and
$75,000,000 revolving line of credit (see Note 7). On August 4, 1996, the term
loan was fully drawn and $32,300,000 was borrowed on the revolving line of
credit.
40
<PAGE>
On July 30, 1996, the Company used approximately $108,800,000 in cash to
complete a Tender Offer to the shareholders of Sterile Concepts (see Note 6),
approximately $34,200,000 in cash to repay the outstanding debt of Sterile
Concepts, and $72,700,000 in cash to repay outstanding debt related to the
previous credit agreement with its primary lender.
During the first quarter of fiscal 1995 the Company used approximately
$11,000,000 in cash to acquire the Medica common stock and certain assets of
S.A. DPC N.V. The Medica and S.A. DPC N.V. assets acquired consist primarily of
receivables, inventory, property, plant and equipment, and certain intangible
assets.
In addition, during the first quarter of fiscal 1995 the Company purchased
fixed assets, inventory, machinery and equipment related to injection molding of
plastic hospital disposals for $1,500,000 and 25,000 shares of common stock,
subject to valuation adjustments.
During the second quarter of fiscal 1995 the Company used approximately
$13,400,000 in cash to purchase assets, inventory, machinery and equipment, and
patents related to the manufacture of pressure monitoring transducers.
On June 1, 1995 the Company used approximately $2,600,000 in cash to
purchase machinery and equipment, inventory and goodwill associated with the
Bovie line of electrosurgical products.
On June 30, 1995 the Company used approximately $70,600,000 in cash to
purchase property, plant and equipment and inventory associated with Glove
Operation of Becton Dickinson.
Pursuant to the terms of an Amended Credit Agreement with NationsBank
dated June 30, 1995, the Company established a $75,000,000 term loan and a
$25,000,000 revolving line of credit. In connection with NationsBank's
syndication of the credit facility, the revolving line of credit was increased
to $45,000,000 on August 25, 1995. The term loan was fully drawn on June 30,
1995 and the proceeds were used to purchase the Glove Operation and for related
working capital requirements. This credit facility has now been modified
pursuant to the Credit Agreement.
As the Company did not purchase the accounts receivable associated with
the Glove Operations, during the fourth quarter the Company used a portion of
the revolving line of credit to finance accounts receivable and for other
working capital purposes. From August 1, 1995 through September 21, 1995 the
Company regularly borrowed on the line of credit to a peak borrowing of
approximately $20,000,000. From September 22, 1995 to October 29, 1995 the
Company regularly paid down the line of credit to its October 29, 1995 balance
of approximately $4,800,000. In addition, on September 30, 1995 the Company made
its first quarterly principal payment, in the amount of $2,812,500, on the
$75,000,000 term note.
During the third quarter of fiscal 1995, the Company formed its Case
Management division by combining the Boundary and Sterile Design divisions with
the newly acquired Glove Operations and Bovie product line. As a result of this
decision, the Company incurred a noncash special charge of $9,380,000. This
noncash portion of the nonrecurring charge consists of a write down of
intangibles and an estimated restructuring reserve.
The 6 3/4% Convertible Subordinated Debentures ("Debentures") are
redeemable for cash at the option of the Company at any time on or after March
1, 1996. Initially the Debentures are redeemable at 105% of the principal and
then declining by 1% a year to par. In addition, the Debentures are convertible
into common stock at the option of the holders at a price of $18.00 per share.
LIQUIDITY
As a result of the Prior Offering and borrowings under the Credit
Agreement, the Company has substantially increased its indebtedness and interest
expense. As of September 24, 1996, the Company had approximately $258,200,000 in
indebtedness (including current maturities). The Company anticipates that its
principal source of
41
<PAGE>
liquidity will be approximately $37,700,000 in additional potential borrowing
available under the line of credit as of September 24, 1996. The Company
believes that its present cash balances, together with internally generated cash
flow and borrowings under the Credit Agreement, will be sufficient to meet the
Company's cash needs for at least the next twelve months.
INFLATION
The Company believes inflation has not had a material effect on its
results of operations for the past three years. Historically, the Company
believes it has been able to minimize the effect of inflation by increasing the
selling prices of its products, improving its manufacturing efficiency and
increasing its employee productivity.
DESCRIPTION OF NOTES
EXCEPT AS OTHERWISE INDICATED BELOW, THE FOLLOWING SUMMARY APPLIES TO BOTH THE
OLD NOTES AND THE NEW NOTES. AS USED HEREIN, THE TERM "NOTES" SHALL MEAN THE OLD
NOTES AND THE NEW NOTES, UNLESS OTHERWISE INDICATED.
The form and terms of the New Notes are substantially identical to the
form and terms of the Old Notes, except that (i) the exchange of the New Notes
pursuant to the Exchange Offer will be registered under the Securities Act, (ii)
the new Notes will not provide for payment of penalty interest as Liquidated
Damages, which terminate upon consummation of the Exchange Offer, and (iii) the
New Notes will not bear any legends restricting transfer thereof. The New Notes
will be issued solely in exchange for an equal principal amount of Old Notes. As
of the date hereof, $100 million aggregate principal amount of Old Notes is
outstanding. See "The Exchange Offer."
GENERAL
The New Notes will be issued pursuant to the Indenture among the Company,
as issuer, Maxxim Delaware and each of the Company's other existing Subsidiaries
(including Sterile Concepts and its Subsidiaries since the date of the Merger),
as Guarantors, and the Trustee. The terms of the Notes include those stated in
the Indenture and those made part of the Indenture by reference to the Trust
Indenture Act of 1939, as amended (the "Trust Indenture Act"). The Notes are
subject to all such terms, and Holders of Notes are referred to the Indenture
and the Trust Indenture Act for a statement thereof. The following summary of
certain provisions of the Indenture does not purport to be complete and is
qualified in its entirety by reference to the Indenture, including the
definitions therein of certain terms used below. Copies of the Indenture and the
Registration Rights Agreement are available as set forth under "Additional
Information." The definitions of certain terms used in the following summary are
set forth below under the caption "Certain Definitions."
The Notes will be unsecured senior subordinated general obligations of the
Company. The Notes will be unconditionally guaranteed on a senior subordinated
and unsecured basis by Maxxim Delaware and the Company's other existing and
future Subsidiaries (each, a "Note Guarantee" and, collectively, the "Note
Guarantees") (including Sterile Concepts and its Subsidiaries, since the date of
the Merger) that guarantee the Company's obligations under the Credit Agreement
or any other Senior Indebtedness. The Company, subject to certain exceptions,
will cause (i) each future Subsidiary of the Company that guarantees the
Company's obligations under the Credit Agreement or any other Senior
Indebtedness and (ii) each future Wholly Owned Subsidiary of the Company to
enter into a supplemental indenture providing for a Note Guarantee as required
in the Indenture; provided that any Guarantor that is not a Wholly Owned
Subsidiary of the Company which is released from its guarantee of the Company's
obligations under the Credit Agreement shall also be released from its Note
Guarantee so long as such Guarantor does not guarantee any Senior Indebtedness.
As of the date of the Indenture, none of the Company's Subsidiaries is an
Unrestricted Subsidiary; however, the Company will be able to designate any
non-U.S. Subsidiary of the Company, at the time of its formation or acquisition,
as an Unrestricted Subsidiary, subject to certain limitations. If so designated,
any such Unrestricted
42
<PAGE>
Subsidiary (as well as each of its Subsidiaries) will not be considered a
Subsidiary of the Company for any purpose and accordingly will not be subject to
the restrictive covenants set forth in the Indenture, including, without
limitation, the restrictions on the incurrence of Indebtedness by Subsidiaries
of the Company described herein, nor shall any Unrestricted Subsidiary be a
Guarantor. See the definition of "Unrestricted Subsidiary."
An Unrestricted Subsidiary shall continue to be an Unrestricted Subsidiary
only if it (a) has no Indebtedness other than Non-Recourse Debt; and (b) is a
Person with respect to which neither the Company nor any of its Subsidiaries has
any direct or indirect obligation (x) to subscribe for additional Equity
Interests or (y) to maintain or preserve such Person's financial condition or to
cause such Person to achieve any specified levels of operating results. If, at
any time, any Unrestricted Subsidiary fails to meet the foregoing requirements,
it shall thereafter cease to be an Unrestricted Subsidiary for purposes of the
Indenture and any Indebtedness of such Unrestricted Subsidiary shall be deemed
to be incurred by a Subsidiary of the Company as of such date (and, if such
Indebtedness is not permitted to be incurred as of such date under the covenant
described under the caption " -- Incurrence of Indebtedness and Issuance of
Preferred Stock," the Company shall be in default of such covenant).
PRINCIPAL, MATURITY AND INTEREST
The Notes will be limited in aggregate principal amount to $100 million
and will mature on August 1, 2006. Interest on the Notes will accrue at the rate
of 10 1/2% per annum and will be payable semiannually in arrears on February 1
and August 1, commencing on February 1, 1997, to Holders of record on the
immediately preceding January 15 and July 15. Interest on the Notes will accrue
from the most recent date to which interest has been paid or, if no interest has
been paid, from the date on which the Notes were originally issued. Interest
will be computed on the basis of a 360-day year comprised of twelve 30-day
months. Principal, premium, if any, interest and Liquidated Damages on the Notes
will be payable at the office or agency of the Company maintained for such
purpose within the City and State of New York or, at the option of the Company,
payment of interest and Liquidated Damages may be made by check mailed to the
Holders of the Notes at their respective addresses set forth in the register of
Holders of Notes; PROVIDED that all payments with respect to Global Notes and
Certificated Notes (as such terms are defined below under the caption "Book
Entry, Delivery and Form") the Holders of which have given wire transfer
instructions to the Company will be required to be made by wire transfer of
immediately available funds to the accounts specified by the Holders thereof.
Until otherwise designated by the Company, the Company's office or agency in New
York will be in the office of the Trustee maintained for such purpose. The Notes
will be issued only in fully registered form, without coupons and in
denominations of $1,000 and integral multiples thereof.
NOTE GUARANTEES
Under the Note Guarantees, each Guarantor will irrevocably and
unconditionally, jointly and severally, guarantee the performance and punctual
payment when due, whether at stated maturity, by acceleration or otherwise, of
all Obligations of the Company under the Indenture and the Notes. Each of the
Guarantors will agree to pay, in addition to any amount stated above, any and
all expenses (including reasonable counsel fees and expenses) incurred by the
Trustee in enforcing any rights under the Note Guarantees. Each of the Note
Guarantees will be limited in amount to an amount not to exceed the maximum
amount that can be guaranteed by the relevant Guarantor without rendering such
Note Guarantee as it relates to such Guarantor voidable under applicable law
relating to fraudulent conveyance or fraudulent transfer or similar laws
affecting the rights of creditors generally. See "Risk Factors -- Fraudulent
Conveyance Statutes."
Each of the Note Guarantees will be a continuing guarantee and shall (a)
remain in full force and effect until payment in full of all of the Company's
Obligations under the Indenture and the Notes or upon such Guarantor's no longer
being a Subsidiary of the Company and being released from its guarantee of
Indebtedness of the Company under the Credit Agreement and (b) inure to the
benefit of and be enforceable by the Trustee, the Holders and their successors,
transferees and assigns; provided that any Guarantor that is not a Wholly Owned
Subsidiary of the Company which is released from its guarantee of the Company's
obligations under the Credit Agreement shall also be released from its Note
43
<PAGE>
Guarantee so long as such Guarantor does not guarantee any Senior Indebtedness.
Each of the Note Guarantees shall be a guarantee of payment and not of
collection. Each of the Company's current Subsidiaries (including Sterile
Concepts and its Subsidiaries since the date of the Merger) is a Guarantor.
SUBORDINATION
The payment of principal of, premium, if any, interest and Liquidated
Damages, if any, on the Notes will be subordinated in right of payment, as set
forth in the Indenture, to the prior payment in full in cash of Senior
Indebtedness, which will include borrowings under the Credit Agreement, whether
outstanding on the date of the Indenture or thereafter incurred.
Upon any distribution to creditors of the Company in a liquidation or
dissolution of the Company or in a bankruptcy, reorganization, insolvency,
receivership or similar proceeding relating to the Company or its property, an
assignment for the benefit of creditors or any marshaling of the Company's
assets and liabilities, the holders of Senior Indebtedness will be entitled to
receive payment in full in cash of all Obligations due in respect of Senior
Indebtedness (including interest after the commencement of any such proceeding
at the rate specified in the applicable Senior Indebtedness) before the Holders
of Notes will be entitled to receive any payment with respect to the Notes, and
until all Obligations with respect to Senior Indebtedness are paid in full in
cash, any distribution to which the Holders of Notes would be entitled shall be
made to the holders of Senior Indebtedness (except that Holders of Notes may
receive securities that are subordinated at least to the same extent as the
Notes to Senior Indebtedness and any securities issued in exchange for Senior
Indebtedness and Holders of Notes may recover payments made from the trust
described under the caption "Legal Defeasance and Covenant Defeasance").
The Company also may not make any payment upon or in respect of the Notes
(except in such subordinated securities or from the trust described under the
caption "Legal Defeasance and Covenant Defeasance") if (i) a default in the
payment of the principal of, premium, if any, or interest on Designated Senior
Indebtedness occurs and is continuing beyond any applicable period of grace or
(ii) any other default occurs and is continuing with respect to Designated
Senior Indebtedness which permits holders of the Designated Senior Indebtedness
as to which such default relates to accelerate its maturity and the Trustee
receives a notice of such default (a "Payment Blockage Notice") from the Agent
Bank or the holders or the representative of the holders of any Designated
Senior Indebtedness. Payments on the Notes may and shall be resumed (a) in the
case of a payment default, upon the date on which such default is cured or
waived and (b) in case of a nonpayment default, the earlier of the date on which
such nonpayment default is cured or waived or 179 days after the date on which
the applicable Payment Blockage Notice is received, unless the maturity of any
Designated Senior Indebtedness has been accelerated. No new period of payment
blockage may be commenced by a Payment Blockage Notice unless and until 360 days
have elapsed since the first day of the effectiveness of the immediately prior
Payment Blockage Notice. No nonpayment default that existed or was continuing on
the date of delivery of any Payment Blockage Notice to the Trustee shall be, or
be made, the basis for a subsequent Payment Blockage Notice, unless such default
has been cured or waived for a period of not less than 90 days.
The Indenture further requires that the Company promptly notify holders of
Senior Indebtedness if payment of the Notes is accelerated because of any Event
of Default.
As a result of the subordination provisions described above, in the event
of an insolvency, bankruptcy, reorganization or liquidation of the Company, or
upon the occurrence of a Change of Control or an Asset Sale requiring repurchase
by the Company of any Notes, there may not be sufficient assets remaining to
satisfy the claims of the Holders after satisfying the claims of creditors of
the Company who are holders of Senior Indebtedness and claims of creditors of
the Company's Subsidiaries. See "Risk Factors -- Subordination of Notes." After
giving effect to the Acquisition and the Financing Transactions, including the
application of the net proceeds from the issuance of the Notes, the principal
amount of Senior Indebtedness outstanding at August 4, 1996, was approximately
$122.3 million. The terms of the Indenture permit the Company and its
Subsidiaries to incur additional Indebtedness, subject to certain limitations,
including additional Senior Indebtedness and Indebtedness that may be secured by
Liens on property of the
44
<PAGE>
Company and its Subsidiaries. See the discussion below under the captions
"Certain Covenants -- Incurrence of Indebtedness and Issuance of Preferred
Stock" and "Certain Covenants -- Liens."
The Notes will rank senior in right of payment to the Company's 6-3/4%
Convertible Subordinated Debentures due March 1, 2003.
SUBORDINATION OF NOTE GUARANTEES; RELEASE OF NOTE GUARANTEES
The Note Guarantees are subordinated in right of payment, as set forth in
the Indenture, to the prior payment in full in cash of Senior Indebtedness of
the relevant Guarantor, which includes guarantees of each Guarantor of
Indebtedness of the Company under the Credit Agreement, whether outstanding on
the date of the Indenture or thereafter incurred.
Upon any distribution to creditors of a Guarantor in a liquidation or
dissolution of such Guarantor or in a bankruptcy, reorganization, insolvency,
receivership or similar proceeding relating to such Guarantor or its property,
an assignment for the benefit of creditors or any marshaling of such Guarantor's
assets and liabilities, the holders of Senior Indebtedness of such Guarantor
will be entitled to receive payment in full in cash of all Obligations due in
respect of such Senior Indebtedness (including interest after the commencement
of any such proceeding at the rate specified in the applicable Senior
Indebtedness of such Guarantor) before the Holders of Notes will be entitled to
receive any payment with respect to the relevant Note Guarantee, and until all
Obligations with respect to Senior Indebtedness of such Guarantor are paid in
full in cash, any payment that would have been made under such Note Guarantee
shall be made to the holders of Senior Indebtedness of such Guarantor (except
that Holders of Notes may receive securities that are subordinated at least to
the same extent as such Note Guarantee to Senior Indebtedness of such Guarantor
and to any securities issued in exchange for Senior Indebtedness of such
Guarantor). As of August 4, 1996 and September 24, 1996, the Guarantors had
$122.3 million and $127.3 million, respectively, in the aggregate of Senior
Indebtedness, $122.3 million and $127.3 million of which, respectively,
consisted of guarantees under the Credit Agreement.
Such Guarantor also may not make any payment upon or in respect of its
Note Guarantee (except in such subordinated securities of such Guarantor) if (i)
a default in the payment of the principal of, premium, if any, or interest on
Designated Senior Indebtedness of the relevant Guarantor occurs and is
continuing beyond any applicable period of grace or (ii) any other default
occurs and is continuing with respect to Designated Senior Indebtedness of such
Guarantor which permits holders of the Designated Senior Indebtedness of such
Guarantor as to which such default relates to accelerate its maturity and the
Trustee receives a Payment Blockage Notice from the Agent Bank or the holders or
the representative of the holders of any Designated Senior Indebtedness of such
Guarantor. Payments under any Note Guarantee may and shall be resumed (a) in the
case of a payment default, upon the date on which such default is cured or
waived and (b) in the case of a nonpayment default, the earlier of the date on
which such nonpayment default is cured or waived or 179 days after the date on
which the applicable Payment Blockage Notice is received, unless the maturity of
any Designated Senior Indebtedness of the relevant Guarantor has been
accelerated. No new period of payment blockage may be commenced by a Payment
Blockage Notice unless and until 360 days have elapsed since the effectiveness
of the immediately prior Payment Blockage Notice. No nonpayment default that
existed or was continuing on the date of delivery of any Payment Blockage Notice
to the Trustee shall be, or be made, the basis for a subsequent Payment Blockage
Notice, unless such default has been cured or waived for a period of not less
than 90 days.
As a result of the subordination provisions described above, in the event
of an insolvency, bankruptcy, reorganization or liquidation of a Guarantor, or
upon occurrence of a Change of Control or an Asset Sale requiring repurchase by
the Company of any Notes, there may not be sufficient assets remaining to
satisfy the claims of the Holders with respect to the relevant Note Guarantee
after satisfying the claims of creditors of such Guarantor who are holders of
Senior Indebtedness of such Guarantor. The terms of the Indenture permit
Subsidiaries of the Company to incur additional Indebtedness, subject to certain
limitations, including additional Senior Indebtedness and Indebtedness that may
be secured by Liens on property of the Subsidiaries. See the discussion below
under the captions "Certain Covenants -- Incurrence of Indebtedness and Issuance
of Preferred Stock" and "Certain Covenants -- Liens."
45
<PAGE>
The Indenture provides that any Guarantor that is not a Wholly Owned
Subsidiary of the Company which is released from its guarantee of the Company's
obligations under the Credit Agreement shall also be released from its Note
Guarantee so long as such Guarantor does not guarantee any Senior Indebtedness.
One of the circumstances in which this could occur is in the event of a sale or
other disposition of all or substantially all of the assets of any Guarantor or
a sale or other disposition of all of the Capital Stock of any Guarantor,
provided, in each case, that such transaction is carried out in accordance with
the covenants described below under the captions "Repurchase at the Option of
Holders -- Asset Sales" and "Certain Covenants -- Merger, Consolidation or Sale
of Assets."
OPTIONAL REDEMPTION
The Notes will not be redeemable at the Company's option prior to August
1, 2001. Thereafter, the Notes will be subject to redemption at the option of
the Company, in whole or in part, upon not less than 30 nor more than 60 days'
notice, at the redemption prices (expressed as percentages of principal amount)
set forth below plus accrued and unpaid interest and Liquidated Damages, if any,
thereon to the applicable redemption date, if redeemed during the twelve-month
period beginning on August 1 of the years indicated below:
YEAR PERCENTAGE
------------ ----------
August 1, 2001............. 105.25%
August 1, 2002............. 103.50%
August 1, 2003............. 101.75%
August 1, 2004 and thereafter 100.00%
If less than all of the Notes are to be redeemed at any time, selection of
Notes for redemption will be made by the Trustee in compliance with the
requirements of the principal national securities exchange, if any, on which the
Notes are listed, or, if the Notes are not so listed, on a pro rata basis;
provided that no Notes of $1,000 or less shall be redeemed in part. Notices of
redemption shall be mailed by first class mail at least 30 but not more than 60
days before the redemption date to each Holder of Notes to be redeemed at its
registered address. If any Note is to be redeemed in part only, the notice of
redemption that relates to such Note shall state the portion of the principal
amount thereof to be redeemed. A new Note in principal amount equal to the
unredeemed portion thereof will be issued in the name of the Holder thereof upon
cancellation of the original Note. On and after the redemption date, interest
ceases to accrue on Notes or portions of them called for redemption.
MANDATORY REDEMPTION
The Company is not required to make mandatory redemption or sinking fund
payments with respect to the Notes.
REPURCHASE AT THE OPTION OF HOLDERS
CHANGE OF CONTROL
Upon the occurrence of a Change of Control, each Holder of Notes will have
the right to require the Company to repurchase all or any part (equal to $1,000
or an integral multiple thereof) of such Holder's Notes pursuant to the offer
described below (the "Change of Control Offer") at an offer price in cash equal
to 101% of the principal amount thereof plus accrued and unpaid interest and
Liquidated Damages thereon (the "Change of Control Purchase Price") to the date
of purchase (the "Change of Control Payment Date"). Within 30 days after the
date of any Change of Control, the Company will mail a notice to each Holder
describing the transaction or transactions that constitute the Change of Control
and offering to repurchase Notes pursuant to the procedures required by the
Indenture and described in such
46
<PAGE>
notice. The Change of Control Payment Date shall be a business day not less than
30 days nor more than 60 days after such notice is mailed.
On the Change of Control Payment Date, the Company will, to the extent
lawful, (1) accept for payment all Notes or portions thereof properly tendered
pursuant to the Change of Control Offer, (2) deposit with the Paying Agent an
amount equal to the Change of Control Purchase Price in respect of all Notes or
portions thereof so tendered and (3) deliver or cause to be delivered to the
Trustee the Notes so tendered together with an officers' certificate stating the
aggregate principal amount of Notes or portions thereof being purchased by the
Company. The Paying Agent will promptly mail to each Holder of Notes so tendered
the Change of Control Payment for such Notes, and the Trustee will promptly
authenticate and mail (or cause to be transferred by book entry) to each Holder
a new Note equal in principal amount to any unpurchased portion of the Notes
surrendered, if any; provided that each such new Note will be in a principal
amount of $1,000 or an integral multiple thereof. The Indenture provides that,
prior to complying with the provisions of this covenant, but in any event within
30 days following a Change of Control, the Company will either repay all
outstanding Senior Indebtedness or obtain the requisite consents, if any, under
all agreements governing outstanding Senior Indebtedness to permit the
repurchase of Notes required by this covenant. The Company will publicly
announce the results of the Change of Control Offer on or as soon as practicable
after the Change of Control Payment Date.
Except as described above with respect to a Change of Control, the
Indenture does not contain provisions that permit the Holders of the Notes to
require that the Company repurchase or redeem the Notes in the event of a
takeover, recapitalization or similar restructuring. Although the existence of a
Holder's right to require the Company to repurchase the Notes in respect of a
Change of Control may deter a third party from acquiring the Company in a
transaction that constitutes a Change of Control, the provisions of the
Indenture relating to a Change of Control in and of themselves may not afford
Holders of the Notes protection in the event of a highly leveraged transaction,
reorganization, recapitalization, restructuring, merger or similar transaction
involving the Company that may adversely affect Holders, if such transaction is
not the type of transaction included within the definition of a Change of
Control.
The Credit Agreement provides that certain change of control events with
respect to the Company would constitute a default thereunder. Any future credit
agreements or other agreements relating to Senior Indebtedness to which the
Company becomes a party may contain similar restrictions and provisions. In the
event a Change of Control occurs at a time when the Company is prohibited from
purchasing Notes, the Company could seek the consent of its lenders to the
purchase of Notes or could attempt to refinance the borrowings that contain such
prohibition. If the Company does not obtain such a consent or repay such
borrowings, the Company will remain prohibited from purchasing Notes. In such
case, the Company's failure to purchase tendered Notes would constitute an Event
of Default under the Indenture which would, in turn, constitute a default under
the Credit Agreement. In such circumstances, the subordination provisions in the
Indenture would likely restrict payments to the Holders of Notes.
The meaning of the phrase "all or substantially all" as used in the
definition of "Change of Control" with respect to a sale of assets varies
according to the facts and circumstances of the subject transaction, has no
clearly established meaning under relevant law and is subject to judicial
interpretation. Accordingly, in certain circumstances, there may be a degree of
uncertainty in ascertaining whether a particular transaction would involve a
disposition of "all or substantially all" of the assets of the Company, and
therefore it may be unclear whether a Change of Control has occurred and whether
the Notes are subject to a Change of Control Offer.
Restrictions in the Indenture described herein on the ability of the
Company and its Subsidiaries to incur additional Indebtedness, to grant Liens on
its or their property, to make Restricted Payments and to make Asset Sales may
also make more difficult or discourage a takeover of the Company, whether
favored or opposed by the management of the Company. Consummation of any such
transaction in certain circumstances may require redemption or repurchase of the
Notes, and there can be no assurance that the Company or the acquiring party
will have sufficient financial resources to effect such redemption or
repurchase. In certain circumstances, such restrictions and the restrictions on
transactions with Affiliates may make more difficult or discourage any leveraged
buyout of the Company or any of its
47
<PAGE>
Subsidiaries. While such restrictions cover a variety of arrangements which have
traditionally been used to effect highly leveraged transactions, the Indenture
may not afford the Holders of Notes protection in all circumstances from the
adverse aspects of a highly leveraged transaction, reorganization,
restructuring, merger or similar transaction.
ASSET SALES
The Indenture provides that the Company will not, and will not permit any
of its Subsidiaries to, directly or indirectly, engage in an Asset Sale except
an Exempt Asset Sale, as defined below, unless (i) the Company (or such
Subsidiary) receives consideration at the time of such Asset Sale at least equal
to the fair market value of the assets sold or otherwise disposed of, and in the
case of a lease of assets, a lease providing for rent and other conditions which
are no less favorable to the Company (or such Subsidiary) in any material
respect than the then prevailing market conditions (evidenced in each case by a
resolution of the Board of Directors of the Company set forth in an officers'
certificate delivered to the Trustee), and (ii) at least 75% (100% in the case
of lease payments) of the consideration therefor received by the Company or such
Subsidiary is in the form of cash or Cash Equivalents; provided that an Asset
Sale of the Company's sterilization unit in Oldsmar, Florida shall not be
subject to the requirement set forth in this clause (ii). An "Exempt Asset Sale"
means an Asset Sale on or after the date of the Indenture the Net Proceeds of
which plus the Net Proceeds of all other Asset Sales (other than Net Proceeds
from a sale of the Company's sterilization unit in Oldsmar, Florida)
concurrently or previously made on or after the date of the Indenture do not
exceed $10.0 million.
The Company may apply, and may permit its Subsidiaries to apply, Net
Proceeds of an Asset Sale (other than an Exempt Asset Sale), at its option,
within 365 days after the consummation of such an Asset Sale (a) to permanently
reduce Senior Indebtedness other than Senior Revolving Debt, (b) to permanently
reduce Senior Revolving Debt (and to correspondingly reduce the commitments, if
any, with respect thereto), (c) to permanently reduce any outstanding
Indebtedness of any Guarantor (and to correspondingly reduce the commitments, if
any, with respect thereto), (d) to acquire another business or any substantial
part of another business or other long-term assets, in each case, in, or used or
useful in, the same or a similar line of business as the Company or any of its
Subsidiaries was engaged in on the date of the Indenture or any reasonable
extensions or expansions thereof (including the Capital Stock of another Person
engaged in such business, provided such other Person is, or immediately after
giving effect to any such acquisition shall become, a Wholly Owned Subsidiary of
the Company), or (e) to reimburse the Company or its Subsidiaries for
expenditures made, and costs incurred, to repair, rebuild, replace or restore
property subject to loss, damage or taking to the extent that the Net Proceeds
consist of insurance proceeds received on account of such loss, damage or
taking. Pending the final application of any such Net Proceeds, the Company may
temporarily reduce Senior Revolving Debt or otherwise invest such Net Proceeds
temporarily in Cash Equivalents. Any Net Proceeds from Asset Sales (other than
Exempt Asset Sales) that are not applied within 365 days after the consummation
of an Asset Sale as provided in the first sentence of this paragraph will be
deemed to constitute "Excess Proceeds." When the aggregate amount of Excess
Proceeds exceeds $5.0 million, the Company will be required to make an offer to
all Holders of Notes (an "Asset Sale Offer") to purchase, on a pro rata basis,
the principal amount of Notes equal in amount to the Excess Proceeds (and not
just the amount thereof that exceeds $5.0 million), at a purchase price in cash
in an amount equal to 100% of the principal amount thereof plus accrued and
unpaid interest and Liquidated Damages thereon to the date of purchase, in
accordance with the procedures set forth in the Indenture. If the aggregate
principal amount of Notes surrendered by Holders thereof exceeds the amount of
Excess Proceeds, the Trustee shall select the Notes to be purchased on a pro
rata basis. Upon completion of such offer to purchase, the amount of Excess
Proceeds shall be reset at zero, subject to any subsequent Asset Sale.
In the event of the transfer of substantially all (but not all) of the
property and assets of the Company and its Subsidiaries as an entirety to a
Person in a transaction permitted under the caption "Certain Covenants --
Merger, Consolidation or Sale of Assets" below, the successor corporation shall
be deemed to have sold the properties and assets of the Company and its
Subsidiaries not so transferred for purposes of this covenant, and shall comply
with the provisions of this covenant with respect to such deemed sale as if it
were an Asset Sale. In addition, the fair market value of such properties and
assets of the Company or its Subsidiaries deemed to be sold shall be deemed to
be Net Proceeds for purposes of this covenant.
48
<PAGE>
If at any time any non-cash consideration received by the Company or any
Subsidiary in connection with any Asset Sale is converted into or sold or
otherwise disposed of for cash, then such conversion or disposition shall be
deemed to constitute an Asset Sale hereunder and the Net Proceeds thereof shall
be applied in accordance with this covenant.
The Company will comply with the requirements of Section 14(e) of, and
Rule 14e-1 under, the Exchange Act and any other securities laws and regulations
thereunder to the extent such laws and regulations are applicable in connection
with the repurchase of the Notes as a result of a Change of Control or an Asset
Sale.
The Company may use Net Proceeds from Exempt Asset Sales for general
corporate purposes (subject to the other provisions of the Indenture).
CERTAIN COVENANTS
OWNERSHIP OF AND LIENS ON CAPITAL STOCK
The Indenture provides that the Company (i) will not permit any Person
(other than the Company or any Wholly Owned Subsidiary of the Company) to own
any Capital Stock of any Subsidiary of the Company, and (ii) will not permit any
Subsidiary of the Company to issue Capital Stock (except to the Company or to a
Wholly Owned Subsidiary) or create, incur, assume or suffer to exist any Lien
thereon, in each case except (a) directors' qualifying shares, (b) Capital Stock
issued prior to the time such Person became a Subsidiary of the Company,
provided that such Capital Stock was not issued in anticipation of such
transaction, (c) if such Subsidiary merges with another Subsidiary of the
Company, (d) if such Subsidiary ceases to be a Subsidiary of the Company (as a
result of the sale of 100% of the shares of such Subsidiary, the Net Proceeds
from which are applied in accordance with "Repurchase at the Option of Holders
- -- Asset Sales"), (e) Liens on Capital Stock of any Subsidiary of the Company to
secure Indebtedness incurred under the Credit Agreement or other Senior
Indebtedness incurred in compliance with the Fixed Charge Coverage Ratio test
set forth in the first paragraph of the covenant described under the caption "--
Incurrence of Indebtedness and Issuance of Preferred Stock" or (f) Liens on
Capital Stock of any Subsidiary of the Company granted in accordance with the
provisions of the Indenture described below in the first sentence under the
caption "Liens."
RESTRICTED PAYMENTS
The Indenture provides that the Company will not, and will not permit any
of its Subsidiaries to, directly or indirectly: (i) declare or pay any dividend
or make any distribution of any kind or character (whether in cash, securities
or other property) on account of any class of the Company's or any of its
Subsidiaries' Equity Interests or to holders thereof (including, without
limitation, any payment to stockholders of the Company in connection with a
merger or consolidation involving the Company), other than (a) dividends or
distributions payable solely in Equity Interests (other than Disqualified Stock)
of the Company or (b) dividends or distributions payable solely to the Company
or any Wholly Owned Subsidiary of the Company and, if such Subsidiary is not a
Wholly Owned Subsidiary of the Company, payable simultaneously to its minority
shareholders on a pro rata basis; (ii) purchase, redeem or otherwise acquire or
retire for value any Equity Interests of the Company, any Subsidiary of the
Company, any Unrestricted Subsidiary or any other Affiliate of the Company
(other than any such Equity Interests owned by the Company or any Wholly Owned
Subsidiary of the Company); (iii) make any principal payment on, or purchase,
redeem, defease or otherwise acquire or retire for value any Indebtedness of the
Company or any Guarantor that is PARI PASSU with or subordinated to the Notes or
the Note Guarantees prior to any scheduled repayment date, mandatory sinking
fund payment date or final maturity date (other than the Notes), other than
through the purchase, redemption or acquisition by the Company of Indebtedness
of the Company or any of its Subsidiaries through the issuance in exchange
therefor of Equity Interests (other than Disqualified Stock) of the Company; or
(iv) make any Investment (other than Permitted Investments) (all such payments
and other actions set forth in clauses (i) through (iv) above being collectively
referred to as "Restricted Payments"), unless, at the time of and after giving
effect to such Restricted Payment:
49
<PAGE>
(a) no Default or Event of Default shall have occurred and be continuing
or would occur as a consequence thereof;
(b) at the time of such Restricted Payment and after giving pro forma
effect thereto as if such Restricted Payment had been made at the of the
applicable four-quarter period, the Company would have been permitted to
incur at least $1.00 of additional Indebtedness pursuant to the Fixed
Charge Coverage Ratio test set forth in the first paragraph of the
covenant described below under the caption "-- Incurrence of Indebtedness
and Issuance of Preferred Stock"; and
(c) such Restricted Payment, together with the aggregate amount of all
other Restricted Payments declared or made by the Company and its
Subsidiaries on or after the date of the Indenture (excluding Restricted
Payments permitted by clauses (ii), (iii) and (iv) of the second of the
next succeeding paragraph), is less than the sum of (i) 50% of the
Consolidated Net Income of the Company for the period (taken as one
accounting period) from the beginning of the first fiscal quarter
commencing after the date of the Indenture to the end of the Company's
most recently ended fiscal quarter for which internal financial statements
are available at the time of such Restricted Payment (or, if such
Consolidated Net Income for such period is a deficit, less 100% of such
deficit), plus (ii) 100% of the aggregate net cash proceeds received by
the Company from the issue or sale after the date of the Indenture of
Equity Interests of the Company or of debt securities of the Company that
have been converted into such Equity Interests (other than Equity
Interests (or convertible debt securities) sold to a Subsidiary of the
Company or an Unrestricted Subsidiary and other than Disqualified Stock or
debt securities that have been converted into Disqualified Stock), subject
to the provision in the first sentence of the next succeeding paragraph.
The foregoing clause (c), however, will not prohibit the Company and its
Subsidiaries from declaring or making up to an aggregate amount of $10 million
of Restricted Payments, in addition to the aggregate amount of Restricted
Payments that are permitted under paragraph (c), provided, however, that if the
aggregate amount of Restricted Payments declared or made under this sentence
equals $10 million, neither the Company nor any of its Subsidiaries may declare
or make any further Restricted Payments under the foregoing paragraph (c)
unless, and only to the extent that, the aggregate amount of Restricted Payments
that would, but for this sentence, be permitted by paragraph (c) exceeds $10
million. The foregoing clauses (b) and (c) will also not prohibit (i) the
payment of any dividend on any class of Capital Stock of the Company or any
Subsidiary of the Company within 60 days after the date of declaration thereof,
if on the date on which such dividend was declared such payment would have
complied with the provisions of the Indenture; (ii) the making of any Investment
in exchange for, or out of the proceeds of, the substantially concurrent sale
(other than to a Subsidiary of the Company or to any Unrestricted Subsidiary) of
Equity Interests of the Company (other than Disqualified Stock); provided that
any net cash proceeds that are utilized for any such Investment, and any Net
Income resulting therefrom, shall be excluded from clause (c) of the preceding
paragraph; (iii) the redemption, repurchase, retirement or other acquisition of
any Equity Interests of the Company in exchange for, or out of the proceeds of,
the substantially concurrent sale (other than to a Subsidiary of the Company or
to any Unrestricted Subsidiary) of other Equity Interests of the Company (other
than any Disqualified Stock); provided that any net cash proceeds that are
utilized for any such redemption, repurchase, retirement or other acquisition,
and any Net Income resulting therefrom, shall be excluded from clause (c) of the
preceding paragraph; and (iv) the defeasance, redemption or repurchase of PARI
PASSU or subordinated Indebtedness with the net cash proceeds from an incurrence
of Permitted Refinancing Indebtedness or the substantially concurrent sale
(other than to a Subsidiary of the Company or to any Unrestricted Subsidiary) of
Equity Interests of the Company (other than Disqualified Stock); provided that
any net cash proceeds that are utilized for any such defeasance, redemption or
repurchase, and any Net Income resulting therefrom, shall be excluded from
clause (c) of the preceding paragraph.
The amount of all Restricted Payments (other than cash) shall be the fair
market value (evidenced by a resolution of the Board of Directors set forth in
an officers' certificate delivered to the Trustee) on the date of the Restricted
Payment of the asset(s) proposed to be transferred by the Company or such
Subsidiary, as the case may be,
50
<PAGE>
pursuant to the Restricted Payment. Not later than the date of making any
Restricted Payment, the Company shall deliver to the Trustee an officers'
certificate stating that such Restricted Payment is permitted and setting forth
the basis upon which the calculations required by the covenant described under
this caption were computed, which calculations may be based upon the Company's
latest available financial statements.
INCURRENCE OF INDEBTEDNESS AND ISSUANCE OF PREFERRED STOCK
The Indenture provides that the Company will not, and will not permit any
of its Subsidiaries to, directly or indirectly, create, incur, issue, assume,
guarantee or otherwise become directly or indirectly liable, contingently or
otherwise, with respect to (collectively, "incur") any Indebtedness (including
Acquired Indebtedness) and that the Company will not issue any Disqualified
Stock and will not permit any of its Subsidiaries to issue any shares of
preferred stock; provided, however, that the Company and any Guarantor that is
organized under the laws of a jurisdiction other than the United States of
America, any state thereof or the District of Columbia may incur Indebtedness
(including Acquired Indebtedness) and the Company may issue shares of
Disqualified Stock if: (i) the Fixed Charge Coverage Ratio for the Company's
most recently ended four full fiscal quarters for which internal financial
statements are available immediately preceding the date on which such additional
Indebtedness is incurred or such Disqualified Stock is issued would have been at
least 2 to 1, determined on a pro forma basis (including a pro forma application
of the net proceeds therefrom), as if the additional Indebtedness had been
incurred, or the Disqualified Stock had been issued, as the case may be, at the
beginning of such four-quarter period; and (ii) no Default or Event of Default
shall have occurred and be continuing or would occur as a consequence thereof;
proved that the aggregate principal amount of any such Indebtedness incurred by
all such non-U.S. Guarantors pursuant to this paragraph and outstanding at any
time shall not exceed $15 million.
The foregoing limitations on the incurrence of Indebtedness will not apply
to:
(i) the incurrence by the Company of Indebtedness under the Credit
Agreement (and the incurrence by Subsidiaries of the Company of guarantees
thereof) in an aggregate principal amount at any time outstanding (with
letters of credit being deemed to have a principal amount equal to the
maximum potential liability of the Company and its Subsidiaries
thereunder) not to exceed $165 million, less the aggregate amount of all
Net Proceeds of Asset Sales applied to permanently reduce the outstanding
amount or the commitments with respect to such Indebtedness pursuant to
the covenant described above under the caption "-- Asset Sales";
(ii) the incurrence by the Company and the Guarantors of Indebtedness
represented by the Notes and the Note Guarantees;
(iii) the incurrence by the Company or any of its Subsidiaries of
Indebtedness represented by Capital Lease Obligations, mortgage financings
or Purchase Money Obligations, in each case incurred for the purpose of
financing all or any part of the purchase price or cost of construction or
improvement of property used in the business of the Company or such
Subsidiary or any Permitted Refinancing Indebtedness thereof (provided
that the requirements of clause (ii) of the definition of Permitted
Refinancing Indebtedness need not be met for the purposes of this clause
(iii)), in an aggregate principal amount not to exceed $5.0 million at any
time outstanding;
(iv) the incurrence by the Company of Permitted Refinancing Indebtedness
in exchange for, or the net proceeds of which are used to extend,
refinance, renew, replace, defease or refund, any Indebtedness described
in the first paragraph or Indebtedness evidenced by the Company's 6 3/4%
Convertible Subordinated Debentures due 2003;
(v) the incurrence by the Company or any of its Subsidiaries of
intercompany Indebtedness between or among the Company and any of its
Wholly Owned Subsidiaries or between or among any Wholly Owned
Subsidiaries; provided that, in the case of Indebtedness of the Company,
such obligations shall be unsecured
51
<PAGE>
and subordinated in case of an event of default in all respects to the
Company's obligations pursuant to the Notes; and provided, however, that
(a) any subsequent issuance or transfer of Equity Interests that results
in any such Indebtedness being held by a Person other than the Company or
a Wholly Owned Subsidiary of the Company and (b) any sale or other
transfer of any such Indebtedness to a Person that is not either the
Company or a Wholly Owned Subsidiary of the Company shall be deemed, in
each case, to constitute an incurrence of such Indebtedness by the Company
or such Subsidiary, as the case may be;
(vi) the incurrence by the Company of Hedging Obligations;
(vii) the incurrence by Subsidiaries of Indebtedness represented by
Guarantees of Indebtedness of the Company permitted under the first
paragraph of this covenant or clause (iv) of this covenant; and
(viii)the incurrence by the Company and its Subsidiaries of Indebtedness
(in addition to Indebtedness permitted by any other clause of this
paragraph) in an aggregate principal amount at any time outstanding not to
exceed $10.0 million.
LIENS
The Indenture provides that the Company will not, and will not permit any
of its Subsidiaries to, directly or indirectly, create, incur, assume or suffer
to exist any Lien on any of its assets, now owned or hereafter acquired,
securing any Indebtedness other than Senior Indebtedness or Indebtedness
specified in clauses (w) or (y) of the second sentence of the definition of
"Senior Indebtedness," unless the Notes, in the case of the Company, or the Note
Guarantees, in the case of the Guarantors, are secured equally and ratably with
such other Indebtedness; PROVIDED that, if such Indebtedness is by its terms
expressly subordinate to the Notes or the Note Guarantees, the Lien securing
such subordinate or junior Indebtedness shall be subordinate and junior to the
Lien securing the Notes or the Note Guarantees with the same relative priority
as such subordinated or junior Indebtedness shall have with respect to the Notes
or the Note Guarantees.
DIVIDEND AND OTHER PAYMENT RESTRICTIONS AFFECTING SUBSIDIARIES
The Indenture provides that the Company will not, and will not permit any
of its Subsidiaries to, directly or indirectly, create or otherwise cause or
suffer to exist or become effective any encumbrance or restriction on the
ability of any Subsidiary of the Company to (i)(a) pay dividends or make any
other distributions to the Company or any of its Subsidiaries on its Capital
Stock or with respect to any other interest or participation in, or measured by,
its profits, or (b) pay any Indebtedness or other obligation owed to the Company
or any of its Subsidiaries, (ii) make loans or advances to the Company or any of
its Subsidiaries, (iii) sell, lease or transfer any of its properties or assets
to the Company or any of its Subsidiaries, or (iv) guarantee the obligations of
the Company evidenced by the Notes or any renewals, refinancings, exchanges,
refundings or extensions thereof, except for such encumbrances or restrictions
existing under or by reason of (A) Existing Indebtedness as in effect on the
date of the Indenture consisting of capital leases whose encumbrances or
restrictions are limited to the property subject to such leases, (B) the
Indenture and the Notes, (C) applicable law, (D) any instrument governing
Acquired Indebtedness or Capital Stock of a Person acquired by the Company or
any of its Subsidiaries as in effect at the time of such acquisition (except to
the extent such Acquired Indebtedness was incurred in connection with or in
contemplation of such acquisition), which encumbrance or restriction is not
applicable to any Person, or the properties or assets of any Person, other than
the Person, or the property or assets of the Person, so acquired, provided that
the Consolidated EBITDA of such Person is not taken into account in determining
whether such acquisition was permitted by the terms of the Indenture, or (E) any
document or instrument governing Indebtedness incurred pursuant to clause (iii)
of the second paragraph under the caption "Incurrence of Indebtedness and
Issuance of Preferred Stock," provided that any such restriction contained
therein relates only to the asset or assets constructed or acquired in
connection therewith, or (F) Permitted Refinancing Indebtedness of Indebtedness
described in clause (D) hereof, provided that the restrictions contained in the
agreements governing such
52
<PAGE>
Permitted Refinancing Indebtedness are no more restrictive than those contained
in the agreements governing the Indebtedness being refinanced.
LIMITATION ON LAYERING DEBT
The Indenture provides that the Company will not incur, create, issue,
assume, guarantee or otherwise become liable for any Indebtedness that is
subordinate or junior in right of payment to any Senior Indebtedness and senior
in any respect in right of payment to the Notes.
MERGER, CONSOLIDATION OR SALE OF ASSETS
The Indenture provides that the Company will not, and the Company will not
permit any Subsidiary of the Company to, in a single transaction or series of
related transactions, consolidate or merge with or into (other than the
consolidation or merger of a Wholly Owned Subsidiary of the Company with another
Wholly Owned Subsidiary of the Company or into the Company) (whether or not the
Company or such Subsidiary is the surviving corporation), or directly and/or
indirectly through its Subsidiaries sell, assign, transfer, lease, convey or
otherwise dispose of all or substantially all of the properties or assets of the
Company and its Subsidiaries (determined on a consolidated basis for the Company
and its Subsidiaries taken as a whole) in one or more related transactions to,
another corporation, Person or entity unless
(i) either (a) the Company, in the case of a transaction involving the
Company, or such Subsidiary, in the case of a transaction involving a
Subsidiary of the Company, is the surviving corporation or (b) in the case
of a transaction involving the Company or such Subsidiary, the entity or
the Person formed by or surviving any such consolidation or merger (if
other than the Company or such Subsidiary) or to which such sale,
assignment, transfer, lease, conveyance or other disposition shall have
been made is a corporation organized or existing under the laws of the
United States of America, any state thereof or the District of Columbia
and expressly assumes all the obligations of the Company under the Notes
and the Indenture or such Subsidiary under the relevant Note Guarantee and
the Indenture, as the case may be, pursuant to a supplemental indenture in
a form reasonably satisfactory to the Trustee;
(ii) immediately after such transaction no Default or Event of Default
exists;
(iii) in the case of a transaction involving the Company, the Company or,
if other than the Company, the entity or Person formed by or surviving any
such consolidation or merger, or to which such sale, assignment, transfer,
lease, conveyance or other disposition shall have been made (A) will have
Consolidated Net Worth immediately after the transaction equal to or
greater than the Consolidated Net Worth of the Company immediately
preceding the transaction and (B) will, at the time of such transaction
and after giving pro forma effect thereto as if such transaction had
occurred at the beginning of the applicable four-quarter period, be
permitted to incur at least $1.00 of additional Indebtedness pursuant to
the Fixed Charge Coverage Ratio test set forth in the first paragraph of
the covenant described above under the caption "-- Incurrence of
Indebtedness and Issuance of Preferred Stock";
(iv) if, as a result of any such transaction, property or assets of the
Company or a Guarantor would become subject to a Lien securing
Indebtedness not excepted from the provisions of the Indenture described
above under the caption "-- Liens," the Company, any such Guarantor or the
surviving entity, as the case may be, shall have secured the Notes and the
relevant Note Guarantee, as required by such provisions; and
(v) the Company shall have delivered to the Trustee an officers'
certificate and, except in the case of a merger of a Subsidiary of the
Company into the Company or into a Wholly Owned Subsidiary of the Company,
an opinion of counsel, each stating that such consolidation, merger,
conveyance, lease or disposition and any supplemental indenture with
respect thereto, comply with all of the terms of this covenant and that
all
53
<PAGE>
conditions precedent provided for in this provision relating to such
transaction or series of transactions have been complied with.
For purposes of the foregoing, the transfer (by lease, assignment, sale or
otherwise, in a single transaction or series of transactions) of all or
substantially all of the properties or assets of one or more Subsidiaries of the
Company the Capital Stock of which constitutes all or substantially all of the
properties and assets of the Company, shall be deemed to be the transfer of all
or substantially all of the properties and assets of the Company.
TRANSACTIONS WITH AFFILIATES
The Indenture provides that the Company will not, and will not permit any
of its Subsidiaries to, directly or indirectly, after the date of the Indenture,
in any one transaction or a series of related transactions, sell, lease,
transfer or otherwise dispose of any of its properties, assets or services to,
or make any payment to, or purchase any property, assets or services from, or
enter into or make any agreement, loan, advance or guarantee with, or for the
benefit of, any Affiliate (each of the foregoing, an "Affiliate Transaction"),
other than Exempt Affiliate Transactions, unless (i) such Affiliate Transaction
is on terms that are no less favorable to the Company or the relevant Subsidiary
than those that would have been obtained in a comparable arm's length
transaction by the Company or such Subsidiary with a Person that is not an
Affiliate and (ii) the Company delivers to the Trustee (a) with respect to any
Affiliate Transaction entered into after the date of the Indenture involving
aggregate consideration in excess of $1.0 million, a resolution of the Board of
Directors of the Company set forth in an officers' certificate certifying that
such Affiliate Transaction complies with clause (i) above and that such
Affiliate Transaction has been approved by a majority of the disinterested
members of the Board of Directors of the Company and (b) with respect to any
Affiliate Transaction involving aggregate consideration in excess of $5.0
million, a written opinion issued by an independent financial advisor of
national standing that such Affiliate Transaction is fair to the Company or such
Subsidiary, as the case may be, from a financial point of view.
REPORTS
The Indenture provides that, whether or not required by the rules and
regulations of the Commission, so long as any Notes are outstanding, the Company
will furnish to the Holders of Notes, and file with the Trustee, within 15 days
after it is or would have been required to file such with the Commission (i) all
quarterly and annual financial information that is or would be required to be
contained in a filing with the Commission on Forms 10-Q and 10-K if the Company
is or were required to file such Forms, including a "Management's Discussion and
Analysis of Financial Condition and Results of Operations" and, with respect to
the annual information only, a report thereon by the Company's certified
independent accountants and (ii) all current reports that is or would be
required to be filed with the Commission on Form 8-K if the Company is or were
required to file such reports. In addition, whether or not required by the rules
and regulations of the Commission, at any time after the Company files a
registration statement with respect to the Exchange Offer or a Shelf
Registration Statement, the Company will file a copy of all such information and
reports with the Commission for public availability (unless the Commission will
not accept such a filing) and make such information available to securities
analysts and prospective investors upon request. In addition, the Company has
agreed that, for so long as any Notes remain outstanding, it will furnish to the
Holders and to securities analysts and prospective investors, upon their
request, the information specified in Rule 144A(d)(4) under the Securities Act.
EVENTS OF DEFAULT AND REMEDIES
The Indenture provides that each of the following constitutes an Event of
Default: (i) default for 30 days in the payment when due of interest on, or
Liquidated Damages with respect to, the Notes (whether or not prohibited by the
subordination provisions of the Indenture); (ii) default in payment when due of
the principal of or premium, if any, on the Notes (whether or not prohibited by
the subordination provisions of the Indenture); (iii) failure by the Company to
comply with the provisions described under the captions "Repurchase at Option of
Holders -- Change of Control," "Repurchase at Option of Holders -- Asset Sales,"
"-- Ownership of and Liens on Capital Stock," "-- Restricted
54
<PAGE>
Payments," "-- Incurrence of Indebtedness and Issuance of Preferred Stock" or
"-- Merger, Consolidation or Sale of Assets"; (iv) failure by the Company to
consummate the merger of Maxxim Acquisition Co. with and into Sterile Concepts
Holdings, Inc. on or prior to December 15, 1996; (v) failure by the Company to
comply with any of its other agreements or covenants in the Indenture or the
Notes for 60 days after written notice by the Trustee or Holders of at least 25%
of the aggregate principal amount of the Notes outstanding; (vi) default under
any mortgage, indenture or instrument under which there may be issued or by
which there may be secured or evidenced any Indebtedness for money borrowed by
the Company or any of its Subsidiaries (or the payment of which is guaranteed by
the Company or any of its Subsidiaries) whether such Indebtedness or guarantee
now exists, or is created after the date of the Indenture, which default (a) is
caused by a failure to pay principal of such Indebtedness at final maturity
thereof (a "Payment Default") or (b) results in the acceleration of such
Indebtedness prior to its express maturity and, in each case, the principal
amount of any such Indebtedness, together with the principal amount of any other
such Indebtedness as to which there has been a Payment Default or the maturity
of which has been so accelerated, exceeds in the aggregate $5.0 million; (vii)
failure by the Company or any of its Subsidiaries to pay final judgments (not
fully covered by insurance) which exceed in the aggregate $5.0 million, which
judgments are not paid, discharged or stayed for a period of 60 days; (viii)
certain events of bankruptcy, insolvency or reorganization with respect to the
Company or any of its Subsidiaries; and (ix) the Note Guarantee of any Guarantor
is held in any judicial proceeding to be unenforceable or invalid or ceases for
any reason to be in full force and effect (other than in accordance with the
terms of the Indenture) or any Guarantor or any Person acting on behalf of any
Guarantor denies or disaffirms such Guarantor's obligations under its Note
Guarantee (other than by reason of a release of such Guarantor from its Note
Guarantee in accordance with the terms of the Indenture).
If any Event of Default occurs and is continuing, the Trustee or the
Holders of at least 25% in aggregate principal amount of all of the then
outstanding Notes may declare all the Notes to be due and payable immediately.
After such acceleration, but before a judgment or decree based on acceleration,
the Holders of a majority in aggregate principal amount of outstanding Notes
may, under certain circumstances, rescind and annul such acceleration if all
Events of Default, other than the non-payment of principal, interest, premium or
Liquidated Damages that have become due solely because of such acceleration,
have been cured or waived as provided in the Indenture. Notwithstanding the
foregoing, in the case of an Event of Default arising from certain events of
bankruptcy or insolvency with respect to the Company or any Subsidiary of the
Company, all outstanding Notes will become due and payable without further
action or notice. Holders of the Notes may not enforce the Indenture or the
Notes except as provided in the Indenture. Subject to certain limitations,
Holders of a majority in principal amount of the then outstanding Notes may
direct the Trustee in its exercise of any trust or power. The Indenture provides
that if a Default occurs and is continuing, generally the Trustee must give
notice of such Default to the Holders within 90 days after the occurrence of
such Default. The Trustee may withhold from Holders of the Notes notice of any
continuing Default or Event of Default (except a Default or Event of Default
relating to the payment of principal or premium, if any, or interest or
Liquidated Damages) if it determines that withholding notice is in their
interest.
The Holders of a majority in aggregate principal amount of the Notes then
outstanding by notice to the Trustee may on behalf of the Holders of all of the
Notes waive any existing Default or Event of Default and its consequences under
the Indenture except a continuing Default or Event of Default in the payment of
interest or premium or Liquidated Damages on, or the principal of, any Note
(except a payment default resulting from an acceleration that has been
rescinded) or in respect of a provision that cannot be amended or waived without
the consent of the Holder affected.
See "Amendment, Supplement and Waiver."
The Company is required to deliver to the Trustee annually a statement
regarding compliance with the Indenture, and upon becoming aware of any Default
or Event of Default, the Company is required to deliver to the Trustee a
statement specifying such Default or Event of Default.
55
<PAGE>
NO PERSONAL LIABILITY OF DIRECTORS, OFFICERS, EMPLOYEES AND STOCKHOLDERS
No director, officer, employee, incorporator or stockholder of the
Company, as such, shall have any liability for any obligations of the Company
under the Notes or the Indenture or for any claim based on, in respect of, or by
reason of, such obligations or their creation. No director, officer, employee,
incorporator or stockholder of any Guarantor, as such, shall have any liability
for any obligations of such Guarantor under its Note Guarantee or the Indenture
or for any claim based on, in respect of, or by reason of, such obligations or
their creation. Each Holder of Notes by accepting a Note waives and releases all
such liability. The waiver and release are part of the consideration for
issuance of the Notes and the Note Guarantees. Such waiver may not be effective
to waive liabilities under the federal securities laws and it is the view of the
Commission that such waiver is against public policy.
LEGAL DEFEASANCE AND COVENANT DEFEASANCE
At its option and at any time, the Company may elect to have all of the
obligations of the Company and the Guarantors discharged with respect to the
outstanding Notes ("Legal Defeasance") except for (i) the rights of Holders of
outstanding Notes to receive payments in respect of the principal of, premium,
if any, and interest and Liquidated Damages on such Notes when such payments are
due from the trust referred to below, (ii) the Company's obligations with
respect to the Notes concerning issuing temporary Notes, registration of Notes,
mutilated, destroyed, lost or stolen Notes and the maintenance of an office or
agency for payment and money for security payments held in trust, (iii) the
Company's obligations under the Registration Rights Agreement, (iv) the rights,
powers, trusts, duties and immunities of the Trustee, and the Company's
obligations in connection therewith and (v) the Legal Defeasance provisions of
the Indenture. In addition, the Company may, at its option and at any time,
elect to have the obligations of the Company released with respect to certain
covenants that are described in the Indenture ("Covenant Defeasance") and
thereafter any omission to comply with such obligations shall not constitute a
Default or Event of Default with respect to the Notes. In the event Covenant
Defeasance occurs, certain events (not including nonpayment, bankruptcy and
insolvency events) described under "Events of Default" will no longer constitute
an Event of Default with respect to the Notes.
In order to exercise either Legal Defeasance or Covenant Defeasance, (i)
the Company must irrevocably deposit with the Trustee, in trust, for the benefit
of the Holders of the Notes, cash in U.S. dollars, U.S. Government Obligations,
or a combination thereof, in such amounts as will be sufficient, in the opinion
of a nationally recognized firm of independent public accountants, to pay the
principal of, premium, if any, and interest and Liquidated Damages on the
outstanding Notes on the stated maturity or on the applicable redemption date,
as the case may be, and the Company must specify whether the Notes are being
defeased to maturity or to a particular redemption date; (ii) in the case of
Legal Defeasance, the Company shall have delivered to the Trustee an opinion of
counsel in the United States reasonably acceptable to the Trustee confirming
that (A) the Company has received from, or there has been published by, the
Internal Revenue Service a ruling or (B) since the date of the Indenture, there
has been a change in the applicable federal income tax law, in either case to
the effect that, and based thereon such opinion of counsel shall confirm that,
the Holders of the outstanding Notes will not recognize income, gain or loss for
federal income tax purposes as a result of such Legal Defeasance and will be
subject to federal income tax on the same amounts, in the same manner and at the
same times as would have been the case if such Legal Defeasance had not
occurred; (iii) in the case of Covenant Defeasance, the Company shall have
delivered to the Trustee an opinion of counsel in the United States reasonably
acceptable to the Trustee confirming that the Holders of the outstanding Notes
will not recognize income, gain or loss for federal income tax purposes as a
result of such Covenant Defeasance and will be subject to federal income tax on
the same amounts, in the same manner and at the same times as would have been
the case if such Covenant Defeasance had not occurred; (iv) no Default or Event
of Default shall have occurred and be continuing on the date of such deposit
(other than a Default or Event of Default resulting from the borrowing of funds
to be applied to such deposit) or insofar as Events of Default from bankruptcy
or insolvency events are concerned, at any time in the period ending on the
123rd day after the date of deposit; (v) such Legal Defeasance or Covenant
Defeasance will not result in a breach or violation of, or constitute a default
under, any material agreement or instrument (other than the Indenture) to which
the Company or any of its Subsidiaries is a party or by which the Company or any
of its Subsidiaries is bound; (vi) the Company must deliver to the Trustee an
officers' certificate stating that the deposit was not made by the Company with
the intent of
56
<PAGE>
preferring the Holders of Notes over other creditors of the Company or the
Guarantors or with the intent of defeating, hindering, delaying or defrauding
creditors of the Company, the Guarantors or others; (vii) such Legal Defeasance
or Covenant Defeasance shall not result in the trust arising from such deposit
constituting an investment company within the meaning of the Investment Company
Act of 1940, as amended, unless such trust shall be registered under such Act or
exempt from registration thereunder; and (viii) the Company must deliver to the
Trustee an officers' certificate and a opinion of counsel, each stating that all
conditions precedent relating to Legal Defeasance or Covenant Defeasance, as the
case may be, have been complied with.
TRANSFER AND EXCHANGE
A Holder may transfer or exchange Notes in accordance with the Indenture.
The Trustee will act as paying agent and registrar for the Notes. The Company,
the Registrar and the Trustee may require a Holder, among other things, to
furnish appropriate endorsements and transfer documents as well as
certifications, legal opinions and other information and the Company may require
a Holder to pay any taxes and fees required by law or permitted by the
Indenture. The Company is not required to transfer or exchange any Note selected
for redemption. Also, the Company is not required to transfer or exchange any
Note for a period of 15 days before a selection of Notes to be redeemed.
The registered Holder of a Note will be treated as the owner of it for all
purposes.
AMENDMENT, SUPPLEMENT AND WAIVER
Except as provided in the next two succeeding paragraphs, the Indenture or
the Notes may be amended or supplemented with the consent of the Holders of at
least a majority in principal amount of the Notes then outstanding (including
consents obtained in connection with a tender offer or exchange offer for the
Notes), and any existing default or failure to comply with any provision of the
Indenture or the Notes may be waived with the consent of the Holders of a
majority in principal amount of the then outstanding Notes (including consents
obtained in connection with a tender offer or exchange offer for the Notes).
Without the consent of each Holder, an amendment or waiver may not: (i)
reduce the principal amount of Notes whose Holders must consent to an amendment,
supplement or waiver, (ii) reduce the principal of or premium on or change the
fixed maturity of any Note or alter the provisions with respect to the
redemption of the Notes (other than provisions relating to the covenants
described above under the caption "-- Repurchase at the Option of Holders"),
(iii) reduce the rate of or change the time for payment of interest on any Note,
(iv) waive a Default or Event of Default in the payment of principal of or
premium, if any, or interest or Liquidated Damages on the Notes (except a
rescission of acceleration of the Notes by the Holders of at least a majority in
aggregate principal amount of the then outstanding Notes and a waiver of the
payment default that resulted from such acceleration), (v) make any Note payable
in money other than that stated in the Notes, (vi) make any change in the
provisions of the Indenture relating to waivers of past Defaults or the rights
of Holders of Notes to receive payments of principal of or premium, if any, or
interest or Liquidated Damages on the Notes, (vii) waive a redemption payment
with respect to any Note (other than a payment required by one of the covenants
described above under the caption "Repurchase at the Option of Holders"), (viii)
modify the ranking or priority of the Notes or the Note Guarantee of any
Guarantor, (ix) release any Guarantor from any of its obligations under its Note
Guarantee or the Indenture other than in accordance with the terms of the
Indenture or (x) make any change in the foregoing amendment and waiver
provisions.
Notwithstanding the foregoing, without the consent of any Holder of Notes,
the Company and the Trustee may amend or supplement the Indenture or the Notes
to cure any ambiguity, defect or inconsistency, to provide for uncertificated
Notes in addition to or in place of Certificated Notes, to provide for the
assumption of the Company's obligations to Holders of Notes in the case of a
merger or consolidation, to make any change that would provide any additional
rights or benefits to the Holders of Notes or that does not adversely affect the
interests of the Holders of the Notes in any material respect, or to comply with
requirements of the Commission in order to effect or maintain the qualification
of the Indenture under the Trust Indenture Act.
57
<PAGE>
PAYMENTS FOR CONSENT
Neither the Company nor any of its Subsidiaries or Unrestricted
Subsidiaries shall, directly or indirectly, pay or cause to be paid any
consideration, whether by way of interest, fee or otherwise, to any Holder of
any Notes for or as an inducement to any consent, waiver or amendment of any
terms or provisions of the Notes, unless such consideration is offered to be
paid or agreed to be paid to all Holders of the Notes which so consent, waive or
agree to amend in the time frame set forth in the solicitation documents
relating to such consent, waiver or agreement.
CONCERNING THE TRUSTEE
First Union National Bank of North Carolina is the Trustee under the
Indenture. The Trustee's current address is 230 South Tryon Street, Eighth
Floor, Charlotte, North Carolina 28288.
The Holders of a majority in principal amount of the then outstanding
Notes have the right to direct the time, method and place of conducting any
proceeding for exercising any remedy available to the Trustee, subject to
certain exceptions. The Indenture provides that in case an Event of Default
shall occur (which shall not have been cured), the Trustee will be required, in
the exercise of its power, to use the degree of care of a prudent man in the
conduct of his own affairs. Subject to such provisions, the Trustee will be
under no obligation to exercise any of its rights or powers under the Indenture
at the request of any Holder of Notes, unless such Holder shall have offered to
the Trustee security and indemnity satisfactory to it against any loss,
liability or expense.
ADDITIONAL INFORMATION
Anyone who receives this Prospectus may obtain a copy of the Indenture and
Registration Rights Agreement without charge by writing to Maxxim Medical, Inc.,
104 Industrial Boulevard, Sugar Land, Texas 77478, Attention:
Chief Operating Officer.
BOOK-ENTRY, DELIVERY AND FORM
The Notes will initially be issued in the form of one Global Note (the
"Global Note"). The Global Note will be deposited on the date of consummation of
the Exchange Offer with the Trustee as custodian for The Depository Trust
Company (the "Depositary") and registered in the name of Cede & Co., as nominee
of the Depositary (such nominee being referred to herein as the "Global Note
Holder").
The Depositary is a limited-purpose trust company that was created to hold
securities for its participating organizations (collectively, the "Participants"
or the "Depositary's Participants") and to facilitate the clearance and
settlement of transactions in such securities between Participants through
electronic book-entry changes in accounts of its Participants. The Depositary's
Participants include securities brokers and dealers (including the Initial
Purchasers), banks and trust companies, clearing corporations and certain other
organizations. Access to the Depositary's system is also available to other
entities such as banks, brokers, dealers and trust companies (collectively, the
"Indirect Participants" or the "Depositary's Indirect Participants") that clear
through or maintain a custodial relationship with a Participant, either directly
or indirectly. Persons who are not Participants may beneficially own securities
held by or on behalf of the Depositary only through the Depositary's
Participants or the Depositary's Indirect Participants.
The Company expects that pursuant to procedures established by the
Depositary (i) upon deposit of the Global Note, the Depositary will credit the
accounts of Participants exchanging Old Notes for New Notes with portions of the
principal amount of the Global Note and (ii) ownership of the Notes evidenced by
the Global Note will be shown on, and the transfer of ownership thereof will be
effected only through, records maintained by the Depositary (with respect to the
interests of the Depositary's Participants), the Depositary's Participants and
the Depositary's Indirect Participants. Holders are advised that the laws of
some states require that certain persons take physical delivery in definitive
form
58
<PAGE>
of securities that they own. Consequently, the ability to own, transfer or
pledge Notes evidenced by the Global Note will be limited to such extent.
So long as the Global Note Holder is the registered owner of any Notes,
the Global Note Holder will be considered the sole Holder under the Indenture of
any Notes evidenced by the Global Note. Beneficial owners of Notes evidenced by
the Global Note will not be considered the owners or Holders thereof under the
Indenture for any purpose, including with respect to the giving of any
directions, instructions or approvals to the Trustee thereunder. Neither the
Company nor the Trustee will have any responsibility or liability for any aspect
of the records of the Depositary or for maintaining, supervising or reviewing
any records of the Depositary relating to the Notes.
Payments in respect of the principal of, premium, if any, and interest, if
any, on any Notes registered in the name of the Global Note Holder on the
applicable record date will be payable by the Trustee to or at the direction of
the Global Note Holder in its capacity as the registered Holder under the
Indenture. Under the terms of the Indenture, the Company and the Trustee may
treat the persons in whose names Notes, including the Global Note, are
registered as the owners thereof for the purpose of receiving such payments.
Consequently, neither the Company nor the Trustee has or will have any
responsibility or liability for the payment of such amounts to beneficial owners
of Notes. The Company believes, however, that it is currently the policy of the
Depositary to immediately credit the accounts of the relevant Participants with
such payments, in amounts proportionate to their respective holdings of
beneficial interests in the relevant security as shown on the records of the
Depositary. Payments by the Depositary's Participants and the Depositary's
Indirect Participants to the beneficial owners of Notes will be governed by
standing instructions and customary practice and will be the responsibility of
the Depositary's Participants or the Depositary's Indirect Participants.
CERTIFICATED NOTES
Any beneficial owner of Notes evidenced by the Global Note may obtain
Notes in the form of registered definitive Notes ("Certificated New Notes"). If
(i) the Company notifies the Trustee in writing that the Depositary is no longer
willing or able to act as a depositary and the Company is unable to locate a
qualified successor within 90 days or (ii) the Company, at its option, notifies
the Trustee in writing that it elects to change the issuance of Notes in the
form of Certificated Securities under the Indenture then, upon surrender by the
Global Note Holder of its Global Note, Certificated Notes will be issued to each
person that the Global Note Holder and the Depositary identify as being the
beneficial owner of the related Notes.
Neither the Company nor the Trustee will be liable for any delay by the
Global Note Holder or the Depositary in identifying the beneficial owners of
Notes and the Company and the Trustee may conclusively rely on, and will be
protected in relying on, instructions from the Global Note Holder or the
Depositary for all purposes.
SAME-DAY SETTLEMENT AND PAYMENT
The Indenture requires that payments in respect of the Notes represented
by the Global Note (including principal, premium, if any, interest and
Liquidated Damages, if any) be made by wire transfer of immediately available
funds to the accounts specified by the Global Note Holder. With respect to
Certificated Notes, the Company will make all payments of principal, premium, if
any, interest and Liquidated Damages, if any, by wire transfer of immediately
available funds to the accounts specified by the Holders thereof or, if no such
account is specified, by mailing a check to each such Holder's registered
address. Secondary trading in long-term notes and debentures of corporate
issuers is generally settled in clearing-house or next-day funds. In contrast,
the Notes represented by the Global Note are expected to be eligible to trade in
the Depositary's Same-Day Funds Settlement System, and any permitted secondary
market trading activity in such Notes will, therefore, be required by the
Depositary to be settled in immediately available funds. The Company expects
that secondary trading in the Certificated Notes will also be settled in
immediately available funds.
59
<PAGE>
CERTAIN DEFINITIONS
Set forth below are certain defined terms used in the Indenture. Reference
is made to the Indenture for a full disclosure of all such terms, as well as any
other capitalized terms used herein for which no definition is provided.
"ACQUIRED INDEBTEDNESS" means, with respect to any specified Person, (i)
any Indebtedness or Disqualified Stock of any other Person existing at the time
such other Person is merged with or into or becomes a Subsidiary of such
specified Person, including, without limitation, Indebtedness incurred in
connection with, or in contemplation of, such other Person merging with or into
or becoming a Subsidiary of such specified Person, and (ii) Indebtedness secured
by a Lien encumbering any asset acquired by such specified Person, and in either
case for purposes of the Indenture shall be deemed to be incurred by such
specified Person at the time such other Person is merged with or into or becomes
a Subsidiary of such specified Person or at the time such asset is acquired by
such specified Person, as the case may be.
"AFFILIATE" of any specified Person means (i) any other Person directly or
indirectly controlling or controlled by or under direct or indirect common
control with such specified Person or (ii) any other Person who is a director or
executive officer of (a) such specified Person or (b) any Person described in
the preceding clause (i). For purposes of this definition, "control" (including,
with correlative meanings, the terms "controlling," "controlled by" and "under
common control with"), as used with respect to any Person, shall mean the
possession, directly or indirectly, of the power to direct or cause the
direction of the management or policies of such Person, whether through the
ownership of voting securities, by agreement or otherwise; provided that
beneficial ownership of 10% or more of any class, or any series of any class, of
equity securities of a Person, whether or not voting, shall be deemed to be
control.
"AGENT BANK" means NationsBank of Texas, N.A. and its successors under the
Credit Agreement.
"ASSET SALE" means with respect to any Person, the sale, lease, conveyance
or other disposition, that does not constitute a Restricted Payment or an
Investment, by such Person of any of its assets (including, without limitation,
by way of a sale and leaseback and including the issuance, sale or transfer of
any Equity Interests in any Subsidiary of the Company or the sale or transfer of
Equity Interests in any Unrestricted Subsidiary) other than to the Company
(including the receipt of proceeds of insurance paid on account of the loss of
or damage to any asset and awards of compensation for any asset taken by
condemnation, eminent domain or similar proceeding, and including the receipt of
proceeds of business interruption insurance), in each case, in one or a series
of related transactions; provided, that notwithstanding the foregoing, the term
"Asset Sale" shall not include: (a) the sale, lease, conveyance, disposition or
other transfer of all or substantially all of the assets of the Company, in
accordance with the terms of the covenant described under the caption "Certain
Covenants -- Merger, Consolidation or Sale of Assets," (b) the sale or lease of
equipment, inventory, accounts receivable or other assets in the ordinary course
of business consistent with past practice, (c) a transfer of assets by the
Company to a Wholly Owned Subsidiary of the Company or by a Wholly Owned
Subsidiary of the Company to the Company or to another Wholly Owned Subsidiary
of the Company, (d) an issuance of Equity Interests by a Wholly Owned Subsidiary
of the Company to the Company or to another Wholly Owned Subsidiary of the
Company, provided that the consideration paid by the Company or such Wholly
Owned Subsidiary of the Company for such Equity Interests shall be deemed to be
an Investment, or (e) the sale or other disposition of cash or Cash Equivalents.
"CAPITAL LEASE OBLIGATION" means, at the time any determination thereof is
to be made, the amount of the liability in respect of a capital lease that would
at such time be required to be capitalized on a balance sheet in accordance with
GAAP.
"CAPITAL STOCK" means (i) in the case of a corporation, capital stock,
(ii) in the case of an association or business entity, any and all shares,
interests, participations, rights or other equivalents (however designated) of
capital stock, (iii) in the case of a partnership, partnership interests
(whether general or limited) and (iv) any other interest or participation that
confers on a Person the right to receive a share of the profits and losses of,
or distributions of assets of, the issuing Person.
60
<PAGE>
"CASH EQUIVALENT" means (a) securities issued or directly and fully
guaranteed or insured by the United States of America or any agency or
instrumentality thereof (provided that the full faith and credit of the United
States is pledged in support thereof) having maturities not more than twelve
months from the date of acquisition, (b) U.S. dollar denominated (or foreign
currency fully hedged) time deposits, certificates of deposit, Eurodollar time
deposits or Eurodollar certificates of deposit of (i) any domestic commercial
bank of recognized standing having capital and surplus in excess of $500 million
or (ii) any bank whose short-term commercial paper rating from S&P is at least
A-1 or the equivalent thereof or from Moody's is at least P-1 or the equivalent
thereof (any such bank being an "Approved Lender"), in each case with maturities
of not more than twelve months from the date of acquisition, and (c) commercial
paper issued by any Approved Lender (or by the parent company thereof) or any
variable rate notes issued by, or guaranteed by, any domestic corporation rated
A-2 (or the equivalent thereof) or better by S&P or P-2 (or the equivalent
thereof) or better by Moody's and maturing within twelve months of the date of
acquisition.
"CHANGE OF CONTROL" means such time as either:
(i) any Person or group (within the meaning of Section 13(d) or 14(d) of
the Exchange Act) (other than an underwriter conducting a firm commitment
underwriting of the Company's Voting Stock) has become, directly or
indirectly, the beneficial owner, by way of merger, consolidation or
otherwise, of 35% or more of the voting power of the Voting Stock of the
Company on a fully-diluted basis, after giving effect to the conversion
and exercise of all outstanding warrants, options and other securities of
the Company convertible into or exercisable for Voting Stock of the
Company (whether or not such securities are then currently convertible or
exercisable); or
(ii) the sale, lease or transfer of all or substantially all of the assets
of the Company to any Person or group; or
(iii) during any period of two consecutive calendar years, individuals who
at the beginning of such period constituted the Board of Directors of the
Company, together with any new members of such Board of Directors whose
election by such Board of Directors or whose nomination for election by
the stockholders of the Company was approved by a vote of a majority of
the members of such Board of Directors then still in office who either
were directors at the beginning of such period or whose election or
nomination for election was previously so approved, cease for any reason
to constitute a majority of the directors of the Company then in office;
or
(iv) the Company consolidates with or merges with or into another Person
or any Person consolidates with, or merges with or into, the Company (in
each case, whether or not in compliance with the terms of the Indenture),
in any such event pursuant to a transaction in which immediately after the
consummation thereof Persons owning a majority of the Voting Stock of the
Company immediately prior to such consummation shall cease to own a
majority of the Voting Stock of the Company or the surviving entity if
other than the Company.
"CONSOLIDATED EBITDA" means, with respect to any Person for any period,
the sum of, without duplication, (i) the Consolidated Net Income of such Person
and its Subsidiaries for such period, plus (ii) the Fixed Charges for such
period, plus (iii) amortization of deferred financing charges for such period,
plus (iv) provision for taxes based on income or profits for such period (to the
extent such income or profits were included in computing Consolidated Net Income
for such period), plus (v) consolidated depreciation, amortization and other
noncash charges of such Person and its Subsidiaries required to be reflected as
expenses on the books and records of such Person, minus (vi) cash payments with
respect to any nonrecurring, noncash charges previously added back pursuant to
clause (v), and excluding (vii) the impact of foreign currency translations.
Notwithstanding the foregoing, the provision for taxes based on the income or
profits of, and the depreciation and amortization and other noncash charges of,
a Subsidiary of a Person shall be added to Consolidated Net Income to compute
Consolidated EBITDA only to the extent (and in the same proportion) that the Net
Income of such Subsidiary was included in calculating the Consolidated Net
Income of such Person and only if a corresponding amount would be permitted at
the date of determination to be dividended to such Person by such
61
<PAGE>
Subsidiary without prior approval (unless such approval has been obtained),
pursuant to the terms of its charter and all agreements, instruments, judgments,
decrees, orders, statutes, rules and governmental regulations applicable to that
Subsidiary or its stockholders.
"CONSOLIDATED NET INCOME" means, with respect to any Person for any
period, the aggregate of the Net Income of such Person and its Subsidiaries for
such period, on a consolidated basis, determined in accordance with GAAP;
PROVIDED that (i) the Net Income (but not loss) of any Person that is not a
Subsidiary or that is accounted for by the equity method of accounting shall be
included only to the extent of the amount of dividends or distributions paid in
cash to the referent Person or a Wholly Owned Subsidiary thereof, (ii) the Net
Income of any Subsidiary shall be excluded to the extent that the declaration or
payment of dividends or similar distributions by that Subsidiary of that Net
Income is not at the date of determination permitted without any prior
governmental approval (unless such approval has been obtained) or, directly or
indirectly, by operation of the terms of its charter or any agreement,
instrument, judgment, decree, order, statute, rule or governmental regulation
applicable to that Subsidiary or its stockholders, (iii) the Net Income of any
Person acquired in a pooling of interests transaction for any period prior to
the date of such acquisition shall be excluded, (iv) the cumulative effect of a
change in accounting principles shall be excluded, and (v) the Net Income of, or
any dividends or other distributions from, any Unrestricted Subsidiary, to the
extent otherwise included, shall be excluded, until distributed in cash to the
Company or one of its Subsidiaries.
"CONSOLIDATED NET WORTH" means, with respect to any Person as of any date,
the sum of (i) the consolidated equity of the common stockholders of such Person
and its consolidated Subsidiaries as of such date plus (ii) the respective
amounts reported on such Person's balance sheet as of such date with respect to
any series of preferred stock (other than Disqualified Stock) that by its terms
is not entitled to the payment of dividends unless such dividends may be
declared and paid only out of net earnings in respect of the year of such
declaration and payment, but only to the extent of any cash received by such
Person upon issuance of such preferred stock, less (x) all write-ups subsequent
to the date of the Indenture in the book value of any asset owned by such Person
or a consolidated Subsidiary of such Person (other than purchase accounting
adjustments made, in connection with any acquisition of any entity that becomes
a consolidated Subsidiary of such Person after the date of the Indenture, to the
book value of the assets of such entity), (y) all investments as of such date in
unconsolidated Subsidiaries and in Persons that are not Subsidiaries (except, in
each case, Permitted Investments), and (z) all unamortized debt discount and
expense and unamortized deferred charges as of such date, all of the foregoing
determined on a consolidated basis in accordance with GAAP.
"CREDIT AGREEMENT" means that certain Second Amended and Restated Credit
Agreement, dated as of the date of the Indenture, by and among the Company and
NationsBank of Texas, N.A., as agent, and the lenders parties thereto, including
any related notes, guarantees, collateral documents, instruments and agreements
executed in connection therewith, and in each case as amended, modified,
increased, renewed, refunded, replaced, restated or refinanced from time to
time.
"DEFAULT" means any event that is or with the passage of time or the
giving of notice or both would be an Event of Default.
"DESIGNATED SENIOR INDEBTEDNESS" means in respect of the Company, (i) so
long as the Senior Bank Debt is outstanding, the Senior Bank Debt and (ii) any
other Senior Indebtedness permitted under the Indenture the principal amount of
which is $15.0 million or more and that has been designated by the Company as
"Designated Senior Indebtedness" and, in respect of any Guarantor, any guarantee
by such Guarantor of Designated Senior Indebtedness of the Company.
"DISQUALIFIED STOCK" means (a) with respect to any Person, Capital Stock
of such Person that, by its terms (or by the terms of any security into which it
is convertible or for which it is exchangeable), or upon the happening of any
event matures or is mandatorily redeemable, pursuant to a sinking fund
obligation or otherwise, or is redeemable at the option of the Holder thereof,
in whole or in part, on or prior to the date which is one year after the date on
which the Notes mature and (b) with respect to any Subsidiary of such Person
(including with respect to any Subsidiary of the
62
<PAGE>
Company), any Capital Stock other than any common stock with no preference,
privileges, or redemption or repayment provisions.
"EQUITY INTERESTS" means Capital Stock and all warrants, options or other
rights to acquire Capital Stock (but excluding any debt security that is
convertible into, or exchangeable for, Capital Stock), whether outstanding prior
to, on or after the date of the Indenture.
"EXEMPT AFFILIATE TRANSACTIONS" means (a) transactions between or among
the Company and/or its Wholly Owned Subsidiaries, (b) advances to officers of
the Company or any Subsidiary of the Company in the ordinary course of business
to provide for the payment of reasonable expenses incurred by such persons in
the performance of their responsibilities to the Company or such Subsidiary or
in connection with any relocation, (c) fees and compensation paid to and
indemnity provided on behalf of directors, officers or employees of the Company
or any Subsidiary of the Company in the ordinary course of business, (d) any
employment agreement that is in effect on the date of the Indenture in the
ordinary course of business and any such agreement entered into by the Company
or a Subsidiary of the Company after the date of the Indenture in the ordinary
course of business of the Company or such Subsidiary and (e) any Restricted
Payment that is not prohibited by the covenant set forth under the caption
"Certain Covenants -- Restricted Payments" above.
"EXISTING INDEBTEDNESS" means the Indebtedness of the Company and its
Subsidiaries (other than Indebtedness under the Credit Agreement) in existence
on the date of the Indenture, until such amounts are repaid.
"FIXED CHARGE COVERAGE RATIO" means with respect to any Person for any
period, the ratio of the Consolidated EBITDA of such Person and its Subsidiaries
for such period to the Fixed Charges of such Person and its Subsidiaries for
such period. In the event that the Company or any of its Subsidiaries incurs,
assumes, guarantees or repays or redeems any Indebtedness (other than revolving
credit borrowings) or issues or redeems preferred stock subsequent to the
commencement of the four-quarter reference period for which the Fixed Charge
Coverage Ratio is being calculated but on or prior to the date on which the
event for which the calculation of the Fixed Charge Coverage Ratio is made (the
"Calculation Date"), then the Fixed Charge Coverage Ratio shall be calculated
giving pro forma effect to such incurrence, assumption, guarantee, repayment or
redemption of Indebtedness, or such issuance or redemption of preferred stock,
as if the same had occurred at the beginning of the applicable four-quarter
reference period. For purposes of making the computation referred to above, (i)
acquisitions that have been made by the Company or any of its Subsidiaries,
including through mergers or consolidations and including any related financing
transactions, during the four-quarter reference period or subsequent to such
reference period and on or prior to the Calculation Date shall be deemed to have
occurred on the first day of the four-quarter reference period, and (ii) the
Consolidated EBITDA attributable to discontinued operations, as determined in
accordance with GAAP, and operations or businesses disposed of prior to the
Calculation Date, shall be excluded, and (iii) the Fixed Charges attributable to
discontinued operations, as determined in accordance with GAAP, and operations
or businesses disposed of prior to the Calculation Date, shall be excluded, but
only to the extent that the obligations giving rise to such Fixed Charges will
not be obligations of the referent Person or any of its Subsidiaries following
the Calculation Date.
"FIXED CHARGES" means, with respect to any Person for any period, the sum,
without duplication, of (i) the consolidated interest expense of such Person and
its Subsidiaries for such period (net of any interest income) including, without
limitation, amortization of original issue discount, noncash interest payments,
the interest component of any deferred payment obligations, the interest
component of all payments associated with Capital Lease Obligations,
commissions, discounts and other fees and charges incurred in respect of letter
of credit or bankers' acceptance financings, and net payments (if any) pursuant
to Hedging Obligations, but excluding amortization of deferred financing charges
for such period and (ii) the consolidated interest expense of such Person and
its Subsidiaries that was capitalized during such period, and (iii) any interest
expense on Indebtedness of another Person that is guaranteed by such Person or
one of its Subsidiaries or secured by a Lien on assets of such Person or one of
its Subsidiaries (whether or not such guarantee or Lien is called upon) and (iv)
the product of (a) all cash dividend payments (and noncash dividend payments in
the case of a Person that is a Subsidiary) on any series of preferred stock of
such Person payable to a party other than
63
<PAGE>
the Company or a Wholly Owned Subsidiary, multiplied by (b) a fraction, the
numerator of which is one and the denominator of which is one minus the then
current combined federal, state and local statutory tax rate of such Person,
expressed as a decimal, on a consolidated basis and in accordance with GAAP.
"GAAP" means generally accepted accounting principles set forth in the
opinions and pronouncements of the Accounting Principles Board of the American
Institute of Certified Public Accountants and statements and pronouncements of
the Financial Accounting Standards Board or in such other statements by such
other entity as have been approved by a significant segment of the accounting
profession of the United States, that are applicable to the circumstances as of
the date of determination; provided that, except as specifically provided in the
Indenture, all calculations made for purposes of determining compliance with the
covenants set forth in Article IV and Section 5.01 of the Indenture (which
include the covenants described above under "-- Certain Covenants") shall use
GAAP as in effect on the date of the Indenture for financial statements for
fiscal years ending on or after December 31, 1996.
"GUARANTEE" means a guarantee (other than by endorsement of negotiable
instruments for collection in the ordinary course of business), direct or
indirect, in any manner (including, without limitation, letters of credit and
reimbursement agreements in respect thereof), of all or any part of any
Indebtedness.
"GUARANTOR" means (i) Maxxim Medical, Inc., a Delaware corporation, (ii)
Maxxim Acquisition Co., through the date of the Merger, (iii) each other
existing Subsidiary of the Company, (iv) each Subsidiary of the Company formed
or acquired (and each other Person that becomes a Subsidiary of the Company)
after the date of the Indenture that guarantees the Company's obligations under
the Credit Agreement or any other Senior Indebtedness and (v) each other Wholly
Owned Subsidiary formed or acquired or that becomes such after the date of the
Indenture ; provided that (a) Sterile Concepts Holdings, Inc. and its
Subsidiaries did not become Guarantors until the consummation of the Merger; (b)
any Subsidiary of the Company acquired after the date of the Indenture which is
prohibited from entering into a Note Guarantee pursuant to restrictions
contained in any debt instrument in existence at the time such Subsidiary was so
acquired and not entered into in anticipation or contemplation of such
acquisition shall not be required to become a Guarantor so long as any such
restriction is in existence and to the extent of any such restriction and so
long as such Subsidiary does not guarantee any Senior Indebtedness; and (c) any
non-Wholly Owned Subsidiary of the Company that is released from its guarantee
of the Company's obligations under the Credit Agreement shall also be released
from its Note Guarantee so long as such Subsidiary does not guarantee any Senior
Indebtedness.
"HEDGING OBLIGATIONS" means, with respect to any Person, the obligations
of such Person entered into in the ordinary course of business under (i)
interest rate swap agreements, interest rate cap agreements and interest rate
collar agreements and other similar financial agreements or arrangements
designed to protect such Person against, or manage the exposure of such Person
to, fluctuations in interest rates, and (ii) forward exchange agreements,
currency swap, currency option and other similar financial agreements or
arrangements designed to protect such Person against, or manage the exposure of
such Person to, fluctuations in foreign currency exchange rates.
"INDEBTEDNESS" means, with respect to any Person, any indebtedness of such
Person, whether or not contingent, in respect of borrowed money or evidenced by
bonds, notes, debentures or similar instruments or letters of credit (or
reimbursement agreements in respect thereof) or banker's acceptances or
representing Capital Lease Obligations, or the balance deferred and unpaid of
the purchase price of any property or representing any Hedging Obligations,
except any such balance that constitutes an accrued expense or trade payable
incurred in the ordinary course of business, if and to the extent any of the
foregoing indebtedness (other than letters of credit and Hedging Obligations)
would appear as a liability upon a balance sheet of such Person prepared in
accordance with GAAP, as well as all indebtedness of others secured by a Lien on
any asset of such Person (whether or not such indebtedness is assumed by such
Person) and, to the extent not otherwise included, the guarantee by such Person
of any indebtedness of any other Person.
"INVESTMENTS" means, with respect to any Person, all investments by such
Person in other Persons (including Affiliates) in the form of direct or indirect
loans (including guarantees of Indebtedness or other obligations), advances or
capital contributions (excluding advances to officers of the type specified in
clause (b) of the definition of Exempt
64
<PAGE>
Affiliate Transactions), purchases or other acquisitions for consideration of
Indebtedness, Equity Interests or other securities and all other items that are
or would be classified as investments on a balance sheet prepared in accordance
with GAAP; PROVIDED that an acquisition of assets, Equity Interests or other
securities by the Company for consideration consisting of common equity
securities of the Company shall not be deemed to be an Investment.
"LIEN" means, with respect to any asset, any mortgage, lien, pledge,
charge, security interest or encumbrance of any kind in respect of such asset,
whether or not filed, recorded or otherwise perfected under applicable law
(including any conditional sale or other title retention agreement, any lease in
the nature thereof, any option or other agreement to sell or give a security
interest in and any filing of or agreement to give any financing statement under
the Uniform Commercial Code (or equivalent statutes) of any jurisdiction).
"NET INCOME" means, with respect to any Person for any period, the net
income (loss) of such Person, determined in accordance with GAAP and before any
reduction in respect of preferred stock dividends, excluding, however, (i) any
gain (but not loss), together with any related provision for taxes on such gain
(but not loss), realized in connection with (a) any Asset Sale (including,
without limitation, dispositions pursuant to sale and leaseback transactions) or
(b) the disposition of any securities by such Person or any of its Subsidiaries
or the extinguishment of any Indebtedness of such Person or any of its
Subsidiaries and (ii) any extraordinary or nonrecurring gain (but not loss),
together with any related provision for taxes on such extraordinary or
nonrecurring gain (but not loss).
"NET PROCEEDS" means the aggregate cash proceeds received by the Company
or any of its Subsidiaries in respect of any Asset Sale (including, without
limitation, any cash received upon the sale or other disposition of any noncash
consideration received in any Asset Sale), net of the direct costs relating to
such Asset Sale (including, without limitation, legal, accounting and investment
banking fees, and sales commissions), taxes paid or payable as a result thereof,
and any reserve for adjustment in respect of the sale price of such asset or
assets established in accordance with GAAP.
"NON-RECOURSE DEBT" means Indebtedness (i) as to which neither the Company
nor any of its Subsidiaries (a) provides credit support of any kind (including
any undertaking, agreement or instrument that would constitute Indebtedness),
(b) is directly or indirectly liable (as a guarantor or otherwise), or (c)
constitutes the lender; and (ii) no default with respect to which (including any
rights that the holders thereof may have to take enforcement action against an
Unrestricted Subsidiary) would permit (upon notice, lapse of time or both) any
holder of any other Indebtedness of the Company or any of its Subsidiaries to
declare a default on such other Indebtedness or cause the payment thereof to be
accelerated or payable prior to its stated maturity.
"OBLIGATIONS" means any principal, interest, penalties, premiums, fees,
indemnifications, reimbursements, damages and other liabilities payable under
the documentation governing any Indebtedness.
"PERMITTED INVESTMENTS" means (a) any Investments in the Company; (b) any
Investments in Cash Equivalents; (c) Investments made as a result of the receipt
of noncash consideration from an Asset Sale that was made pursuant to and in
compliance with the covenant described above under the caption "Repurchase at
the Option of Holders -- Asset Sales"; (d) Investments outstanding as of the
date of the Indenture; and (e) Investments in Wholly Owned Subsidiaries of the
Company and any entity that (i) is engaged in the same or a similar line of
business as the Company or any of its Subsidiaries was engaged in on the date of
the Indenture or any reasonable extensions or expansions thereof and (ii) as a
result of such Investment, becomes a Wholly Owned Subsidiary of the Company.
"PERMITTED REFINANCING INDEBTEDNESS" means any Indebtedness of the Company
or any of its Subsidiaries issued in exchange for, or the net proceeds of which
are used to extend, refinance, renew, replace, defease or refund other
Indebtedness of the Company or any of its Subsidiaries; provided that: (i) the
principal amount of such Permitted Refinancing Indebtedness does not exceed the
principal amount of the Indebtedness so extended, refinanced, renewed, replaced,
defeased or refunded (plus the amount of reasonable expenses incurred in
connection therewith); (ii) such Permitted Refinancing Indebtedness has a
Weighted Average Life to Maturity equal to or greater than the Weighted
65
<PAGE>
Average Life to Maturity of, the Indebtedness being extended, refinanced,
renewed, replaced, defeased or refunded; (iii) if the Indebtedness being
extended, refinanced, renewed, replaced, defeased or refunded is subordinated in
right of payment to the Notes, such Permitted Refinancing Indebtedness has a
final maturity date later than the final maturity date of, and is subordinated
in right of payment to, the Notes on terms at least as favorable to the Holders
of Notes as those contained in the documentation governing the Indebtedness
being extended, refinanced, renewed, replaced, defeased or refunded; and (iv)
such Indebtedness is incurred either by the Company or by the Subsidiary of the
Company that is the obligor on the Indebtedness being extended, refinanced,
renewed, replaced, defeased or refunded.
"PERSON" means any individual, corporation, limited or general
partnership, joint venture, association, joint stock company, trust,
unincorporated organization or government or any agency or political subdivision
thereof.
"PURCHASE MONEY OBLIGATIONS" of any Person means any obligations of such
Person to any seller or any other Person incurred or assumed to finance the
construction and/or acquisition of real or personal property to be used in the
business of such Person or any of its Subsidiaries in an amount that is not more
than 100% of the cost of such property, and incurred within 180 days after the
date of such construction or acquisition (excluding accounts payable to trade
creditors incurred in the ordinary course of business).
"SENIOR BANK DEBT" means the Obligations outstanding under the Credit
Agreement.
"SENIOR INDEBTEDNESS" means, with respect to the Company, (i) the Senior
Bank Debt and (ii) any other Indebtedness permitted to be incurred by the
Company under the terms of the Indenture, unless the instrument under which such
Indebtedness is incurred expressly provides that it is subordinated in right of
payment to any Indebtedness for money borrowed. Notwithstanding anything to the
contrary in the foregoing, Senior Indebtedness will not include (w) any
liability for federal, state, local or other taxes owed or owing by the Company,
(x) any Indebtedness of the Company to any of its Subsidiaries, Unrestricted
Subsidiaries or other Affiliates, (y) any trade payables or (z) any Indebtedness
to the extent that is incurred in violation of the Indenture. "Senior
Indebtedness" means, with respect to any Guarantor, any guarantee by such
Guarantor of Senior Indebtedness of the Company.
"SENIOR REVOLVING DEBT" means revolving credit borrowings and letters of
credit under the Credit Agreement and/or any successor facility or facilities.
"SUBSIDIARY" means, with respect to any Person, (i) any corporation,
association or other business entity of which more than 50% of the total voting
power of shares of Capital Stock entitled (without regard to the occurrence of
any contingency) to vote in the election of directors, managers or trustees
thereof is at the time owned or controlled, directly or indirectly, by such
Person or one or more of the other Subsidiaries of such Person (or a combination
thereof) and (ii) any partnership (a) the sole general partner or the managing
general partner of which is such Person or a Subsidiary of such Person or (b)
the only general partners of which are such Person or of one or more
Subsidiaries of such Person (or any combination thereof). Notwithstanding the
foregoing, an Unrestricted Subsidiary and all of its Subsidiaries shall not be
Subsidiaries of the Company for any purposes of the Indenture.
"UNRESTRICTED SUBSIDIARY" means (i) any Person that (a) is acquired or
formed after the date of the Indenture and that is organized under the laws of a
jurisdiction other than the United States of America, any state thereof or the
District of Columbia, (b) at the time of acquisition or formation shall be
designated an Unrestricted Subsidiary by the Board of Directors of the Company
in the manner provided below and (c) would, but for such designation, be a
Subsidiary of the Company and (ii) any Subsidiary of an Unrestricted Subsidiary.
The Board of Directors of the Company shall make any such designation if (i)
such Subsidiary does not, directly or indirectly, own any Capital Stock or
Indebtedness of, or own or hold any Lien on any property of, the Company or any
other Subsidiary of the Company that is not a Subsidiary of the Subsidiary to be
so designated; (ii) the amount of the Investment by the Company or any of its
Subsidiaries in such Unrestricted Subsidiary would be permitted under " --
Certain Covenants -- Restricted Payments" as a "Restricted Payment" after giving
effect to the designation; and (iii) all Indebtedness of such Unrestricted
Subsidiary is Non-Recourse Debt. The Board of Directors of the Company may
designate any Unrestricted Subsidiary
66
<PAGE>
to be a Subsidiary; provided, HOWEVER, that immediately after giving pro forma
effect to such designation (1) the Company could incur $1.00 of additional
Indebtedness pursuant to the Consolidated Interest Coverage Ratio test in " --
Certain Covenants -- Limitation on Indebtedness" and (2) no Default or Event of
Default shall have occurred and be continuing following such designation. Any
such designation by the Board of Directors of the Company shall be evidenced to
the Trustee by promptly filing with the Trustee a copy of the board resolution
giving effect to such designation and an officers' certificate certifying that
such designation complies with the foregoing provisions.
"U.S. GOVERNMENT OBLIGATIONS" means (i) securities that are (a) direct
obligations of the United States of America for the payment of which the full
faith and credit of the United States of America is pledged or (b) obligations
of a Person controlled or supervised by and acting as an agency or
instrumentality of the United States of America the payment of which is
unconditionally guaranteed as a full faith and credit obligation by the United
States of America, which, in either case, are not callable or redeemable at the
option of the issuer thereof; and (ii) depositary receipts issued by a bank (as
defined in Section 3(a)(2) of the Securities Act) as custodian with respect to
any U.S. Government Obligation which is specified in clause (i) above and held
by such bank for the account of the holder of such depositary receipt, or with
respect to any specific payment of principal or interest on any U.S. Government
Obligation which is so specified and held, PROVIDED that (except as required by
law) such custodian is not authorized to make any deduction from the amount
payable to the holder of such depository receipt from any amount received by the
custodian in respect of the U.S. Government Obligation or the specific payment
of principal or interest of the U.S. Government Obligation evidenced by such
depositary receipt.
"VOTING STOCK" of a corporation means all classes of Capital Stock of such
corporation then outstanding and normally entitled to vote in the election of
directors.
"WEIGHTED AVERAGE LIFE TO MATURITY" means, when applied to any
Indebtedness at any date, the number of years obtained by dividing (i) the sum
of the product obtained by multiplying (a) the amount of each then remaining
installment, sinking fund, serial maturity or other required payments of
principal, including payments at final maturity, in respect thereof, by (b) the
number of years (calculated to the nearest one-twelfth) that will elapse between
such date and the making of such payment, by (ii) the then outstanding principal
amount of such Indebtedness.
"WHOLLY OWNED SUBSIDIARY" of any Person means a Subsidiary of such Person
all of the outstanding Capital Stock or other ownership interests of which
(other than directors' qualifying shares) shall at the time be owned by such
Person or by one or more Wholly Owned Subsidiaries of such Person. Unrestricted
Subsidiaries shall not be included in the definition of Wholly Owned Subsidiary
for any purpose of the Indenture.
DESCRIPTION OF CERTAIN INDEBTEDNESS
CREDIT AGREEMENT
Concurrently with the consummation of the Tender Offer and the issuance of
the Old Notes, the Company executed the Credit Agreement with Agent Bank with
respect to a $165 million credit facility consisting of a $75 million revolving
credit facility, which included a $15 million sublimit for the issuance of
standby and commercial letters of credit, and a $90 million term loan facility.
The proceeds of the Credit Agreement were used to finance a portion of the
Acquisition, and to refinance the credit facilities of Maxxim Delaware and
Sterile Concepts, and will be used for working capital, capital expenditures,
and other purposes. Portions of Agent Bank's rights and obligations under the
Credit Agreement and the documents, instruments and agreements executed in
connection therewith were subsequently assigned to and assumed by members of a
syndicate of lenders (the "Lenders") which includes Agent Bank.
The principal portion of the revolving loan will mature and become due and
payable July 31, 2002. The principal of the term loan portion of the Credit
Agreement is to be repaid in quarterly installments aggregating annual amounts
during each year of the term loan of $6 million, $12 million, $15 million, $17.5
million, $17.5 million and $22 million, and will mature and become due and
payable July 31, 2002. The indebtedness evidenced by the Credit
67
<PAGE>
Agreement bears interest at a rate equal to LIBOR or the Alternate Base Rate
(defined as the higher of (1) the Agent Bank's prime rate and (2) the Federal
Funds rate plus 0.50%), plus a margin which depends on the ratio of total Funded
Debt to EBITDA. The Company is permitted to prepay the Indebtedness evidenced by
the Credit Agreement in whole or in part at any time without penalty or premium
(subject to reimbursement of Lenders' breakage and redeployment costs actually
incurred in the case of prepayment of LIBOR borrowings), and must prepay such
Indebtedness with the proceeds of certain asset sales, and permitted debt and
equity issuances.
Repayment of the Indebtedness evidenced by the Credit Agreement is secured
by a first priority security interest in all of the capital stock of Maxxim's
domestic Subsidiaries (including Sterile Concepts and its Subsidiaries since the
date of the Merger), and sixty-five percent of the capital stock of each of its
foreign Subsidiaries, which capital stock shall not be subject to any other lien
or encumbrance. In addition, repayment is guaranteed by all existing and newly
created subsidiaries of the Company, including, since the date of the Merger,
Sterile Concepts and its Subsidiaries.
The Credit Agreement contains representations and warranties, events of
default, financial and other covenants, cost and yield protections,
indemnification and other provisions which are usual and customary for
transactions of this type. In addition, the Agent Bank, which has been and will
be paid customary fees in connection with the establishment and administration
of the loans described in the Credit Agreement, is an affiliate of NCMI, one of
the Initial Purchasers of the Old Notes.
6 3/4% CONVERTIBLE SUBORDINATED DEBENTURES
The Company is also currently indebted in the aggregate principal amount
of approximately $28,750,000 under certain 6 3/4% Convertible Subordinated
Debentures (the "Debentures") issued under an Indenture (the "1993 Indenture")
dated as of March 18, 1993, between the Company, as Issuer, and Chemical Bank,
as Trustee (the "Debenture Trustee"). The Debentures represent unsecured general
obligations of the Company, subordinate in right of payment to the Notes and
certain other obligations of the Company, and are convertible into Common Stock
of the Company. Interest on the indebtedness evidenced by the Debentures is
payable at the annual rate of 6 3/4% semiannually on March 1 and September 1.
The Debentures were issued in fully registered form, and will mature on March 1,
2003. The 1993 Indenture does not contain any financial covenants, nor any
limitation on the Company's ability to incur Debenture Senior Indebtedness, as
hereinafter defined. The 1993 Indenture was filed as an exhibit to the
Registration Statement filed with the Commission in order to register the
Debentures, and is also available for inspection at the office of the Debenture
Trustee.
SUBORDINATION OF DEBENTURES. The indebtedness evidenced by the Debentures
and the payment of principal and interest thereon, including any redemption or
repurchase price, are subordinate and subject in right of payment to the prior
payment in full of all Debenture Senior Indebtedness, including the Notes.
"Debenture Senior Indebtedness" means all indebtedness of the Company for money
borrowed, other than the Debentures, whether outstanding on the date of the 1993
Indenture or thereafter created, incurred or assumed, except indebtedness that
by the terms of the instrument or instruments by which such indebtedness was
created, incurred or assumed expressly provides that it (i) is junior in right
of payment to the Debentures or (ii) ranks PARI PASSU with the Debentures.
CONVERSION OF DEBENTURES. The holders of Debentures are entitled at any
time prior to the close of business on March 1, 2003, subject to prior
redemption, to convert any Debentures or portions thereof into Common Stock of
the Company, at the conversion price of $18 per share, subject to adjustment on
certain standard terms and conditions.
OPTIONAL REDEMPTION BY THE COMPANY. The Debentures are redeemable at the
option of the Company at any time, on at least 30 but not more than 60 days'
notice, at the option of the Company, as a whole or in part, at redemption
prices which are currently 105% of the principal amount, and decline to 100% of
the principal amount in 2002.
67
<PAGE>
REPURCHASE AT OPTION OF HOLDERS. If a Repurchase Event (as described
below) occurs, each holder of Debentures will have the right, at the holder's
option, to require the Company to redeem all or a portion of such holder's
Debentures on a date designated by the Company (the "Repurchase Date") that is
not less than 30 nor more than 60 days after the date of the Company's notice of
such Repurchase Event. The Company will redeem such Debentures at a price equal
to the principal amount of the Debentures, plus accrued interest to the
Repurchase Date. The term "Repurchase Event" includes (i) acquisitions of stock
by a person or group that results in such person or group having 50% of the
voting power allocable to the Company's voting capital stock, (ii) acquisition
by the Company in any twelve-month period of more than 30% of its capital stock,
(iii) certain changes in the composition of the Board of Directors, (iv) certain
consolidations or mergers, or the sale of more than two-thirds of the Company's
assets, or (v) certain distributions by the Company with respect to its capital
stock, resulting in the payment or distribution to holders of capital stock of
the Company of over 30% of the Company's assets in any twelve-month period.
PLAN OF DISTRIBUTION
Each broker-dealer that receives New Notes for its own account pursuant to
the Exchange Offer must acknowledge that it will deliver a prospectus in
connection with any resale of such New Notes. This Prospectus, as it may be
amended or supplemented from time to time, may be used by a broker-dealer in
connection with resales of New Notes received in exchange for Old Notes where
such Old Notes were acquired as a result of market-making activities or other
trading activities. The Company has agreed that, starting on the Expiration Date
and ending on the close of business one year after the Expiration Date, it will
make this Prospectus, as amended or supplemented, available to any broker-dealer
for use in connection with any such resale. In addition, until such date all
dealers effecting transactions in the New Notes may be required to deliver a
prospectus.
The Company will not receive any proceeds from any sales of New Notes by
broker-dealers or others. New Notes received by broker-dealers for their own
account pursuant to the Exchange Offer may be sold from time to time in one or
more transactions in the over-the-counter market, in negotiated transactions,
through the writing of options on the New Notes or a combination of such methods
of resale, at market prices prevailing at the time of resale, at prices related
to such prevailing market prices or negotiated prices. Any such resale may be
made directly to purchasers or to or through brokers or dealers who may receive
compensation in the form of commissions or concessions from any such
broker-dealer and/or the purchasers of any such New Notes. Any broker-dealer
that resells New Notes that were received by it for its own account pursuant to
the Exchange Offer and any broker or dealer that participates in a distribution
of such New Notes may be deemed to be an "underwriter" within the meaning of the
Securities Act and any profit from any such resale of New Notes and any
commissions received by any such persons may be deemed to be underwriting
compensation under the Securities Act. The Letter of Transmittal states that by
acknowledging that it will deliver and by delivering a prospectus, a
broker-dealer will not be deemed to admit that it is an "underwriter" within the
meaning of the Securities Act.
For a period of one year after the Expiration Date, the Company will
promptly send additional copies of this Prospectus and any amendment or
supplement to this Prospectus to any broker-dealer that requests such documents
in the Letter of Transmittal. The Company has agreed to pay all expenses
incident to the Exchange Offer (including the expenses of one counsel for the
holders of the Notes) other than commissions or concessions of any brokers or
dealers and will indemnify the holders of the Notes (including any
broker-dealers) against certain liabilities, including liabilities under the
Securities Act.
69
<PAGE>
LEGAL MATTERS
The legality of the Notes and the Note Guarantees will be passed upon for
the Company by Boyer, Ewing & Harris Incorporated, Houston, Texas.
EXPERTS
The financial statements of the Company as of October 29, 1995 and October
30, 1994, and for each of the years in the three-year period ended October 29,
1995 have been incorporated by reference herein and in the registration
statement in reliance upon the report of KPMG Peat Marwick LLP, independent
certified public accountants, incorporated by reference herein, and upon the
authority of said firm as experts in accounting and auditing.
The financial statements of Sterile Concepts as of September 30, 1995 and
1994, and for each of the years in the three-year period ended September 30,
1995 have been incorporated by reference herein and in the registration
statement in reliance upon the report of KPMG Peat Marwick LLP, independent
certified public accountants, incorporated by reference herein, and upon the
authority of said firm as experts in accounting and auditing.
70
<PAGE>
================================================================================
ALL TENDERED OLD NOTES, EXECUTED LETTERS OF TRANSMITTAL AND OTHER RELATED
DOCUMENTS SHOULD BE DIRECTED TO THE EXCHANGE AGENT. QUESTIONS AND REQUESTS FOR
ASSISTANCE AND REQUESTS FOR ADDITIONAL COPIES OF THE PROSPECTUS, THE LETTER OF
TRANSMITTAL AND OTHER RELATED DOCUMENTS SHOULD BE ADDRESSED TO THE EXCHANGE
AGENT AS FOLLOWS:
BY HAND, REGISTERED OR CERTIFIED MAIL
OR OVERNIGHT CARRIER:
FIRST UNION NATIONAL BANK
OF NORTH CAROLINA
230 South Tryon Street, 11th Floor
Charlotte, North Carolina 28288-1153
Attn: Corporate Trust Operations
BY FACSIMILE: (704) 383-9716
Confirm by telephone: (704) 383-0048
(ORIGINALS OF ALL DOCUMENTS SUBMITTED BY FACSIMILE SHOULD BE SENT PROMPTLY
BY HAND, OVERNIGHT COURIER, OR REGISTERED OR CERTIFIED MAIL).
NO DEALER, SALESPERSON OR OTHER PERSON IS AUTHORIZED IN CONNECTION WITH
ANY OFFERING MADE HEREBY TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATION
NOT CONTAINED IN THIS PROSPECTUS, AND, IF GIVEN OR MADE, SUCH INFORMATION OR
REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY
OR BY THE INITIAL PURCHASERS. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO
SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY OTHER THAN THE SECURITIES
OFFERED HEREBY, NOR DOES IT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN
OFFER TO BUY ANY OF THE SECURITIES OFFERED HEREBY TO ANY PERSON IN ANY
JURISDICTION IN WHICH IT IS UNLAWFUL TO MAKE SUCH AN OFFER OR SOLICITATION TO
SUCH PERSON. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER
SHALL UNDER ANY CIRCUMSTANCE CREATE ANY IMPLICATION THAT THE INFORMATION
CONTAINED HEREIN IS CORRECT AS OF ANY DATE SUBSEQUENT TO THE DATE HEREOF.
UNTIL NOVEMBER __, 1996 (25 DAYS AFTER THE DATE OF THIS EXCHANGE OFFER),
ALL DEALERS EFFECTING TRANSACTIONS IN NEW NOTES, WHETHER OR NOT PARTICIPATING IN
THIS EXCHANGE OFFER, MAY BE REQUIRED TO DELIVER A PROSPECTUS.
OFFER TO EXCHANGE ALL OUTSTANDING
10 1/2% SENIOR SUBORDINATED
NOTES DUE 2006
($100,000,000 PRINCIPAL AMOUNT)
FOR
10 1/2% SENIOR SUBORDINATED
NOTES DUE 2006
[MAXXIM MEDICAL LOGO]
P R O S P E C T U S
OCTOBER __ , 1996
================================================================================
71
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 20. INDEMNIFICATION OF OFFICERS AND DIRECTORS
Under Article 1302-7.06 of the Texas Miscellaneous Corporation Laws Act,
the articles of incorporation of a Texas corporation may provide that a director
of that corporation shall not be liable, or shall be liable only to the extent
provided in the articles of incorporation, to the corporation or its
shareholders for monetary damages for acts or omissions in the director's
capacity as a director, except that the articles of incorporation cannot provide
for the elimination or limitation of liability of a director to the extent that
the director is found liable for (i) a breach of the director's duty of loyalty
to the corporation or its shareholders, (ii) acts or omissions not in good faith
that constitute a breach of duty of the director to the corporation or an act or
omission that involves intentional misconduct or a knowing violation of the law,
(iii) any transaction from which the director received an improper personal
benefit, or (iv) an act or omission for which the liability of a director is
expressly provided by an applicable statute. Article XI of the Company's
Restated Articles of Incorporation sets forth specific provisions for limitation
of director liability which are substantially identical to the provisions of
Article 1302-7.06 described above and further states that a director of the
Company will not be liable to the Company or its shareholders for monetary
damages to the fullest extent permitted by any provision of the statutes of
Texas that limits the liability of a director.
In addition, Article 2.02-1 of the Texas Business Corporation Act
authorizes a Texas corporation to indemnify a person who was, is, or is
threatened to be made a named defendant or respondent in a proceeding, including
any threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative, arbitrative, or investigative because the person is or
was a director. The indemnification is permitted only if it is determined that
the person (1) conducted himself in good faith; (2) reasonably believed (a) in
the case of conduct in his official capacity as a director of the corporation,
that his conduct was in the corporation's best interests; and (b) in all other
cases, that his conduct was at least not opposed to the corporation's best
interests; and (3) in the case of any criminal proceeding, had no reasonable
cause to believe his conduct was unlawful. A person may be indemnified under
Article 2.02-1 against judgments, penalties (including excise and similar
taxes), fines, settlements, and reasonable expenses actually incurred by the
person (including court costs and attorneys' fees), but if the person is found
liable to the corporation or is found liable on the basis that personal benefit
was improperly received by him, the indemnification is limited to reasonable
expenses actually incurred and may not be made in respect of any proceeding in
which the person has been found liable for willful or intentional misconduct in
the performance of his duty to the corporation. A corporation is obligated under
Article 2.02-1 to indemnify a director or officer against reasonable expenses
incurred by him in connection with a proceeding in which he is named a defendant
or respondent because he is or was a director or officer if he has been wholly
successful, on the merits or otherwise, in the defense of the proceeding. Under
Article 2.02-1 a corporation may (i) indemnify and advance expenses to an
officer, employee, agent or other person who are or were serving at the request
of the corporation as a director, officer, partner venturer, proprietor,
trustee, employee, agent or similar functionary of another entity to the same
extent that it may indemnify and advance expenses to directors, (ii) indemnify
and advance expenses to directors and such other persons to such further extent,
consistent with law, as may be provided in the corporation's articles of
incorporation, bylaws, action of its board of directors, or contract or as
permitted by common law and (iii) purchase and maintain insurance or another
arrangement on behalf of directors and such other persons against any liability
asserted against him and incurred by him in such a capacity or arising out of
his status as such a person. The Bylaws of the Company set forth specific
provisions for indemnification of directors, officers, agents and other persons
which are substantially identical to the provisions of Article 2.02-1 described
above. The Company maintains directors and officers insurance in the amount of
$2,000,000, with a $50,000 deductible, that will be effective through November
1, 1996.
II-1
<PAGE>
ITEM 21. EXHIBITS
EXHIBIT
NUMBER EXHIBIT DESCRIPTION
1.1 Purchase Agreement dated July 18, 1996 between Maxxim and Initial
Purchasers relating to the Old Notes (Filed as Exhibit No. 3 to the Form
8-K of Maxxim, filed with the Commission on August 14, 1996 and
incorporated herein by reference).
2.1 Agreement and Plan of Merger dated as of June 10, 1996, by and among
Maxxim-Delaware, Maxxim Acquisition and Sterile Concepts (Filed as
Exhibit (d) to the Schedule 14D-1 of Maxxim, Maxxim-Delaware, and
Purchaser, with the Commission on June 14, 1996 and incorporated herein
by reference).
4.1 Indenture dated July 30, 1996, by and among Maxxim, as Issuer,
Maxxim-Delaware, Purchaser, Fabritek La Romana, Inc., Maxxim Medical
Canada Limited, Medica B.V. and Medica Hospital Supplies, N.V., as
Guarantors and First Union National Bank of North Carolina, as Trustee
(Filed as Exhibit No. 4 to the Form 8-K of Maxxim, filed with the
Commission on August 14, 1996 and incorporated herein by reference).
*4.4 Registration Rights Agreement dated as of July 18, 1996, executed by
Maxxim and Initial Purchasers.
5.1 Opinion of Boyer, Ewing & Harris Incorporated, counsel to the Company,
as to the validity of the New Note.
10.1 Second Amended and Restated Credit Agreement, dated July 30, 1996, by
and among Maxxim, NationsBank of Texas, N.A. and the banks named therein
(Filed as Exhibit No. 2 to the 8-K of Maxxim, filed with the Commission
on August 14, 1996 and incorporated herein by reference).
12.1 Computation of Ratio of Earnings to Fixed Charges.
24.1 Consents of KPMG Peat Marwick LLP
24.2 Consent of Boyer, Ewing & Harris Incorporated is contained in
Exhibit 5.1 to the Registration Statement.
*25.1 Powers of Attorney. A power of attorney, pursuant to which amendments to
this Registration Statement may be filed, is included in the signature
pages contained in Part II.
99.1 Form of Letter of Transmittal
99.2 Form of Notice of Guaranteed Delivery
- ------------
* Previously Filed
II-2
<PAGE>
ITEM 22. UNDERTAKINGS
(a) The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
Registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(b) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question of whether such
indemnification by it is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.
(c) The undersigned registrant hereby undertakes to respond to requests
for information that is incorporated by reference into the Prospectus pursuant
to Items 4, 10(b), 11, or 13 of this Form, within one business day of receipt of
such request, and to send the incorporated documents by first class mail or
other equally prompt means. This includes information contained in documents
filed subsequent to the effective date of the Registration Statement through the
date of responding to the request.
(d) The undersigned registrant hereby undertakes to supply by means of a
post-effective amendment all information concerning a transaction, and the
company being acquired involved therein, that was not the subject of and
included in the Registration Statement when it becomes effective.
(e) The undersigned registrant hereby undertakes that:
(1) For purposes of determining any liability under the Securities
Act of 1933, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and
contained in a form of prospectus filed by the registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933 shall
be deemed to be part of this registration statement as of the time it
was declared effective.
(2) For purposes of determining any liability under the Securities
Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering
thereof.
II-3
<PAGE>
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED,
THE REGISTRANT CERTIFIES THAT IT HAS REASONABLE GROUNDS TO BELIEVE THAT IT MEETS
ALL OF THE REQUIREMENTS FOR FILING ON FORM S-4 AND HAS DULY CAUSED THIS
AMENDMENT NO. 1 TO THE REGISTRATION STATEMENT ON FORM S-4 TO BE SIGNED ON ITS
BEHALF BY THE UNDERSIGNED, THERETO DULY AUTHORIZED, IN THE CITY OF HOUSTON,
STATE OF TEXAS, ON OCTOBER 23, 1996.
MAXXIM MEDICAL, INC.
By: /s/ KENNETH W. DAVIDSON
Kenneth W. Davidson, Chairman of the Board,
President and Chief Executive Officer
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1933, AS
AMENDED, THIS AMENDMENT NO. 1 TO THE REGISTRATION STATEMENT ON FORM S-4 HAS BEEN
SIGNED BY THE FOLLOWING PERSONS IN THE CAPACITIES AND ON THE DATES INDICATED.
SIGNATURES TITLES DATE
/s/ KENNETH W. DAVIDSON Chairman of the Board of October 23 , 1996
(KENNETH W. DAVIDSON) Directors, President and Chief
Executive Officer (principal
executive officer)
/s/ PETER M. GRAHAM Executive Vice President, October 23, 1996
(PETER M. GRAHAM) Treasurer and Chief Operating
Officer (principal financial officer)
/s/ ALAN S. BLAZEI Vice President - Controller October 23, 1996
(ALAN S. BLAZEI) (principal accounting officer)
II-4
<PAGE>
* /s/ DONALD R. DEPRIEST Director October 23, 1996
(DONALD R. DEPRIEST)
__________________________ Director October __, 1996
(PETER G. DORFLINGER)
* /s/ MARTIN GRABOIS, M.D. Director October 23, 1996
(MARTIN GRABOIS, M.D.)
* /s/ ERNEST J. HENLEY, PH.D. Director October 23, 1996
(ERNEST J. HENLEY, PH.D.)
__________________________ Director October __, 1996
(RICHARD O. MARTIN, PH.D.)
__________________________ Director October __, 1996
(HENK R. WAFELMAN)
A Power of Attorney authorizing Kenneth W. Davidson to execute
amendments to this Registration Statement on behalf of the above-named directors
and officers was included in the Registration Statement as originally filed by
the Registrant with the Commission on October 1, 1996.
* By: /s/ KENNETH W. DAVIDSON
(Kenneth W. Davidson)
Attorney-in-Fact
II-5
EXHIBIT 5.1
October 23, 1996
Maxxim Medical, Inc.
104 Industrial Boulevard
Sugar land, Texas 77478
Attn: Mr. Kenneth W. Davidson
Gentlemen:
We have acted as counsel for Maxxim Medical, Inc., a Texas corporation
(the "Corporation"), in connection with the registration with the Securities and
Exchange Commission (the "Commission") under the Securities Act of 1933, as
amended (the "Securities Act"), $100,000,000 in principal amount of 10-1/2% of
its Senior Subordinated Notes due 2006 (the "Notes") in connection with the
exchange offer (the "Exchange Offer") of $100,000,000 in previously issued
10-1/2% Senior Subordinated Notes due 2006 (the "Old Notes") for the Notes.
We have made such inquiries and examined such documents as we have
considered necessary or appropriate for the purpose of giving the opinions
hereinafter set forth, including:
(i) the Articles of Incorporation of the Corporation, as filed with the
Secretary of State of Texas and as amended to date;
(ii) the Bylaws and stock ledgers and transfer books of the Corporation
and the records of the official proceedings of shareholders or
stockholders and directors of the Corporation through the date of this
opinion;
(iii) the Indenture dated July 30, 1996, by and among Maxxim, as
Issuer, Maxxim-Delaware, Purchaser, Fabritek La Romana, Inc., Maxxim
Medical Canada Limited, Medica B.V. and Medica Hospital Supplies,
N.V., as Guarantors and First Union National Bank of North Carolina, as
Trustee, filed as Exhibit No. 4 to the Form 8-K of Maxxim filed with the
Commission on August 14, 1996;
(iv) the Registration Statement of the Corporation on Form S-4
(Registration No. 333-13215), filed with the Commission on October 1, 1996
pursuant to Rule 145 of the Securities Act and Amendment No. 1 to the
Registration Statement to be filed with the Commission on October 23, 1996
(collectively, the "Registration Statement"); and
(v) such other documents as we have deemed necessary for the expression of
the opinions contained herein, including, but not limited to, all of the
Exhibits to the Registration Statement.
<PAGE>
Maxxim Medical, Inc.
October 23, 1996
Page 2
We have assumed the genuineness and authenticity of all signatures on all
original documents, the authenticity of all documents submitted to us as
originals, the conformity to originals of all documents submitted to us as
copies, the due authorization, execution, delivery or recordation of all
documents where due authorization, execution, delivery or recordation are
prerequisites to the effectiveness thereof.
Based upon the foregoing, and having regard for such legal considerations
as we deem relevant, we are of the opinion (limited, in all respects, to the
laws of the United States and the State of Texas) that:
(i) the Corporation is a corporation duly organized, validly existing,
and in good standing under the laws of the State of Texas; and
(ii) upon valid tender of the Old Notes (as defined in the Registration
Statement) to First Union National Bank of North Carolina, as exchange
agent for the Exchange Offer, and issuance of the Notes in exchange for
such tendered Old Notes, in accordance with the terms and provisions of
the Registration Statement, the Notes issued and exchanged for such
tendered Old Notes will be validly issued obligations of the Corporation.
We hereby consent to the filing of this opinion with the Commission as an
Exhibit to the Registration Statement and to the use of our name under the
caption "Legal Matters" in the prospectus constituting a part of the
Registration Statement.
Yours very truly,
BOYER, EWING & HARRIS INCORPORATED
EXHIBIT 12.1
MAXXIM
RATIO OF EARNINGS TO FIXED CHARGES
<TABLE>
<CAPTION>
Pro Forma
----------------------------------------------
9 months 9 months 9 months 9 months
1991 1992 1993 1994 1995 1995 1996 1995 1996
------ ------ ------ ------ ------ ------ ------ ------ ------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Pre-tax income....... 3,494 5,853 8,887 13,464 8,893 2,498 19,618 26,390 28,463
Interest Expense..... 1,163 999 1,476 2,059 4,088 2,001 5,582 22,415 17,788
Total........... 4,657 6,852 10,363 15,523 12,981 4,499 25,200 48,805 46,251
Ratio of earnings
to fixed charges... 400.43% 685.89% 702.10% 753.91% 317.54% 224.84% 451.45% 217.73% 260.01%
</TABLE>
EXHIBIT 24.1
INDEPENDENT AUDITORS' CONSENT
We consent to the use of our report incorporated herein by reference and to the
reference to our firm under the heading "Experts" in the prospectus.
Richmond, Virginia
October 23, 1996
<PAGE>
INDEPENDENT AUDITORS' CONSENT
The Board of Directors
Maxxim Medical, Inc.
We consent to the use of our report incorporated herein by reference and to the
reference to our firm under the heading "Experts" in the prospectus.
Houston, Texas
October 23, 1996
EXHIBIT 99.1
LETTER OF TRANSMITTAL
MAXXIM MEDICAL, INC.
OFFER TO EXCHANGE
10 1/2% SENIOR SUBORDINATED NOTES DUE 2006 WHICH HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
FOR ANY AND ALL OUTSTANDING
10 1/2% SENIOR SUBORDINATED NOTES DUE 2006
Pursuant to the Prospectus dated October __, 1996.
THE EXCHANGE OFFER WILL EXPIRE AT 5:00 P.M. NEW YORK CITY TIME,
ON NOVEMBER 25, 1996, UNLESS EXTENDED (THE "EXPIRATION DATE").
TENDERS MAY BE WITHDRAWN PRIOR TO 5:00 P.M.,
NEW YORK CITY TIME, ON NOVEMBER 25, 1996.
BY MESSENGER, MAIL, OR OVERNIGHT DELIVERY:
First Union National Bank of North Carolina
230 South Tryon Street, 11th Floor
Charlotte, North Carolina 28288-1153
Attention: Corporate Trust Operations
FACSIMILE TRANSMISSION:
(704) 383-9716
CONFIRM BY TELEPHONE:
(704) 383-0048
Ms. Marilyn Johnson
DELIVERY OF THIS INSTRUMENT TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE,
OR TRANSMISSION OF INSTRUCTIONS VIA FACSIMILE OTHER THAN AS SET FORTH ABOVE,
WILL NOT CONSTITUTE A VALID DELIVERY.
The undersigned acknowledges receipt of the Prospectus, dated October
__, 1996 (the "Prospectus"), of Maxxim Medical, Inc., a Texas corporation (the
"Company"), and this Letter of Transmittal (this "Letter"), which together
constitute the offer (the "Exchange Offer") to exchange an aggregate principal
amount of up to $100,000,000 10 1/2% Senior Subordinated Notes Due 2006 (the
"New Notes") for an equal principal amount of the outstanding 10 1/2% Senior
Subordinated Notes Due 2006 (the "Old Notes").
For each Old Note accepted for exchange, the holder of such Old Note
will receive a New Note having a principal amount at maturity equal to that of
the surrendered Old Note. The New Notes will bear interest at a rate equal to 10
1/2% per annum. Interest on the New Notes is payabLE semiannually, commencing
February 1, 1997, on February 1 and August 1 of each year (each,
<PAGE>
an "Interest Payment Date") and shall accrue from July 30, 1996, or from the
most recent Interest Payment Date with respect to the Old Notes to which
interest was paid or for which interest was duly provided. The New Notes will
mature on August 1, 2006.
Subject to certain exceptions, in the event of a Registration Default
(as defined below), holders of Old Notes are entitled to receive Liquidated
Damages of $0.05 per week per $1,000 principal amount of Old Notes held by such
holders (up to a maximum n of $0.30 per week per $1,000 principal amount of Old
Notes). A "Registration Default" with respect to the Exchange Offer shall occur
if: (i) the Company fails to consummate the Exchange Offer on or prior to
December 15, 1996, or (ii) the Shelf Registration Statement or the Exchange
Offer Registration Statement is declared effective but thereafter ceases to be
effective during the period specified in the Registration Rights Agreement.
Holders of New Notes will not be and, upon consummation of the Exchange Offer,
holders of Old Notes will no longer be, entitled to (i) the right to receive the
Liquidated Damages or (ii) certain other rights under the Registration Rights
Agreement intended for holders of Old Notes. The Exchange Offer shall be deemed
consummated upon the occurrence of the delivery by the Company to the Registrar
under the Indenture of New Notes in the same aggregate principal amount as the
aggregate principal amount of Old Notes that are tendered by holders thereof
pursuant to the Exchange Offer.
The Company reserves the right, in its sole discretion, (i) to delay
accepting any Old Notes, (ii) to extend the Exchange Offer, in which event the
term "Expiration Date" shall mean the latest time and date to which the Exchange
Offer is extended, and (iii) to amend the terms of the Exchange Offer in any
manner. If the Exchange Offer is amended in a manner determined by the Company
to constitute a material change, the Company will promptly disclose such
amendments by means of a prospectus supplement that will be distributed to the
registered holders of the Old Notes. Modifications of the Exchange Offer,
including but not limited to extension of the period during which the Exchange
Offer is open, may require that at least five business days remain in the
Exchange Offer. In order to extend the Exchange Offer, the Company will notify
the Exchange Agent of any extension by oral or written notice and will make a
public announcement thereof, each prior to 9:00 a.m., New York City time, on the
next business day after the previously scheduled Expiration Date.
This Letter is to be completed by a holder of Old Notes either if Old
Notes are to be forwarded herewith or if a tender of Old Notes, if available, is
to be made by book-entry transfer to the account maintained by the Exchange
Agent at The Depository Trust Company (the "Book-Entry Transfer Facility")
pursuant to the procedure set forth in "The Exchange Offer" section of the
Prospectus. Holders of Old Notes whose Notes are not immediately available, or
who are unable to deliver their Notes or confirmation of the book-entry tender
of their Old Notes into the Exchange Agent's account at the Book-Entry Transfer
Facility (a "Book-Entry Confirmation") and all other documents required by this
Letter to the Exchange Agent on or prior to the Expiration Date, must tender
their Old Notes according to the guaranteed delivery procedures set forth in
"The Exchange Offer--Guaranteed Delivery Procedures" section of the Prospectus.
See Instruction 1. Delivery of documents to the Book Entry Transfer Facility
does not constitute delivery to the Exchange Agent.
<PAGE>
The undersigned has completed the appropriate boxes below and signed
this Letter to indicate the action the undersigned desires to take with respect
to the Exchange Offer.
<PAGE>
List below the Old Notes to which this Letter relates. If the space
provided below is inadequate, the Note numbers and principal amount of Old Notes
should be listed on a separate signed schedule affixed hereto.
- --------------------------------------------------------------------------------
<TABLE>
<S> <C> <C> <C>
DESCRIPTION OF OLD 1 2 3
NOTES
Aggregate
Name(s) and Address(es) Note Number(s)* Principal Amount Principal Amount
of Registered Holder(s) of Old Note(s) Tendered**
(Please fill in, if blank)
Total
</TABLE>
- --------------------------------------------------------------------------------
* Need not be completed if Old Notes are being tendered by book-entry
transfer.
** Unless otherwise indicated in this column, a holder will be deemed to have
tendered the entire principal amount represented by the Old Note indicated
in column 2. See Instruction 2. Old Notes tendered hereby must be in
denominations of principal amount of $1,000 and any integral multiple
thereof. See Instruction 1.
- --------------------------------------------------------------------------------
[ ] CHECK HERE IF TENDERED OLD NOTES ARE BEING DELIVERED BY BOOKENTRY TRANSFER
MADE TO THE ACCOUNT MAINTAINED BY THE EXCHANGE AGENT WITH THE BOOK-ENTRY
TRANSFER FACILITY AND COMPLETE THE FOLLOWING:
Name of Tendering Institution _____________________________________________
Account Number _______________ Transaction Code Number _________________
[ ] CHECK HERE IF TENDERED OLD NOTES ARE BEING DELIVERED PURSUANT TO A NOTICE
OF GUARANTEED DELIVERY PREVIOUSLY SENT TO THE EXCHANGE AGENT AND COMPLETE
THE FOLLOWING:
Name of Registered Holder(s) _____________________________________________
Window Ticket Number (if any) ____________________________________________
Date of Execution of Notice of Guaranteed Delivery _______________________
Name of Institution which guaranteed delivery ____________________________
IF DELIVERED BY BOOK-ENTRY TRANSFER, COMPLETE THE FOLLOWING:
Account Number ________________ Transaction Code Number ________________
<PAGE>
[ ] CHECK HERE IF YOU ARE A BROKER-DEALER AND WISH TO RECEIVE 10 ADDITIONAL
COPIES OF THE PROSPECTUS AND 10 COPIES OF ANY AMENDMENTS OR SUPPLEMENTS
THERETO.
Name:____________________________________________________________________
Address:_________________________________________________________________
<PAGE>
PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY
Ladies and Gentlemen:
Upon the terms and subject to the conditions of the Exchange Offer, the
undersigned hereby tenders to the Company the aggregate principal amount of Old
Notes indicated above. Subject to, and effective upon, the acceptance for
exchange of the Old Notes tendered hereby, the undersigned hereby sells, assigns
and transfers to, or upon the order of, the Company all right, title and
interest in and to such Old Notes as are being tendered hereby.
The undersigned hereby represents and warrants that the undersigned has
full power and authority to tender, sell, assign and transfer the Old Notes
tendered hereby and that the Company will acquire good and unencumbered title
thereto, free and clear of all liens, restrictions, charges and encumbrances and
not subject to any adverse claim when the same are accepted by the Company. The
undersigned hereby further represents that any New Notes acquired in exchange
for Old Notes tendered hereby will have been acquired in the ordinary course of
business of the person receiving such New Notes, whether or not such person is
the undersigned, that neither the holder of such Old Notes nor any such other
person is engaged in, or intends to engage in, a distribution of such New Notes,
or has an arrangement or understanding with any person to participate in the
distribution of such New Notes, and that neither the holder of such Old Notes
nor any such other person is an "affiliate," as defined in Rule 405 under the
Securities Act of 1933, as amended (the "Securities Act"), of the Company.
The undersigned also acknowledges that this Exchange Offer is being made
based upon the Company's understanding of an interpretation by the staff of the
Securities and Exchange Commission (the "Commission") as set forth in no-action
letters issued to third parties, including Exxon Capital Holdings Corporation,
SEC No-Action Letter (available April 13, 1989) (the "Exxon Capital Letter"),
Morgan Stanley & Co. Incorporated, SEC No-Action Letter (available June 5, 1991)
(the "Morgan Stanley Letter") and Shearman & Sterling, SEC No-Action Letter
(available July 2, 1993) (the "Shearman & Sterling Letter"), that the New Notes
issued in exchange for the Old Notes pursuant to the Exchange Offer may be
offered for resale, resold and otherwise transferred by holders thereof (other
than a broker-dealer who acquires such New Notes directly from the Company for
resale pursuant to Rule 144A under the Securities Act or any other available
exemption under the Securities Act or any such holder that is an "affiliate" of
the Company within the meaning of Rule 405 under the Securities Act), without
compliance with the registration and prospectus delivery provisions of the
Securities Act, provided that such New Notes are acquired in the ordinary course
of such holders' business and such holders are not engaged in, and do not intend
to engage in, a distribution of such New Notes and have no arrangement with any
person to participate in the distribution of such New Notes. If a holder of Old
Notes is engaged in or intends to engage in a distribution of the New Notes or
has any arrangement or understanding with respect to the distribution of the New
Notes to be acquired pursuant to the Exchange Offer, such holder could not rely
on the applicable interpretations of the staff of the Commission and must comply
with the registration and prospectus delivery requirements of the Securities Act
in connection with any secondary resale transaction. If the undersigned is a
broker-dealer that will receive New Notes for its own account in exchange for
Old Notes, it represents that the Old Notes to be exchanged for the New Notes
were acquired by
<PAGE>
it as a result of market-making activities or other trading activities and
acknowledges that it will deliver a prospectus in connection with any resale of
such New Notes; however, by so acknowledging and by delivering a prospectus, the
undersigned will not be deemed to admit that it is an "underwriter" within the
meaning of the Securities Act.
The undersigned will, upon request, execute and deliver any additional
documents deemed by the Company to be necessary or desirable to complete the
sale, assignment and transfer of the Old Notes tendered hereby. All authority
conferred or agreed to be conferred in this Letter and every obligation of the
undersigned hereunder shall be binding upon the successors, assigns, heirs,
executors, administrators, trustees in bankruptcy and legal representatives of
the undersigned and shall not be affected by, and shall survive, the death or
incapacity of the undersigned. This tender may be withdrawn only in accordance
with the procedures set forth in "The Exchange Offer--Withdrawal Rights" section
of the Prospectus.
Unless otherwise indicated herein in the box entitled "Special Issuance
Instructions" below, please deliver the New Notes (and, if applicable,
substitute Notes representing the remaining principal balance of any Old Note
exchanged only in part) in the name of the undersigned or, in the case of a
book-entry delivery of Old Notes, please credit the account indicated above
maintained at the Book-Entry Transfer Facility. Similarly, unless otherwise
indicated under the box entitled "Special Delivery Instructions" below, please
send the New Notes (and, if applicable, substitute Notes representing the
remaining principal balance of any Old Note exchanged only in part) to the
undersigned at the address shown above in the box entitled "Description of Old
Notes."
THE UNDERSIGNED, BY COMPLETING THE BOX ENTITLED "DESCRIPTION OF OLD
NOTES" ABOVE AND SIGNING THIS LETTER, WILL BE DEEMED TO HAVE TENDERED THE OLD
NOTES AS SET FORTH IN SUCH BOX ABOVE.
<PAGE>
SPECIAL ISSUANCE INSTRUCTIONS (See Instructions 3 and 4)
To be completed ONLY if Notes for Old Notes not
exchanged and/or New Notes are to be issued in the
name of and sent to someone other than the person(s)
whose signature(s) appear(s) on this Letter above, or
if Old Notes delivered by book-entry transfer which
are not accepted for exchange are to be returned by
credit to an account maintained at the Book-Entry
Transfer Facility other than the account indicated
above.
Issue New Notes and/or Old Notes to:
Name(s): ..............................................
(Please Type or Print)
.......................................................
(Please Type or Print)
Address:...............................................
.......................................................
(Including Zip Code)
(Complete accompanying Substitute Form W-9)
Credit unexchanged Old Notes delivered by book-
entry transfer to the Book-Entry Transfer Facility
account set forth below.
_______________________________________________________
(Book-Entry Transfer Facility
Account Number, if applicable)
- -------------------------------------------------------
SPECIAL DELIVERY INSTRUCTIONS
(See Instructions 3 and 4)
To be completed ONLY if Notes for Old Notes
not exchanged and/or New Notes are to be sent to
someone other than the person(s) whose signature(s)
appear(s) on this Letter above or to such person(s) at
an address other than shown in the box entitled
"Description of Old Notes" on this Letter above.
Mail New Notes and/or Old Notes to:
Name(s):..............................................
(Please Type or Print)
......................................................
(Please Type or Print)
Address:..............................................
......................................................
(Including Zip Code)
- ----------------------------------------------------------
IMPORTANT: THIS LETTER OR A FACSIMILE HEREOF (TOGETHER WITH THE OLD NOTES OR A
BOOK-ENTRY CONFIRMATION AND ALL OTHER REQUIRED DOCUMENTS OR THE NOTICE OF
GUARANTEED DELIVERY) MUST BE RECEIVED BY THE EXCHANGE AGENT PRIOR TO 5:00 P.M.,
NEW YORK TIME, ON THE EXPIRATION DATE.
PLEASE READ THIS LETTER OF TRANSMITTAL
CAREFULLY BEFORE COMPLETING ANY BOX ABOVE
<PAGE>
PLEASE SIGN HERE
(TO BE COMPLETED BY ALL TENDERING HOLDERS)
(COMPLETE ACCOMPANYING SUBSTITUTE FORM W-9)
Dated:...................................................................., 1996
..........................................................................x
..........................................................................x
(Signature(s) of Owner) (Date)
If a holder is tendering any Old Notes, this Letter must be signed by the
registered holder(s) as the name(s) appear(s) on the Note(s) for the Old Notes
or by any person(s) authorized to become registered holder(s) by endorsements
and documents transmitted herewith. If signature is by a trustee, executor,
administrator, guardian, officer or other person acting in a fiduciary or
representative capacity, please set forth full title. See Instruction 3.
Name(s):...............................................................
.......................................................................
(PLEASE TYPE OR PRINT)
Capacity:..............................................................
Address:...............................................................
.......................................................................
(INCLUDING ZIP CODE)
SIGNATURE GUARANTEE
(IF REQUIRED BY INSTRUCTION 3)
Signature(s) Guaranteed by
an Eligible Institution:...............................................
(AUTHORIZED SIGNATURE)
.......................................................................
(TITLE)
.......................................................................
(NAME AND FIRM)
Dated:..................................................................., 1996
<PAGE>
INSTRUCTIONS
FORMING PART OF THE TERMS AND CONDITIONS OF THE OFFER TO EXCHANGE
10 1/2% SENIOR SUBORDINATED NOTES DUE 2006, WHICH
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
FOR ANY AND ALL OUTSTANDING 10 1/2% SENIOR SUBORDINATED NOTES DUE 2006
MAXXIM MEDICAL, INC.
1. DELIVERY OF THIS LETTER AND OLD NOTES; GUARANTEED DELIVERY PROCEDURES.
This Letter is to be completed by holders of Old Notes either if Notes
are to be forwarded herewith or if tenders are to be made pursuant to the
procedures for delivery by book-entry transfer set forth in "The Exchange
Offer--Procedures for Tendering Old Notes" section of the Prospectus. Physically
tendered Old Notes, or Book-Entry Confirmation, as the case may be, as well as a
properly completed and duly executed Letter of Transmittal (or facsimile
thereof) and any other documents required by this Letter, must be received by
the Exchange Agent at the address set forth herein on or prior to the Expiration
Date, or the tendering holder must comply with the guaranteed delivery
procedures set forth below. Old Notes tendered hereby must be in denominations
of principal amount of $ 1,000 or any integral multiple thereof.
Holders whose Old Notes are not immediately available or who cannot
deliver their Notes and all other required documents to the Exchange Agent on or
prior to the Expiration Date, or who cannot complete the procedure for
book-entry transfer on a timely basis, may tender their Old Notes pursuant to
the guaranteed delivery procedures set forth in "The Exchange Offer--Guaranteed
Delivery Procedures" section of the Prospectus. Pursuant to such procedures: (i)
such tender must be made by or through an Eligible Institution and a Notice of
Guaranteed Delivery (as defined in the Letter of Transmittal) must be signed by
such Holder, (ii) on or prior to the Expiration Date, the Exchange Agent must
have received from the Holder and the Eligible Institution a properly completed
and duly executed Notice of Guaranteed Delivery (by facsimile transmission, mail
or hand delivery) setting forth the name and address of the Holder, the
certificate number or numbers of the tendered Old Notes, and the principal
amount of tendered Old Notes, stating that the tender is being made thereby and
guaranteeing that, within four (4) business days after the date of delivery of
the Notice of Guaranteed Delivery, the tendered Old Notes, a duly executed
Letter of Transmittal and any other required documents will be deposited by the
Eligible Institution with the Exchange Agent, and (iii) such properly completed
and executed documents required by the Letter of Transmittal and the tendered
Old Notes in proper form for transfer (or confirmation of a book-entry transfer
of such Old Notes into the Exchange Agent's account at DTC) must be received by
the Exchange Agent within four (4) business days after the Expiration Date. Any
Holder who wishes to tender Old Notes pursuant to the guaranteed delivery
procedures described above must ensure that the Exchange Agent receives the
Notice of Guaranteed Delivery and Letter of Transmittal relating to such Old
Notes prior to 5:00 p.m., New York City time, on the Expiration Date.
<PAGE>
The method of delivery of this Letter, the Old Notes and all other
required documents is at the election and risk of the tendering holders, but the
delivery will be deemed made only when actually received or confirmed by the
Exchange Agent. If Old Notes are sent by mail, it is suggested that the mailing
be made sufficiently in advance of the Expiration Date to permit delivery to the
Exchange Agent prior to 5:00 p.m., New York City time, on the Expiration Date.
See "The Exchange Offer" section of the Prospectus.
2. PARTIAL TENDERS (NOT APPLICABLE TO HOLDERS OF OLD NOTES WHO TENDER BY
BOOK-ENTRY TRANSFER).
If less than the entire principal amount of any submitted Note is to be
tendered, the tendering holder(s) should fill in the aggregate principal amount
to be tendered in the box above entitled "Description of Old Notes--Principal
Amount Tendered." A reissued Note representing the balance of nontendered
principal of any submitted Old Notes will be sent to such tendering holder,
unless otherwise provided in the appropriate box on this Letter, promptly after
the Expiration Date. THE ENTIRE PRINCIPAL AMOUNT OF ANY OLD NOTES DELIVERED TO
THE EXCHANGE AGENT WILL BE DEEMED TO HAVE BEEN TENDERED UNLESS OTHERWISE
INDICATED.
3. SIGNATURES ON THIS LETTER; ASSIGNMENTS AND ENDORSEMENT; GUARANTEE OF
SIGNATURES.
If this Letter is signed by the registered holder of the Old Notes
tendered hereby, the signature must correspond exactly with the name as written
on the face of the Notes without any change whatsoever.
If any tendered Old Notes are owned of record by two or more joint
owners, all such owners must sign this Letter.
If any tendered Old Notes are registered in different names on several
Notes, it will be necessary to complete, sign and submit as many separate copies
of this Letter as there are different registrations of Notes.
When this Letter is signed by the registered holder of the Old Notes
specified herein and tendered hereby, no endorsements of the submitted Notes or
separate instruments of assignment are required. If, however, the New Notes are
to be issued, or any untendered Old Notes are to be reissued, to a person other
than the registered holder, then endorsements of any Notes transmitted hereby or
separate instruments of assignment are required. Signatures on such Notes must
be guaranteed by an Eligible Institution.
If this Letter is signed by a person other than the registered holder of
any Notes specified herein, such Notes must be endorsed or accompanied by
appropriate instruments of assignment, in either case signed exactly as the name
of the registered holder appears on the Notes and the signatures on such Notes
must be guaranteed by an Eligible Institution.
<PAGE>
If this Letter or any Notes or instruments of assignment are signed by
trustees, executors, administrators, guardians, attorneys-in-fact, officers of
corporations or others acting in a fiduciary or representative capacity, such
persons should so indicate when signing, and, unless waived by the Company,
proper evidence satisfactory to the Company of their authority to so act must be
submitted.
Endorsements on Old Notes or signatures on instruments of assignment
required by this Instruction 3 must be guaranteed by a firm which is a member of
a registered national securities exchange or a member of the National
Association of Securities Dealers, Inc., by a commercial bank or trust company
having an office or correspondent in the United States or by an "eligible
guarantor" institution within the meaning of Rule 17Ad-15 under the Securities
Exchange Act of 1934 (an "Eligible Institution").
Signatures on this Letter need not be guaranteed by an Eligible
Institution, provided the Old Notes are tendered: (i) by a registered holder of
Old Notes (which term, for purposes of the Exchange Offer, includes any
participant in the Book-Entry Transfer Facility system whose name appears on a
security position listing as the holder of such Old Notes) tendered who has not
completed the box entitled "Special Issuance Instructions" or "Special Delivery
Instructions" on this Letter, or (ii) for the account of an Eligible
Institution.
4. SPECIAL ISSUANCE AND DELIVERY INSTRUCTIONS.
Tendering holders of Old Notes should indicate in the applicable box the
name and address to which New Notes issued pursuant to the Exchange Offer and/or
substitute Notes evidencing Old Notes not exchanged are to be issued or sent, if
different from the name or address of the person signing this Letter. In the
case of issuance in a different name, the employer identification or social
security number of the person named must also be indicated. A holder of Old
Notes tendering Old Notes by book-entry transfer may request that Old Notes not
exchanged be credited to such account maintained at the Book-Entry Transfer
Facility as such holder of Old Notes may designate hereon. If no such
instructions are given, such Old Notes not exchanged will be returned to the
name or address of the person signing this Letter.
5. TAX IDENTIFICATION NUMBER.
Federal income tax law generally requires that a tendering holder whose
Old Notes are accepted for exchange must provide the Company (as payor) with
such Holder's correct Taxpayer Identification Number ("TIN") on Substitute Form
W-9 below, which, in the case of a tendering holder who is an individual, is his
or her social security number. If the Company is not provided with the current
TIN or an adequate basis for an exemption, such tendering holder may be subject
to a $50 penalty imposed by the Internal Revenue Service. In addition, delivery
of New Notes to such tendering holder may be subject to backup withholding in an
amount equal to 31% of all reportable payments made after the exchange. If
withholding results in an overpayment of taxes, a refund may be obtained.
<PAGE>
Exempt holders of Old Notes (including, among others, all corporations
and certain foreign individuals) are not subject to these backup withholding and
reporting requirements. See the enclosed Guidelines of Certification of Taxpayer
Identification Number on Substitute Form W-9 (the "W-9 Guidelines") for
additional instructions.
To prevent backup withholding, each tendering holder of Old Notes must
provide its correct TIN by completing the "Substitute Form W-9" set forth below,
certifying that the TIN provided is correct (or that such holder is awaiting a
TIN) and that (i) the holder is exempt from backup withholding, (ii) the holder
has not been notified by the Internal Revenue Service that such holder is
subject to a backup withholding as a result of a failure to report all interest
or dividends or (iii) the Internal Revenue Service has notified the holder that
such holder is no longer subject to backup withholding. If the tendering holder
of Old Notes is a nonresident alien or foreign entity not subject to backup
withholding, such holder must give the Company a completed Form W-8, Notice of
Foreign Status. These forms may be obtained from the Exchange Agent. If the Old
Notes are in more than one name or are not in the name of the actual owner, such
holder should consult the W-9 Guidelines for information on which TIN to report.
If such holder does not have a TIN, such holder should consult the W-9
Guidelines for instructions on applying for a TIN, check the box in Part 2 of
the Substitute Form W-9 and write "applied for" in lieu of its TIN. Note:
checking-this box and writing "applied for" on the form means that such holder
has already applied for a TIN or that such holder intends to apply for one in
the near future. If such holder does not provide its TIN to the Company within
60 days, backup withholding will begin and continue until such holder furnishes
its TIN to the Company.
6. TRANSFER TAXES.
The Company will pay all transfer taxes, if any, applicable to the
transfer of Old Notes to it or its order pursuant to the Exchange Offer. If,
however, New Notes and/or substitute Old Notes not exchanged are to be delivered
to, or are to be registered or issued in the name of, any person other than the
registered holder of the Old Notes tendered hereby, or if tendered Old Notes are
registered in the name of any person other than the person signing this Letter,
or if a transfer tax is imposed for any reason other than the transfer of Old
Notes to the Company or its order pursuant to the Exchange Offer, the amount of
any such transfer taxes (whether imposed on the registered holder or any other
persons) will be payable by the tendering holder. If satisfactory evidence of
payment of such taxes or exemption therefrom is not submitted herewith, the
amount of such transfer taxes will be billed directly to such tendering holder.
EXCEPT AS PROVIDED IN THIS INSTRUCTION 6, IT IS NOT NECESSARY FOR
TRANSFER TAX STAMPS TO BE AFFIXED TO THE OLD NOTES SPECIFIED IN THIS LETTER.
7. WAIVER OF CONDITIONS.
The Company reserves the absolute right to waive satisfaction of any or
all conditions enumerated in the Prospectus.
<PAGE>
8. NO CONDITIONAL TENDERS.
No alternative, conditional, irregular or contingent tenders will be
accepted. All tendering holders of Old Notes, by execution of this Letter, shall
waive any right to receive notice of the acceptance of their Old Notes for
exchange.
Neither the Company, the Exchange Agent nor any other person is
obligated to give notice of any defect or irregularity with respect to any
tender of Old Notes nor shall any of them incur any liability for failure to
give any such notice.
9. MUTILATED, LOST, STOLEN OR DESTROYED OLD NOTES.
Any holder whose Old Notes have been mutilated, lost, stolen or
destroyed should contact the Exchange Agent at the address indicated above for
further instructions.
10. REQUESTS FOR ASSISTANCE OR ADDITIONAL COPIES.
Questions relating to the procedure for tendering, as well as requests
for additional copies of the Prospectus and this Letter, may be directed to the
Exchange Agent, at the address and telephone number indicated above.
<PAGE>
TO BE COMPLETED BY ALL TENDERING HOLDERS
(SEE INSTRUCTION 5)
PAYOR'S NAME: MAXXIM MEDICAL, INC.
- --------------------------------------------------------------------------------
SUBSTITUTE Part 1 -- PLEASE PROVIDE YOUR
Form W-9 TIN IN THE BOX AT RIGHT AND
CERTIFY BY SIGNING AND
DATING BELOW.
Department of the
Treasury TIN:___________________________
Internal Revenue (Social Security Number or
Service Employer Identification Number)
Payor's Request for
Taxpayer
Identification
Number ("TIN")
and Certification
Part 2 -- TIN Applied For [ ]
CERTIFICATION: UNDER PENALTIES OF PERJURY, I CERTIFY THAT:
(1) the number shown on this form is my correct Taxpayer Identification Number
(or I am waiting for a number to be issued to me).
(2) I am not subject to backup withholding either because: (a) I am exempt from
backup withholding, or (b) I have not been notified by the Internal Revenue
Service (the "IRS") that I am subject to backup withholding as a result of
a failure to report all interest or dividends, or (c) the IRS has notified
me that I am no longer subject to backup withholding, and
(3) any other information provided on this form is true and correct
SIGNATURE....................................................................
DATE...........................
- --------------------------------------------------------------------------------
You must cross out item (2) of the above certification if you have been notified
by the IRS that you are subject to backup withholding because of under reporting
of interest or dividends on your tax return and you have not been notified by
the IRS that you are no longer subject to backup withholding.
- --------------------------------------------------------------------------------
YOU MUST COMPLETE THE FOLLOWING CERTIFICATE IF YOU CHECKED
THE BOX IN PART 2 OF SUBSTITUTE FORM W-9
- --------------------------------------------------------------------------------
CERTIFICATE OF AWAITING TAXPAYER IDENTIFICATION NUMBER
I certify under penalties of perjury that a taxpayer identification number has
not been issued to me, and either (a) I have mailed or delivered an application
to receive a taxpayer identification number to the appropriate Internal Revenue
Service Center or Social Security Administration Office or (b) I intend to mail
or deliver an application in the near future. I understand that if I do not
provide a taxpayer identification number by the time of the exchange, 31 percent
of all reportable payments made to me thereafter will be withheld until I
provide a number.
- ---------------------------------------------------- --------------------------
Signature Date
- --------------------------------------------------------------------------------
EXHIBIT 99.2
NOTICE OF GUARANTEED DELIVERY FOR
MAXXIM MEDICAL, INC.
This form or one substantially equivalent hereto must be used to accept
the Exchange Offer of Maxxim Medical, Inc. (the "Company") made pursuant to the
Prospectus, dated October ___, 1996 (the "Prospectus"), and the enclosed Letter
of Transmittal (the "Letter of Transmittal") if Old Notes are not immediately
available or if the procedure for book-entry transfer cannot be completed on a
timely basis or time will not permit all required documents to reach the Company
prior to 5:00 P.M., New York City time, on the Expiration Date of the Exchange
Offer. Such form may be delivered or transmitted by facsimile transmission, mail
or hand delivery to First Union National Bank of North Carolina (the "Exchange
Agent") as set forth below. In addition, in order to utilize the guaranteed
delivery procedure to tender Old Notes pursuant to the Exchange Offer, a
completed, signed and dated Letter of Transmittal (or facsimile thereof) must
also be received by the Exchange Agent prior to 5:00 P.M., New York City time,
on the Expiration Date. Capitalized terms not defined herein are defined in the
Prospectus.
DELIVERY TO: FIRST UNION NATIONAL BANK OF NORTH CAROLINA, EXCHANGE AGENT
BY MESSENGER, MAIL, OVERNIGHT DELIVERY:
First Union National Bank of North Carolina
230 South Tryon Street, 11th Floor
Charlotte, North Carolina 28288-1153
Attention: Corporate Trust Operations
FACSIMILE TRANSMISSION:
(704) 383-9716
CONFIRM BY TELEPHONE:
(704) 383-0048
Ms. Marilyn Johnson
DELIVERY OF THIS INSTRUMENT TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE,
OR TRANSMISSION OF INSTRUCTIONS VIA FACSIMILE OTHER THAN AS SET FORTH ABOVE,
WILL NOT CONSTITUTE A VALID DELIVERY.
Ladies and Gentlemen:
Upon the terms and conditions set forth in the Prospectus and the
accompanying Letter of Transmittal, the undersigned hereby tenders to the
Company the principal amount of Old Notes set forth below, pursuant to the
guaranteed delivery procedure described in "The Exchange Offer -- Guaranteed
Delivery Procedures" section of the Prospectus.
<PAGE>
Principal Amount of Old Notes Tendered: Name(s) of Record Holders(s):
$______________________________________ _____________________________
Note Nos. (if available): _____________________________
Address(es):
_______________________________________
_______________________________________ _____________________________
_____________________________
If Old Notes will be delivered by Area Code and Telephone
book-entry transfer to The Depositary Numbers(s):
Trust Company, provide account number.
_____________________________
Signature(s):
Account Number ________________________ _____________________________
_____________________________
THE ACCOMPANYING GUARANTEE MUST BE COMPLETED.
<PAGE>
GUARANTEE
(NOT TO BE USED FOR SIGNATURE GUARANTEE)
The undersigned, a firm that is a member firm of a registered national
securities exchange or of the National Association of Securities Dealers, Inc.,
a commercial bank or trust company having an office correspondent in the United
States or any "eligible guarantor" institution within the meaning of Rule
17Ad-15 of the Exchange Act of 1934, as amended, hereby guarantees to deliver to
the Exchange Agent, at its address set forth above, the Old Notes described
above, in proper form for transfer, or a Book-Entry Confirmation, together with
a properly completed and duly executed Letter of Transmittal (or facsimile
thereof), with any required signature guarantees, and any other documents
required by the Letter of Transmittal within three New York Stock Exchange, Inc.
trading days after the date of execution of this Notice of Guaranteed Delivery.
Name of Firm: _________________________ _____________________________
(Authorized Signature)
Address: ______________________________
_______________________________________
Area Code and
Telephone Number: _____________________
Title: ______________________
Name: ______________________
Date: ______________________
